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Abstract 
Pulmonary arterial hypertension (PAH) is a progressive disease which results from 
increases in mean pulmonary artery pressure and pulmonary vascular resistance.  If 
untreated it leads to right ventricular failure and death.  5-Hydroxytryptamine (5-HT) has 
been implicated in the disease process and is thought to promote both vasoconstriction and 
remodelling of the pulmonary vasculature.  The activity of potassium ion (K
+
) channels 
plays a major role in influencing pulmonary artery tone by regulating resting membrane
 
potential, intracellular Ca
2+
 concentration and
 
contraction of vascular smooth muscle.  This 
study aimed to investigate possible interactions between 5-HT and K
+
 channels in the 
development of PAH in the mouse.  
 
The actions of 5-HT and a range of K
+ 
channel blockers were investigated on isolated 
intralobar pulmonary arteries (IPA) from wild type (WT) mice and mice over-expressing 
the serotonin transporter (5HTT), which spontaneously develop PAH.  Both 5-HT and 
linopirdine, a KCNQ K
+
 channel inhibitor, were found to induce contraction of IPA, but 
were more potent in IPA from WT mice than 5-HTT+ mice.  The 5-HT induced 
vasoconstriction was found to involve influx of Ca
2+
 from the extracellular space, Ca
2+
 
release from the sacroplasmic reticulum and a rho kinase–dependent increase in the 
sensitivity of the contractile machinery of pulmonary artery smooth muscle cells (PASMC) 
to intracellular Ca
2+
.  Ca
2+
 entered the cell via both voltage operated calcium channels 
(VOCC), activated by membrane depolarisation, and a separate Ca
2+ 
entry pathway, the 
latter appearing to contribute more in 5-HTT+ mice.   The effects of linopirdine were 
shown to be due entirely to the entry of Ca
2+
 through VOCC in both WT and 5-HTT+ mice 
IPA.  The difference in vasoconstrictor potency between WT and 5HTT+ mice was not 
seen with any other K
+
 channel blocker, suggesting a selective loss of KCNQ channels 
and/or VOCC in PAH resulting from 5HTT over expression.  
 
KCNQ channel activity was further investigated using the KCNQ channel openers, 
flupirtine and retigabine.  These agents were more potent in dilating IPA from WT mice 
compared to 5-HTT+ mice, consistent with the loss of expression or activity of KCNQ 
channels in 5-HTT+ mice.  Despite this, orally administered flupirtine was shown to 
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reverse two indices of established PAH in the 5HTT+ mice; right ventricular pressure and 
right ventricular hypertrophy.  This action of flupirtine was also seen in chronic hypoxic 
mice, where it prevented the development of PAH.   
 
In conclusion, this study provides evidence of an interaction between KCNQ channels and 
the 5-HT system in the development of PAH.  By showing that a KCNQ channel opener 
can attenuate PAH, both in the developing and established disease situation, this study 
proposes a new potential therapeutic target in the treatment of PAH. 
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There has been a great amount of research into the pulmonary circulation in the past 50 
years.  There is now a greater understanding of the mechanisms responsible for controlling
 
pulmonary vasomotor tone and vascular growth, and this has led to new approaches for the 
treatment
 
of pulmonary circulation disorders. 
 
1.1  Anatomy of the pulmonary circulation 
The pulmonary circulation transmits virtually the entire cardiac output from the right side 
of the heart to the left side (figure 1.1).  The pulmonary artery (PA) leaves the right 
ventricle and bifurcates before entering the lungs.  The left branch extends into the hilum of 
the left lung, and here it divides in two, with a branch extending into each lobe.  The right 
PA also divides into two branches, one branch enters the middle and lower lobe and the 
second branch enters the upper lobe of the right lung.  The pulmonary arteries then run 
parallel to the bronchial tree until the terminal alveoli are reached.  At this stage the 
arterioles become capillaries, which form a mesh like framework around individual alveoli, 
to facilitate gaseous transfer.  Thereafter venules emerge, and these vessels become veins.  
Four main pulmonary veins leave the lungs, and these convey the oxygenated blood into 
the left atrium of the heart, (Berne & Levy, 1998).  There are seventeen orders of 
pulmonary arterial vessels (Singhal et. al ., 1973). 
 
The pulmonary circulation is composed of arteries, capillaries and veins.  PAs have walls 
made up of three layers; tunica intima, tunica media and tunica adventitia (figure 1.2).  The 
intimal layer is composed of a flat sheet of endothelial cells, above a layer of connective 
tissue.  The medial layer is bound by the internal and external laminae and provides the 
vessel with mechanical strength and the ability to contract.  Within the medial layer, 
smooth muscle cells (SMCs) are found embedded within a matrix of elastin and collagen 
fibres.  The adventitial layer is composed of connective tissue, and holds the vessel in 
place. The adventitia of the normal PA contains a range of fibroblast
 
subpopulations 
(Stenmark et. al., 2002). 
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Within the pulmonary arterial system the small muscular arteries have a much thinner 
muscular media, with less elastin, and fewer SMCs than would be found in comparable 
systemic vessels (Berne & Levy, 1998).  The vessels arising immediately from the main 
pulmonary arteries, down to arteries of 1 mm internal diameter, are referred to as elastic 
arteries. This is due to their elastic structure, composed of a thin intima, thick adventitia and 
media layer composed of elastic laminae layers and SMCs.  Arteries of internal diameters 
100 µm – 1 mm are mostly muscular, having ~ six SMC layers, bound by distinct internal 
and external laminae (Brenner et. al., 1935; Heath & Edwards, 1958).  Distally, towards the 
apex of the lungs, arteries become less muscular (Meyrick et. al., 1983).  Beyond the 
terminal bronchioles, within the respiratory acinus, arteries are partially muscularised as the 
vascular SMC layer is reduced. For example, pulmonary arteries that have internal 
diameters of > 100 µm have single elastic laminae, with few SMCs (Heath & Edwards, 
1958).  The intra-acinar arteries have no SMCs present (Demello et. al., 1997).  The 
pulmonary vascular system has a large network of ‘sheet-like’ capillaries.  They are in 
close connection to the alveoli, and hence the surface area for gas exchange is very vast at 
90-126m
2
 in adults (Levick, 2000).   
 
1.2 Function of the pulmonary circulation 
The main function of the pulmonary circulation is gas exchange.  Carbon dioxide from 
venous blood diffuses through the interstitial space and alveoli walls into the alveoli, and 
oxygen is taken up from the alveoli into the PA in the opposite direction.  The pulmonary 
circulation receives the entire cardiac output, with effectively five litres passing through 
this system per minute (Berne & Levy, 1998).  An important factor to take into 
consideration is the ventilation to perfusion ratio, which is essentially a measurement of the 
efficiency of gas exchange (Berne & Levy, 1998).  When the pulmonary system is 
functioning efficiently the ventilation to perfusion ratio is approx. 0.8 in man, which occurs 
when ventilation is four litres per minute and the cardiac output is five litres per minute 
(Levick, 2000).  The pulmonary circulation must accommodate each stroke volume whilst 
maintaining a low arterial pulmonary pressure. 
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Figure 1.1 Diagram of the circulation system.   
RA: right atrium, LA: left atrium, RV: right ventricle, LV: left ventricle  
Deoxygenated blood flows from the right ventricle of the heart into the PA.  It passes to the 
pulmonary capillaries, upon which carbon dioxide is offloaded and oxygen is taken up into 
the blood.  The oxygenated blood then flow into the left side of the heart, and is 
subsequently pumped through to the systemic circuit. 
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Figure 1.2 Illustration of the structure of a pulmonary artery. 
This picture illustrates the position of the layers of cells which make up the pulmonary 
artery wall. 
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The pulmonary circulation is also involved in non-respiratory functions.  The endothelium 
and blood act as metabolic filters, converting hormones and other signalling molecules 
between active and inactive states.  For example, angiotensin converting enzyme, found on 
pulmonary endothelium cells, is involved in the production of angiotensin II and inactivates 
bradykinin (Johnson & Erdos, 1997; Stewart, 1976; Cushman et. al., 1971).  The lung is 
also the major site of 5-HT removal from the bloodstream via uptake by the transporters on 
lung cells (Alabaster & Bakhle 1970).  Endothelial cells, SMCs, platelets and fibroblasts all 
have 5-HT transporters (5-HTTs) on their plasma membranes (Strum & Junod, 1972; 
Bryan-Lluka et. al., 1995; Welsh et. al., 2004). 
 
1.3  Physiology of the pulmonary circulation 
The normal pulmonary circulation is known to be a high flow, low resistance circuit, which 
is very different to that of the systemic circulation.  The total blood volume in the 
pulmonary circulation is approximately 10 % of the total blood circulating in the body.  The 
low resistance ensures that the entire cardiac output can be handled by the lung circulation 
without causing the right ventricle to do excessive work (Berne & Levy, 1998).   
 
The mean pulmonary arterial pressure in the resting normal adult is 15 mmHg, whereas in 
the systemic circuit the mean arterial pressure is 100 mmHg (Morgan, 2004).  Mean 
pulmonary arterial pressure (MPAP) can be calculated from the measured values of 
diastolic pulmonary pressure (DPAP) and systolic pulmonary pressure (SPAP) using 
equation 1.  
(equation 1)   MPAP = DPAP + (SPAP – DPAP)/3 
 
The flow of blood through the pulmonary circulation is influenced by the difference in 
pressure between the pulmonary arteries and the pulmonary veins.  The pressure difference 
is referred to as the perfusion pressure.  Also affecting the blood flow in the pulmonary 
circuit is the resistance imposed by the blood vessels.  In the systemic system most 
resistance to blood flow lies within the pre-capillary muscular arterioles (~ 70 %), however 
in the pulmonary system the resistance is more equally distributed between arteries, 
capillaries and veins (Lumb, 2000). Levick, (2000) suggests that the pressure is divided 
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between the vessels in the following fashion; arterial vessel 30 %, microvasculature 50 % 
and veins 20 %.  As the pre-capillary segment contributes to the majority of pulmonary 
vascular resistance it follows that a small change in tone in this area can lead to large rises 
in pulmonary arterial pressure, as can be seen using Poiseuille’s law for steady flow (see 
equation 2 where L is vascular length, η is blood viscosity, r is vessel radius).     
(equation 2)    PVR = 8ηL/ pir
4
   
 
1.3.1  Regulation of pulmonary blood flow 
As the entire CO flows past the alveoli, perfusion greatly exceeds nutritional needs.  This 
means that metabolic factors exert no influence on flow.  The metabolic needs of the 
bronchi are met via a second distinct blood flow, an independent systemic bronchial 
circulation (Berne & Levy, 1998).  The pulmonary circulation is under the control of 
passive and active factors. 
 
1.3.1.1  Passive factors regulating the control of pulmonary blood flow 
These are the factors that induce a change in the pulmonary vessel resistance, independent 
of the active contraction of SMCs.  Blood flow through the lungs is unevenly distributed in 
a normal upright individual.  Gravity has an effect on blood distribution, as lungs are 
located above and below the point where the PA leaves the heart.  At the apex of the lung 
the pressure is lower relative to that at the base.  This is due to the hydrostatic pressure on 
blood being pumped through this circuit (Morgan, 2004).  Above the heart, as the pressure 
on the blood in the pulmonary arterial system is low, the pressure of air in the alveoli will 
have an impact on perfusion.  As interstitial pressure is more negative at the apex, the 
relative alveolar pressure will be greatest at this level.  This can cause the individual alveoli 
to be fully distended, which can lead to compression of the capillaries, as these are thin and 
soft walled.  The variance of pressure in the pulmonary vascular system within the lung is 
best described by dividing the lung into three distinct regions/ zones: 
• Zone 1- (Apex)  Alveolar pressure ≥ Arterial pressure > Venous pressure 
Alveolar pressure exceeds both arterial pressure and venous pressure, which results in 
capillaries being relatively compressed.  Therefore in zone 1 blood flow will be low or 
non-existent. 
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• Zone 2- (Heart level) Arterial pressure > Alveolar pressure > Venous pressure 
Arterial pressure exceeds alveolar pressure and blood flows progressively along the 
pulmonary vascular system depending on arterial-alveolar pressure difference.  Blood 
flow through capillaries will behave as a starling resistor when alveolar pressure 
exceeds capillary pressure.  The starling resistor phenomenon describes
 
how flow 
through a collapsible tube surrounded by a pressure chamber
 
is determined by the 
upstream pressure minus the pressure chamber,
 
as opposed to the downstream pressure, 
when chamber pressure exceeds
 
downstream pressure (Berne & Levy, 1998).  As long 
as capillary pressure is higher than alveolar pressure at the entrance and lower than 
alveolar pressure at the end of the capillaries, the capillaries are open and blood will 
flow, but when alveolar pressure is higher than the PA pressure, the capillaries will be 
completely closed. 
• Zone 3- (Base) Arterial pressure > Venous pressure > Alveolar pressure 
As blood flows towards the bottom of the lung because of gravity, venous pressure 
increases.  Blood flow is continuous and all vessels are open because both arterial and 
venous pressures exceed alveolar pressure.  (Morgan, 2004; Berne & Levy, 1998).   
 
1.3.1.2  Active regulation of pulmonary blood flow 
Whilst the pulmonary blood flow is mainly controlled normally by the passive factors 
described above, active factors can affect vascular resistance by acting to constrict or relax 
pulmonary artery smooth muscle cells (PASMCs).  Active factors include autonomic 
nerves, humoral factors, the endothelium and respiratory gases. 
 
The pulmonary vasculature is innervated by components of the autonomic nervous system; 
sympathetic (adrenergic) and parasympathetic (cholinergic) nerves (Hebb, 1969), and a 
third, non-adrenergic non-cholinergic system (NANC) has also been identified (Kobayashi 
& Amenta, 1994).  However, the extent of innervation is regional and species specific 
(Kobayashi & Amenta, 1994; Barnes & Liu, 1995).  Species variation can be seen from 
differences in sympathetic innervation; sheep, guinea pig and canine pulmonary arteries are 
richly innervated whereas calf and swine PA have sparse innervation (Hebb, 1969); 
however there is a complete lack of innervation within the intralobar vessels of rat (McLean 
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et. al., 1985) while human intrapulmonary arteries have been shown to be densely 
innervated. The neurotransmitter released from the sympathetic nerve fibres serving the 
pulmonary circulation is noradrenaline (NA).  Species variation also arises from the 
receptors for this catecholamine within the pulmonary vasculature (Kobayashi & Amenta, 
1994; Barnes & Liu, 1995).  α- and β-adrenoceptors mediate NA responses, with α-
receptors mediating vasoconstriction and β-receptor stimulation resulting in vasodilation.  It 
has been suggested that sympathetic activation leads to an increase in vascular resistance 
and a decrease in vascular compliance, and hence an increase in pulmonary arterial pressure 
(Barnes & Liu, 1995), resulting mainly from α-receptor stimulation (Ingram et. al., 1968; 
Hyman, 1986). Vasodilation upon β-receptor stimulation plays a lesser role in pulmonary 
vascular tone regulation as it only occurs upon α-receptor blockade in the feline vascular 
bed (Hyman et. al., 1981).  When β-receptors are inhibited the level of constriction in 
response to sympathetic stimulation is increased (Hyman et. al., 1986).   
 
The parasympathetic influence is less than that of the sympathetic system (Barnes & Liu, 
1995), although there is both species and regional variation in this system within the 
pulmonary vasculature too.  Regional variation is seen in mouse where intralobar arteries 
have no parasympathetic innervation, while extralobar arteries and large pulmonary veins 
from these animals are severed by this part of the autonomic nervous system (Cech, 1973).  
Parasympathetic innervation of the pulmonary vascular system has been shown in many 
animal groups, including rabbit, dog and human (Cech, 1973; Fillenz, 1970), however in rat 
the parasympathetic innervation only serves the pulmonary vein (Bradley et. al., 1970).   
Upon stimulation of the parasympathetic nervous system, acetylcholine (ACh) is released 
(Kobayashi & Amenta, 1994).  This neurotransmitter has been found to induce both 
vasodilation and vasoconstriction of the pulmonary circulation.  In the human pulmonary 
system the response to ACh is vasodilation (Nandiwada et. al., 1983), however in the rabbit 
pulmonary vasculature ACh induces vasoconstriction (Sada et. al., 1987).  This difference 
in ACh response within the pulmonary vasculature has been shown to be the result of 
varying levels of pre-existing tone.  The constrictor response is generated under normal 
physiological conditions while relaxation is the response seen under conditions of increased 
tone (Barnes & Liu, 1995).  It has been shown that in human isolated pulmonary arteries 
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where tone was induced, ACh caused endothelium-dependent relaxation (Greenberg et. al., 
1987; Thom et. al., 1987).  However, at basal tone or after removal of endothelium, ACh 
induced contraction in human pulmonary arteries (Norel et. al., 1996).  Muscarinic (M) 
receptors on endothelial and SMCs mediate the ACh response (Altiere et. al., 1994), and it 
has been shown that species variation exists in the muscarinic receptor types that mediate 
ACh responses.  M3 receptors are thought to be the main receptors involved in the 
contraction of human and rabbit isolated PAs in response to ACh (Norel et. al., 1996; 
Altiere et. al., 1994), whereas both M1 and M2 receptors have been proposed to be 
involved in the ACh induced increases in pulmonary vascular resistance in canine 
pulmonary circulation (El-Kashef et. al., 1991).  With regards to ACh induced relaxation 
responses, M3 receptors have been implicated in rat and rabbit pulmonary arteries  
(MacCormack et. al., 1988; Altiere et. al., 1994), while in human isolated pulmonary 
arteries this response has been linked to both M3 and M1 receptors (Norel et. al., 1996).  
The parasympathetic nervous system is thought to have a minor influence on pulmonary 
vascular tone, as blockade of these fibres does not result in an increase in arterial pressures 
(Murray et. al., 1986).   
 
NANC control has been found within the pulmonary circuit.  This is thought to be 
manifestations of neurotransmission in sympathetic, parasympathetic and sensory nerves 
(Barnes & Liu 1995).  NANC autonomic innervation has been demonstrated to mediate 
relaxation of pulmonary arteries (Liu et. al., 1992; Scott et. al., 1996; Gumusel et. al., 
2001).  Numerous compounds have been proposed as NANC neurotransmitters, including 
substance P, adenosine trisphosphate (ATP), calcitonin gene related peptide, nitric oxide 
(NO) and adenosine (Kobayashi & Amenta 1994; Barnes & Liu 1995).  It has been shown 
that NANC relaxation exists in human and rat pulmonary arteries, where it is partly 
mediated through NO (Scott et. al., 1996; Gumusel et. al., 2001).  In guinea pig pulmonary 
arteries a study showed that NANC relaxation is mediated predominantly through NO 
(Scott & McCormack 1999), although Liu et. al., (1991; 1992) suggest that different 
mechanisms are involved in mediating NANC relaxation in main and branch PA of guinea 
pig.  In the branch PA, this group propose that NANC relaxation is mediated by ATP, 
whereas in the main PA it is likely to be mediated by release of peptides such as calcitonin 
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gene related peptide.  It is thought that NANC vasodilator nerves represent the major neural 
vasodilator mechanism within pulmonary vessels, therefore any alteration in this system 
could result in vasoconstriction (Barnes & Liu, 1995).  
 
There are a number of endogenous agents that alter vascular tone by relaxing or contracting 
the SMCs within the vessel wall.  The action of these endogenous agents can vary between 
species and depend on the level of pre-existing tone.  These humoral factors are secreted 
from the endothelium, the lung parenchyma and the rest of the circulation and have various 
effects, mediated by receptors on either endothelial cells or SMCs.  Within the normoxic 
pulmonary circulation the balance between these vasodilators and vasoconstrictors is 
shifted towards vasodilation and low basal tone.  Humoral factors that in general induce 
vasoconstriction include: angiotensin II (Morrell et. al., 1995), 5-hydroxytryptamine (5-
HT) (MacLean et. al., 1994; 1996), thromboxane A2 (Buzzard et. al., 1993), neuropeptide 
Y (Obara et. al., 1989; Martling et. al., 1990).  Vasodilation has been shown to occur in 
response to many vasoactive mediators, for example atrial natriuretic peptide (Lindberg & 
Andersson 1988), vasoactive intestinal peptide (Nandiwada et. al., 1985; Martling et. al., 
1990), prostacyclin (PGI2) (Hyman & Kadowitz 1979) and NO (Cremona et. al., 1999; 
Ferrario et. al., 1996), bradykinin (Lippton et. al., 1984), histamine (Abcioglu et. al., 1987), 
substance P (Archer et. al., 1986a), prostaglandin E (PGE) (Jourdan et. al., 1997).   In some 
cases humoral factors can induce both constriction and relaxation of the pulmonary 
vasculature, suggesting species variation.  For example ATP has a constrictor action on 
adult cat pulmonary vascular beds (Lippton et. al., 1992), however in fetal sheep 
pulmonary vasculature it induces relaxation (Konduri et. al., 1992a).  
 
1.3.1.3 Endothelial cell control of pulmonary blood flow 
Endothelial cells influence the tone of SMCs via generation, metabolism and degradation of 
many vasoactive substances.  The importance of the endothelium in regulating tone in the 
lung circulation was highlighted with the discovery that the endothelium released PGI2 and 
thromboxane A2 (Gossage et. al., 1994; Prins et. al., 1994).  Another major finding was 
that PGI2 was released by endothelial cells in response to shear stress within pulmonary 
vessels (Frangos et. al., 1985).  In addition, PGI2 was found to be an important hormone for 
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the pulmonary vasodilation that occurs upon birth (Cassin et. al., 1993).   Endothelial cells 
are directly exposed to the shearing forces of blood flow.  In response they synthesise and 
release vasoactive substances, which act to allow local control of flow (Busse & Fleming, 
2003).  By releasing mediators in a paracrine manner, endothelial cells can influence local 
vasodilation or vasoconstriction of the pulmonary circulation.  The release of these 
mediators can be induced by other vasoactive substances, for example, acetylcholine acts 
on endothelial cells to induce the release of NO, which in turn relaxes smooth muscle 
(McMahon et. al., 1992; Gambone et. al., 1997).  Another relaxing factor arising from 
endothelial cells in response to ACh is endothelium-derived hyperpolarising factor (EDHF) 
(Chen et. al., 1988).  NO and PGI2 have been well characterised.  NO is synthesised by NO 
synthase (NOS) and is continuously released from endothelial cells.  NO acts to promote 
increased levels of cyclic guanosine monophosphate (cGMP), a second messenger within 
SMCs.  PGI2 is synthesised by cyclo-oxygenase (COX) and causes vasodilation via the 
second messenger cyclic adenosine monophosphate (cAMP).  cGMP and cAMP mediate 
part of the response to NO and PGI2, by causing hyperpolarisation of the SMC, and hence 
induce vasodilation (Feletou & Vanhouttte, 2000).  The exact pathway by which EDHF 
mediates vasodilation is unknown, however it acts to induce NO- and  PGI2 -independent 
vasodilation.  EDHF has been shown to induce relaxation by hyperpolarising the SMC 
membrane by opening K
+
 channels (Garland et. al., 1995).  Several reports indicate that the 
K
+
 channels involved in the EDHF response are sensitive to the combination of 
charybdotoxin, which inhibits large conductance calcium (Ca
2+
) activated K
+
 channels 
(BKCa), and apamin, which blocks small conductance Ca
2+
 activated K
+
 channels (SKCa) 
(Nelson & Quayle, 1995; Cook & Quast, 1990).  The K
+
 channels that mediate EDHF 
responses differ depending on the vascular bed and species studied.  For example, in rat 
PA, Ca
2+
 activated K
+
 channels (KCa) mediate EDHF (Karamsetty et. al., 2001), whereas in 
the canine PA preparation, ATP activated K
+ 
channels have been shown to mediate EDHF 
responses (Gambone et. al., 1997).  
 
The endothelium also has a metabolic function and thereby regulates the amount of 
vasoactive substances circulating in the blood stream.  This is brought about by enzymes on 
the endothelial cell membrane acting on substances within the blood (Kobayashi & Amenta 
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1994), some of which are discussed above.  By transporting hormones/ mediators into the 
endothelial cytoplasm, vasoactive components can be removed from the blood stream, for 
example 5-HT and NA are removed by the endothelium via endothelial uptake mechanisms 
(Alabaster & Bakhle, 1970).  The endothelial cell layer behaves as a structural barrier 
between the bloodstream and the underlying SMCs.  An example of the importance of this 
barrier can be seen from the fact that bradykinin induces endothelium cell dependent 
vasodilation in the pulmonary circulation, however when the endothelium is removed this 
agonist induces constriction (Altura & Chand, 1981).  Any damage or dysfunction of the 
endothelial layer in the pulmonary circulation may therefore have profound effects on 
vascular tone.  Hence the endothelium is of extreme importance in the maintenance of low 
basal tone via modulation of nervous, humoral and mechanical influences 
 
1.3.1.4  Hypoxic control of pulmonary blood flow 
The composition of, and particularly the partial pressure of oxygen within inspired air can 
affect tone of the pulmonary circulation.  Hypoxia (condition where the partial pressure of 
oxygen level is low), induces vasoconstriction within the pulmonary circulation (Fishman, 
1961), whilst causing vasodilation in most systemic vascular beds.  The pulmonary arterial 
system responds to hypoxia in a distinct manner, which is known as hypoxic pulmonary 
vasoconstriction (HPV).  Before birth HPV has a physiological role in diverting blood flow 
from the lungs to the systemic circulation.  The function of HPV after birth is to match 
ventilation to perfusion, and it does this by changing the vascular resistance in reaction to 
changes in local oxygen content.  HPV can be defined as the rapid, reversible increase in 
pulmonary vascular resistance.  Acute ventilatory hypoxia causes a rapid increase in PVR, 
which plateaus within twenty minutes, and is then maintained.  Upon return to normoxia 
PVR falls promptly to normal physiological levels (Ward & Aaronson, 1999).   
 
As HPV occurs in isolated lungs (free of nerve innervation and blood), isolated arteries and 
PASMCs, it is thought that the process is intrinsic to the PASMCs (Archer, 2001, Madden 
et. al., 1992).  The HPV response varies in relation to the diameter of the vessel involved; 
small intrapulmonary resistance arteries (IPAs) are thought to be the main site of HPV 
(McCulloch et. al., 2000).  This allows for regional control of blood flow without leading to 
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elevation of the entire pulmonary vascular resistance and hence doesn’t cause the 
consequent increase in right heart work (Archer, 2001).  The exact mechanisms underlying 
HPV remain unresolved.  It is well known that an increase in intracellular Ca
2+
 ([Ca
2+
]i) is 
involved in the HPV response, however, the mechanisms by which this rise in Ca
2+
 arises is 
debated.  One hypothesis for HPV induced increase in [Ca
2+
]i, is that Ca
2+
 entry is mediated 
primarily via voltage dependent L-type channels (McMurtry et. al., 1976), as a result of 
hypoxia-induced inhibition of voltage-gated K
+
 channels (KV channels) and resultant 
depolarisation of the cell membrane.  However, studies have shown that blockers of L-type 
Ca
2+
 channels only result in a minimal inhibition of the HPV response (Ward & Aaronson 
1999; Ward et., al., 2005).  Other studies have suggested a role for Ca
2+
 from intracellular 
stores in the HPV response (Jabr et. al., 1997; Liu et. al., 2001).  It has also been suggested 
that mitochondria play a role in the HPV response, with mitochondria responding to 
alterations in oxygen tension, resulting in the generation of a signal that modulates redox-
sensitive K
+
 channels, hence
 
controlling membrane potential and therefore Ca
2+
 influx 
(Archer & Michelakis, 2002). 
 
1.4  Pulmonary artery smooth muscle contraction 
Contraction of PASMCs can be initiated by mechanical, electrical, and chemical stimuli.  
PASMC contraction is initiated by a rise in free [Ca
2+
]i (Hirano et. al., 1991), which can 
arise from flux of Ca
2+ 
into the cells via Ca
2+ 
channels or from intracellular stores such as 
the endoplasmic reticulum.  Calmodulin (CaM) is an intracellular Ca
2+
-binding protein, 
which binds to Ca
2+ 
as the concentration of Ca
2+
 rises within the cell.  Ca
2+
-CaM activates 
myosin light chain kinase (MLCK).  MLCK phosphorylates myosin light chain (MLC) in 
the presence of ATP, thereby activating cross-bridge cycling and contraction (Hartshorne 
et. al., 1987).  Phosphorylation of MLC is reversed by myosin phosphatase (MLCP) (Ito et. 
al., 1991).  MLCK and MLCP exert a balancing effect, allowing contraction and relaxation 
to occur.  Many drugs that induce SMC contraction and relaxation do so via G-protein 
coupled receptors (GPCRs).  
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Figure 1.3 Mechanism of SMC contraction. 
The level of free [Ca
2+
]i is a major determinant of SMC contraction. Ca
2+
 binds and forms a 
complex with calmodulin (CaM). CaM activates MLCK, which subsequently 
phosphorylates MLC. This stimulates myosin ATPase activity and promotes crossbridge 
cycling with actin filaments. The formation of these crossbridges underlies SMC cell 
contraction.  Phosphorylation of MLC is reversed by MLCP.  Figure adapted from 
Nahorski, (2006). 
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Revised Clinical Classification of Pulmonary Hypertension  
(World Health Organisation World Symposium on PAH Venice 2003) 
 
1. Pulmonary Arterial Hypertension (PAH) 
 1.1 Idiopathic (IPAH) 
 1.2 Familial (FPAH) 
 1.3 Associated with: 
   1.3.1 Collagen Vascular Disease 
  1.3.2 Congenital systemic to pulmonary shunts  
   1.3.3 Portal hypertension 
   1.3.4 HIV infection 
   1.3.5 Drugs & toxins 
            1.3.6 Other (Thyroid disorders, Glycogen Storage Disease, Gaucher's Disease, 
Hereditary Hemorrhagic Telangiectasia, Hemoglobinopathies, 
Myeloproliferative Disorders, Splenectomy) 
 1.4 Associated with significant venous or capillary involvement 
   1.4.1 Pulmonary veno-occlusive disease  
   1.4.2 Pulmonary capillary hemangiomatosis 
 1.5 Persistent pulmonary hypertension of the Newborn 
 
2 Pulmonary Venous Hypertension 
 2.1 Left-sided atrial or ventricular heart disease 
 2.2 Left-sided valvular heart disease 
 
3. Pulmonary Hypertension associated with hypoxemia 
 3.1 Chronic obstructive pulmonary disease 
 3.2 Interstitial lung disease 
 3.3 Sleep-disordered breathing 
 3.4 Alveolar hypoventilation disorders 
 3.5 Chronic exposure to high altitude 
 3.6 Developmental abnormalities 
 
4. Pulmonary Hypertension due to chronic thrombotic and/or embolic disease 
 4.1 Thromboembolic obstruction of proximal pulmonary arteries 
 4.2 Thromboembolic obstruction of distal pulmonary arteries 
 4.3 Non-thrombotic pulmonary embolism (tumor, parasites, foreign material) 
 
5. Miscellaneous 
Sarcoidosis, Histiocytosis X, Lymphangiomatosis, Compression of pulmonary vessels 
(adenopathy, tumor, fibrosing mediastinitis) 
 
 
Table 1.1 Revised Clinical Classification of Pulmonary Hypertension.   
This classification identifies different categories of pulmonary 
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1.5  Pulmonary Arterial Hypertension 
Pulmonary arterial hypertension (PAH) represents Group 1 within the Pulmonary 
Hypertension (PH) World Health Organisation clinical classification system (see table 1.1).  
It is a disease which occurs when pulmonary arterial pressure (PAP) increases above 25 
mmHg at rest or 30 mmHg during exericise (Barst et. al., 2004). Dresdale, Michtom and 
Schultz, (1954) were the first to use the term primary pulmonary hypertension, and they 
began to investigate how to treat it.  They treated PPH patients with a pulmonary 
vasodilator drug, tolazoline, which gave relieve to the condition.  Harris et. al. (1957), 
investigated the potential of the vasodilator drug, acetylcholine.  This drug was given via 
the intravascular route, and degraded naturally during first pass of the lungs.  Harris et. al. 
(1957) showed that under normoxic conditions, acetylcholine had no effect.  On the other 
hand, during conditions of hypoxia, acetylcholine caused vasodilation (Fishman, 1976). 
 
1.5.1  Genetic Basis of pulmonary arterial hypertension 
PAH has been shown to occur in families, hence the term familial PAH (FPAH), which 
accounts for 6% of PAH cases (Rich et. al., 1987).  The inheritance pattern is autosomal 
dominant, with a female to male ratio of 2:1 (Loyd et. al., 1984).  Within FPAH there is 
genetic anticipation, in that the disease occurs at younger ages (Gaine & Rubin, 1998).  A 
marker for the disease was found on chromosome 2q31-32 (Morse et. al., 1997).  This led 
to the finding of a mutation in the bone morphogenetic protein type 2 receptor (BMPR2) 
gene, in association with FPAH (Lane et. al., 2000).  Another possible modulating 
influence may be changes in the gene encoding the 5-HTT.  5-HTT is coded by a single 
gene on chromosome 17q11.2 and a variant in the promoter region has been shown (Lesch 
et. al., 1996).   A polymorphism with long (L) and short (S) forms affect the expression of 
the 5-HTT, with the L allele encoding for increased expression of the transporter (Eddahibi 
et. al., 2001).  Genetic predisposition does not automatically lead to FPAH.  Less then 20% 
of individuals with a BMPR2 mutation go on to develop the disease.  Moreover, most 
individuals who develop the disease do not have an identified genetic mutation (Thomson 
et. al., 2000).  PAH can occur secondary to other events and these may include exposure to 
exogenous stimuli, for example hypoxia (Chan & Loscalzo, 2008).   
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1.5.3  Epidemiology of pulmonary arterial hypertension 
PAH is a progressive disease that cannot be cured.  The mean age of developing PAH is 36, 
however it can develop at any age (Rich et. al., 1987) and is independent of race (Rich et. 
al., 1987).   
 
PAH has an estimated prevalence of 30 - 50 cases per million (Peacock, 2003).  PAH 
patients may develop some of the following symptoms: breathlessness, dizziness, fainting, 
chest pain, palpitations and increased lethargy.  As these symptoms are non-specific, i.e., 
they may be caused by conditions other than PAH, diagnosis is extremely difficult.  Right 
heart catheterisation is essential to confirm diagnosis and determine prognosis (Gaine, 
2000).  This investigation measures mean pulmonary arterial pressure, right atrial pressure 
and cardiac output.  There are four functional classes for PAH in table 1.2 with class I 
being the least severe and class IV being the most advanced. 
 
The prognosis for patients with PAH is poor, with the median length of survival after 
diagnosis being 2.8 years (Gaine et. al., 1998).  The current drug therapy for PAH depends 
on the underlying disease (see table 1.1), and treatment is dictated by severity of disease 
and symptoms.  Available drugs used to treat PAH fall into one of four pharmacological 
classes, PGI2 analogues, endothelin receptor antagonists, phosphodiesterase type V 
inhibitors and Ca
2+
 channel blockers (Takaoka, 2007).  The rationale for the use of diuretics 
is provided because of their ability to reduce blood volume, and therefore blood pressure, 
which would reduce right ventricular pre-load (Baumhakel et. al., 2005).  For PAH patients 
whose lungs are still vasoreactive, i.e. when their lungs still have the ability to respond to 
local mediators, targeted drug treatment can be provided.  Ca
2+ 
channels blockers have been 
used in the treatment of PAH, however in clinical trials it was shown that only 10 – 25 % of 
patients with PAH responded to treatment with Ca
2+ 
channel blockers (Rich et. al., 1992; 
Sitbon et. al., 1998).  PGI2 has also been used in the treatment of PAH.  This prostanoid has 
been shown to vasodilate pulmonary vessels, inhibit platelet aggregation and inhibit 
PASMC proliferation.  As PGI2 is very unstable, more stable analogues have been designed 
for the treatment of PAH, and include epoprostenol.  Epoprostenol has been shown to 
improve long term survival for patients with PAH (McLaughlin et. al., 2002; Kim et. al., 
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2003).   Epoprostenol was the first treatment approved by the Food and Drug 
Administration for IPAH, and is suitable for patients with advanced disease (Patients with 
class IV symptoms – see table 1.2) and for those failing other treatments (O’Callaghan et. 
al., 2007).  A third type of drug therapy includes the use of ET receptor anatgonists, as ET 
has been shown to induce pulmonary vasoconstriction, and proliferation of fibroblasts and 
SMCs.  ET acts on two receptors on the PA, action on ET-A receptors results in 
vasoconstriction and proliferation of PASMCs and action on ET-B receptors on endothelial 
cells results in an increase of NO and PGI2 production.   An increase in circulating ET and 
ET-A receptors have been shown in patients with PAH (Stewart et. al., 1991).  Bosentan is 
an ET receptor antagonist with a higher affinity for ET-A relative to ET-B (Clozel et. al., 
1994), and has been shown to be beneficial in patients with PAH (Rubin et. al., 2002).  
Another strategy which is being used to treat PAH, is the NO induced vasodilation 
pathway.  This mediator induces vasodilation of the underlying PASMC in part by 
increasing the levels of cGMP, a second messenger in SMCs.  Increased cGMP levels 
results in PASMC relaxation.  cGMP is degradated by the enzyme phosphodiesterase 5 
(PDE5),  and  by inhibiting the action of PDE5, the action of cGMP can be prolonged.  
Sildenafil is a PDE5 inhibitor and is currently being used to treat patients with PAH.  As 
PDE5 expression is higher in pulmonary vessels relative to other organs (Corbin et. al., 
2005), sildenafil induces selective pulmonary vasodilations without undesirable systemic 
effects (Ghofrani et. al., 2006).  In the Sildenafil Use in Pulmonary Hypertension trial, 
sildenafil was shown to improve exercise capacity, symptoms and heamodynamics in 
patients with PAH (Galie et. al.,  2005). 
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New York Health Association/ World Health Organisation Classification of functional 
status of patients with pulmonary hypertension:  
-------------------------------------------------------------------------------------------------------------- 
 
I Patients with pulmonary hypertension in whom there is no limitation of usual 
physical activity; ordinary physical activity does not cause increased dyspnoea, 
fatigue, chest pain or pre-syncope.  
 
II  Patients with pulmonary hypertension who have mild limitation of physical activity. 
There is no discomfort at rest, but normal physical activity causes increased 
dyspnoea, fatigue, chest pain or pre-syncope.  
 
III Patients with pulmonary hypertension who have a marked limitation of physical 
activity. There is no discomfort at rest, but less than ordinary activity causes 
increased dyspnoea, fatigue, chest pain or pre-syncope.  
 
IV  Patients with pulmonary hypertension who are unable to perform any physical 
activity and who may have signs of right ventricular failure at rest. Dyspnoea and/or 
fatigue may be present at rest and symptoms are increased by almost any physical 
activity.  
 
 
 
Table 1.2 New York Heart Association/ World Health Organisation Classification 
of functional status of patients with pulmonary hypertension.   
This classification has been used to determine treatment for patients with pulmonary 
hypertension.  (Table taken from Barst et. al., 2004) 
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1.5.4  Pathobiology of pulmonary arterial hypertension 
PAH has multifactorial pathology.  Vascular wall remodelling and vasoconstriction are 
seen in the PAH disease process (Mandegar et. al., 2004), with pulmonary vasoconstriction 
believed to be an early characteristic of the disease (Wood, 1958).  The primary 
pathological changes in the vasculature lead to elevation in PVR and PAP.  An increase in 
resistance will result in increased pulmonary pressure.  In PAH the increase in PAP leads to 
an increase in right ventricular after load which is the pressure against which the right 
ventricle has to work in order to push the blood into the pulmonary circulation.  If this 
continues, over time it leads to right ventricular hypertrophy and reduced contractility.  
This leads to right heart failure in PAH patients (Mandegar et. al., 2004).  Cellular pathway 
abnormalities have been described that have a major impact during the development of 
PAH.  These include impaired endothelial cell function, dysfunction or altered expression 
of K
+
 channels in PASMCs, altered 5-HTT regulation in PASMCs, oxidant stress and 
enhanced matrix production (Rubin et. al., 2004).  Evidence shows that PAH is associated 
with a change in both the rates of cell proliferation and apoptosis, which results in 
thickened and sometimes obstructed pulmonary arteries (Humbert et. al., 2004), and these 
two processes can involve all cells that make up the vascular walls of the PAs including 
PASMCs, endothelial cells, fibroblasts and connective tissue fibres.  In PAH, pulmonary 
vascular resistance is increased (Voelkel et. al., 1997) due to vasoconstriction, remodelling 
and thrombosis. 
 
1.5.4.1  Vasoconstriction 
Vasoconstriction is thought to occur early during PAH. The pulmonary vessels constrict 
and narrow, causing an increase in pulmonary blood pressure and resistance to flow.  
Dysfunction of PA endothelial cells plays a critical role in the development of PAH.  In 
PAH there is a reduction in the endothelial production of PGI2 and NO and an increase in 
the amount of ET produced, resulting in vasoconstriction (Humbert et. al., 2004).  The 
humoral factors that potentiate pulmonary hypertension are generally vasoconstrictors, such 
as ET (Eddahibi et. al., 1995).   
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1.5.4.2  Remodelling 
Remodelling of blood vessels involves all layers within the blood vessel wall and is 
complicated by cellular heterogeneity within each compartment of the blood vessel wall 
(Jeffery et. al., 2002).  Within the arteries, there is intimal thickening and fibrosis, medial 
hypertrophy and adventitial changes (Olschewski et. al., 2001).   
 
The earliest structural change seen in PAH is the muscularisation of the terminal portion of 
the pulmonary arterial circulation (see figure 1.4).  The extension of PASMCs into small 
peripheral, normally non-muscularised pulmonary arterioles is a common PAH feature 
(Humbert et. al., 2004).  This is due to hyperplasia of SMCs extending distally in a layer 
internal to the original internal elastic lamina (Heath et. al., 1987), and differentiation of 
precursor cells  into SMCs (Meyrick & Reid, 1980a), and is termed neomuscularisation 
(figure 1.4).  The proximal muscular arteries are subjected to higher intraluminal pressure 
secondary to the vasoconstriction and remodelling of peripheral arteries, which results in a 
reduction in vessel lumen diameter due to the hypertrophy of PASMCs (Hislop et. al., 
1976).  Also seen in PAH is a layer of myofibroblasts and extracellular matrix formation 
between the endothelium and the internal elastic lamina, known as the neointima (Humbert 
et. al., 2004).  Another remodelling feature is adventitial hypertrophy (Chazova et. al., 
1995).  In PAH, adventitial thickening with increased
 
extracellular matrix deposition is 
prominent in the small,
 
muscular PAs (Stenmark et. al., 1997).   
 
These three forms of remodelling can lead to the formation of plexiform lesions within the 
lungs (figure 1.5 & figure 1.6).  These are a mass of disorganised vessels with endothelial 
cells, SMCs, myofibroblasts, and macrophages.  Plexiform lesions are mainly made up of 
proliferating endothelial cells.  These lesions can occlude the lumen of small PAs 
completely (Tuder et. al., 1994).  Plexiform lesions are relatively typical, and they are also 
seen in other forms of PH (Lee et. al., 1998).   
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   (A)       (B)   
 
 
Figure 1.4  Diagrams of pulmonary arteries in the lung. 
A. The normal situation of uneven distribution of PASMC phenotypes and non-
muscular pre-capillary arterioles. 
B. In the pulmonary hypertensive lung there is progression of muscularisation into the 
non-muscular terminal parts of the arterial tree.  (Figure from MacLean et. al., 
2000).
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Figure 1.5    Images of remodelling 
of small muscular PA. 
Image taken from NIH Publication 
No 96- 3291 (1996) 
 
 
 
A. Normal small PA 
B. PA wall becomes more 
muscularised 
C. Fibrous tissue lines the inner wall 
of the small PA 
D. Fibrous tissue builds up around 
the inner wall of the PA, leading 
to narrowing of the PA 
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Figure 1.6 Image of a plexiform lesion. 
There is a tuft of capillaries forming a web that is present in the lumen of a dilated artery.  
(Zabka et. al., 2006) 
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1.6  The 5-HT hypothesis of PAH 
During the period 1967 - 1973 an unexplained epidemic of PAH occurred in Europe.  This 
was the scale of a ten-fold increase in PAH occurrence.  It was caused by the sale of an 
over the counter appetite suppressant, aminorex.  This amphetamine-like drug was brought 
onto the market in 1965 and removed after the outbreak of PAH (Fishman, 1999).  In the 
1980s a second outbreak of PAH happened in France, and this also occurred due to 
anorexigen prescription.  The drug in question this time was fenfluramine (Douglas et. al., 
1981).  Investigations involving fenfluramine derivatives (DL-fenfluramine and 
dexfenfluramine) have also shown that use of these drugs resulted in pulmonary 
hypertension (Brenot et. al., 1993).  Fenfluramines like aminorex, are congeners of the 
amphetamines.
  
Another strategy in the treatment of obesity was to prescribe fenfluramine 
and phentermine (which is a constitutional isomer of methamphetamine) in combination, 
resulting in equivalent weight loss, fewer adverse effects, and better appetite control 
(Weintraub et. al., 1984), however cases of pulmonary hypertension were found in response 
to this treatment (Mark et. al., 1997).  A multicentre study was carried out called the 
International Primary Pulmonary Hypertension study, and it reported a strong association 
between prior use of anorexigens and PAH (Abenhaim et. al., 1996).  It was stated that the 
risk
 
for obese persons who use anorexic agents for more than three
 
months would be more 
than 30 times higher than for non-users (Abenhaim et. al., 1996). 
 
Aminorex, fenfluramine, dexfenfluramine, and phentermine belong to a class of 
amphetamine-like drugs that interact with monoamine systems in the brain.  Fenfluramine 
increases synaptic cleft concentrations of 5-HT through the inhibition of neuronal reuptake 
(Mennini et. al.  1985) and potentiation of 5-HT release from stores in rat brain tissue 
(Costa et. al., 1971).  Fenfluramines also cause an elevation in plasma 5-HT levels by 
inducing 5-HT release from neurones and platelets, and inhibiting reuptake of 5-HT by the 
5-HTT (Herve et. al., 1995).  Dexfenfluramine
 
both inhibits the 5-HTT (Semple et. al., 
1996) and increases exocytotic release
 
of 5-HT (Gobbi et. al., 1993). Aminorex has similar 
actions, and induces release of 5-HT from platelets, inhibits 5-HT reuptake and inhibits 5-
HT metabolism by monoamine oxidase (MAO), collectively resulting in an elevation in 
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plasma 5-HT levels (Humbert, et. al., 2004).  Phentermine has been shown to increase the 
5-HT levels by inhibiting 5-HT degradation via MAO (Ulus et. al., 2000). 
 
5-HT is synthesised by the intestinal enterochromaffin
 
cells, and is actively loaded into 
platelets where it is stored.  5-HT circulates mainly as a reserve pool
 
stored in platelets and 
minimally in plasma with up to 98 % of 5-HT in the body found within platelets.  Free 5-
HT in the plasma is rapidly metabolised in the liver and lung (Hart & Block, 1989).  
Another reason that the pulmonary vascular bed is not exposed to high levels of 5-HT is 
because of the position of the lungs, with the lung being a secondary filter, downstream 
from the liver.  5-HT is released from pulmonary neuroendocrine cells and neuroepithelial 
bodies within the airways.  Airway hypoxia induces secretion of 5-HT from neuroendocrine 
cells and neuroepithelial bodies into the bloodstream (Fu et. al., 2002), which may 
contribute to secondary PAH (Johnson & Geiorgieff, 1989).  The 5-HT hypothesis of PAH 
is strengthened by reports linking increased plasma 5-HT and PAH.  Cases have been 
identified in which patients have increased plasma 5-HT levels caused by a platelet storage 
disease, and who also have PAH (Herve et. al., 1990), and cases have been described where 
patients have PAH associated with elevated serum 5-HT levels (Herve et. al., 1995).  The 
normal plasma concentration of 5-HT is 1 – 2 nM, however this can be elevated to 30 nM 
in conditions of PH (Herve et. al., 1990; 1995; Anderson et. al., 1987). 
 
A number of animal models of PAH support the 5-HT hypothesis of PAH.  The fawn-
hooded rat has a genetic deficit in 5-HT platelet storage which is characterised by the 
deficient uptake of 5-HT into platelets (Aulakh et. al., 1994).  Fawn-hooded rats develop 
PAH from the age of four weeks and this can be accelerated by exposure to altitude 
(Marsboom & Janssens 2004).  Mild hypoxia exposure causes the development of PAH in 
fawn-hooded rats (Sato et. al., 1992).
 
Chronic hypoxic rat models are frequently used to 
investigate PAH.  In conditions of chronic hypoxia, PASMC proliferation and a sustained 
elevation in PAP occurs (Eddahibi et. al., 1998).  In chronic hypoxic mice, structural 
remodelling occurs within the vessels of the lung; muscularisation has been found in 
arterioles, which previously were non-muscular, with vessels which had this 
muscularisation prior to hypoxia having an increased muscular layer (Wohrley et. al., 
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1995).  The result of structural changes within the vasculature leads to an increase in 
resistance of these vessels and an increase in right ventricular workload.  Therefore this 
model represents PAH in that it is characterized by vascular proliferation and remodelling.  
PAH develops following reduction of atmospheric pressure or following reduction of the 
partial oxygen tension at atmospheric pressure (Marsboom & Janssens 2004), and this 
stimulus has been used to study PAH.  Mice lacking the 5-HTT gene (5-HTT-/- mice) have 
been exposed to chronic hypoxia.  5-HTT transports 5-HT into the PASMC from the 
bloodstream (see section 1.6.1.1).  In the chronic hypoxic 5-HTT-/- mouse, 5-HT blood 
concentration was also lower in the 5-HTT-/- mice relative to controls.  This result was 
expected since platelet 5-HT contributes largely to whole blood 5-HT.  The main finding 
of the study was that mice deficient in 5-HTT developed less PAH than controls when 
exposed to hypoxia suggesting that 5-HTT is important in the development of PAH 
(Eddahibi et. al. 2000).  Mice over-expressing 5-HTTs have been generated and used to 
study PAH (MacLean et. al., 2004).  Transgenic mice with 5-HTT over-expression
 
occurring selectively in PASMCs have been shown to spontaneously develop PAH 
(Guignabert et. al., 2006).   
 
1.6.1 5-HT pharmacology  
5-HT (also known as serotonin) was first discovered in 1948, when it was isolated from 
blood serum (Rapport et. al., 1948a).  In 1949, the chemical structure of this compound 
was found to be 5-hydroxytryptamine (Rapport et. al., 1949).  5-HT is found in high 
concentrations within the intestine, blood and the CNS.  5-HT is synthesised (figure 1.7) in 
a two step process from the amino acid precursor, tryptophan, which is converted to 5-
hydroxytryptophan via the enzyme tryptophan hydroxylase (Tph).  There are two genes 
which encode tryptophan hydroxylase, Tph1 and Tph2, with Tph1 catalysing the rate-
limiting step in
 
the synthesis of 5-HT in the periphery (Walther & Bader, 2003).  Recently 
it was shown that Tph1 and peripheral 5-HT are critical to the
 
development of hypoxia 
induced PAH (Morecroft et. al., 2007).  The proposed role of 5-HT in the PAH disease 
process is further strengthened by the findings that expression of the Tph1 gene is 
increased
 
in lungs and pulmonary endothelial cells from patients with
 
idiopathic PAH 
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(Eddahibi et. al., 2006).  5-Hydroxytryptophan is decarboxylated by L-aromatic acid 
decarboxylase to form 5-HT.  Metabolism of 5-HT occurs via oxidative deamination, 
catalysed by MAO, the product of which is then converted to 5-hydroxyindoleacetic acid 
via aldehyde dehydrogenase.  5-HT
 
is preferentially metabolised by type A monoamine 
oxidase (Weyler et. al., 1990). 
 
1.6.1.1  5-HT transporter 
A 5-HT transporter (known as 5-HTT/ SERT) has been identified and cloned (Hoffman et. 
al., 1991; Ramamoorthy et. al., 1993).  The 5-HTT protein is composed of ~ 630 amino 
acids, which form twelve transmembrane (TM) domains with both the amino and carboxyl 
termini on the intracellular side of the membrane (Ni & Watts, 2006).  5-HTT is present in 
many tissues including platelets and nerve endings, and is also abundantly expressed in the 
lung, where it is predominantly located on PASMCs (Ramamoorthy et. al., 1993).  5-HTT 
is sodium (Na
+
) dependant, and it acts to remove 5-HT from the extracellular environment 
and transport it into the cell, where it can be metabolised or repackaged into vesicles (Ni & 
Watts, 2006).  A model has been proposed for the transport of 5-HT via the 5-HTT: one 
sodium ion (Na
+
) binds to the extracellular portion of the protein, then 5-HT
+
 binds to the 
transporter and this is followed by one chloride (Cl
-
) ion (Nelson & Rudnick, 1979).  The 
driving force for this co-transport of Na
+
, Cl
-
 and 5-HT into the cell arises from the Na
+
 
concentration gradient across the cell membrane.  The Na
+
 concentration gradient arises 
from the action of Na
+
/ K
+
 ATPase, which acts to pump K
+
 into the cell and Na
+ 
out of the 
cell against their respective concentration gradients.  The binding of Na
+
, Cl
-
 and 5-HT 
results in a conformational change of the 5-HTT protein which causes it to move from 
facing extracellularly to facing intracellularly upon which 5-HT
+
, Na
+
 and Cl
-
 are released 
into the cytoplasm (Nelson & Rudnick, 1979).  K
+
 within the cytoplasm then bind to the 5-
HTT, which induces the protein to return to its original orientation, and the K
+
 is then 
released into the extracellular environment (Nelson & Rudnick, 1979; Ni & Watts, 2006).  
The result is an overall decrease in the concentration of 5-HT within the extracellular 
environment, hence reduced activation of 5-HT receptors. 
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Figure 1.7 5-HT synthesis and metabolism 
5-HT is synthesised from dietary tryptophan.  Tryptophan is converted to 5-
hydroxytryptophan by the enzyme tryprophan hydroxylase (Tph).  5-hydroxytryptophan is 
then converted to 5-HT by a non-specific decarboxylase. Degradation of 5-HT to 5-
hydroxyindoleacetic acid occurs via the enzyme MAO-A 
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1.6.1.2  5-HT receptors and expression in pulmonary arteries 
The first suggestion that there was more than one 5-HT receptor came from work on guinea 
pig ilieum, as it was found that only part of the 5-HT induced contractile response was 
blocked by morphine (Gaddum & Picarelli, 1957).  Continued research and molecular 
biology techniques have to date identified at least seven classes of 5-HT receptor according 
to their structural, operational, and transduction pathways (Alexander et. al., 2006). 
Alternative splicing occurs within the 5-HT super family of receptors resulting in the 
isoforms of the 5-HT2A, 5-HT2C, 5-HT4 and 5-HT7 receptors (Guest et. al., 2000; Canton 
et. al., 1996; Gerald et. al., 1995).  Molecular diversity also arises from RNA editing, 
which occurs within the 5-HT2C family of channels (Burns et. al., 1997).  5-HT receptors 
belong to the GPCR superfamily, with the exception of the 5-HT3 receptor, which is a 
ligand-gated ion channel (Pauwels, 2000).  GPCR receptors have seven transmembrane α-
helices, with an extracellular N terminus and intracellular C terminus (Kroeze et. al., 2003).  
Upon binding of 5-HT to the extracellular portion of the receptor, G-proteins are activated, 
which initiate second messenger signalling pathways (figure 1.8).  G-proteins consist
 
of 
alpha (α), beta (β), and gamma (γ) subunits.  G-proteins are classified by their alpha 
subunit, which have been divided into four families, known as Gαs, Gαi, Gαq/11, and 
Gα12/13.  These groups differ primarily in effector recognition, but share a similar 
mechanism of activation (Neves et. al., 2002).  5-HT acts on various receptors and 
therefore has different effects within cells according to the signalling/ effector pathway 
activated.  5-HT1 and 5-HT5 receptors are linked to inhibitory G-proteins (Gαi), 5-HT4, 6, 
7 are linked to stimulatory G-proteins (Gαs) (Alexander et. al., 2006; Noda et. al., 2004), 
and 5-HT2 receptors couple preferentially to Gαq proteins (Hoyer et. al., 2002). 
   
The 5-HT1 receptor family has been subdivided into 5-HT1A, 1B, 1D, 1E & 1F (Alexander 
et. al., 2006).  In the past it was thought that the 5-HT1B receptor was exclusively 
expressed in rodent (hamster, mouse, and rat) tissues, whereas the closely related 5-HT1D 
receptor was believed to be expressed in other species (humans, cows, dogs, and guinea 
pigs), which lead to suggestion that the 5-HT1B and 5-HT1D receptors were species 
homologues (Hoyer & Middlemiss, 1989).  It has since been shown that that 5-HT1B and 
5-HT1D receptors are not pharmacologically identical, with selective pharmacological 
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agents being used to distinguish between them (Price et. al., 1997).  Subsequent studies 
have now shown that the 5-HT1B and 5-HT1D receptors are separate gene products which 
are not exclusively expressed in rodent or non rodent mammals (Hamblin et. al., 1992).  In 
cases where 5-HT1B and 5-HT1D receptors could not be distinguished, the receptor was 
referred to as the 5-HT1B/1D receptor.  The major signalling pathway of the 5-HT1 
receptor family is the adenylate cyclase (AC)/ cAMP system (Sumner et. al., 1992; 
Alexander et. al., 2006) (diagram 1.8).  5-HT1 GPCRs are linked to Gαi proteins that 
inhibit AC, which would otherwise catalyse the conversion of ATP to cAMP.  5-HT1 
receptors have been shown to couple to differential signalling cascades, depending on the 
cell line the receptor is expressed in.  Some of the 5-HT1 receptors have also been linked to 
phosphatidylinositol
 
(PI) hydrolysis through activation of phospholipase C (PLC) (Hoyer 
et. al., 1994).  This hydrolysis gives rise to the second messengers diacylglycerol (DAG) 
which activates protein kinase C (PKC) (Nishizuka, 1988),
 
and inositol trisphosphatase 
(IP3) which acts to increase [Ca
2+
]i (Berridge, 1993).   
 
Within the 5-HT2 family there are three subfamilies, 5-HT2A, 2B & 2C (Alexander et. al., 
2006).  The 5-HT2A receptor has 45% amino acid sequence homology with the 5-HT2B 
receptor (Hamblin et. al., 1992).  Signalling transduction from 5-HT2 receptors is mediated 
via the action of Gαq G-proteins.  Gαq proteins couple to PLCβ effector pathway.  
Therefore 5-HT2 receptor activation results in PI hydrolysis through activation of PLCβ 
giving rise to IP3 and DAG (Hoyer et. al., 1994; Alexander et. al., 2006). 
 
 
 
To date several 5-HT receptors have been found in PAs.  In rabbit PAs, mRNA for the 
following receptors has been identified: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3A, 5-HT3B, 5-
HT4, 5-HT6 and 5-HT7.  The expression of 5-HT1A was found at a much lower level than 
that of the other receptors (Molderings et. al., 2006).  5-HT1B/1D, 5-HT2A, 5-HT2B, 5-
HT4 and 5-HT7 receptor mRNA has been found in porcine PAs.  A similar profile of 
receptors was also found in cultured human PASMCs with the exception of 5-HT4 (Ullmer 
et. al., 1995). In PAs, 5-HT1B/1D and 5-HT2A receptors have been shown to mediate the 
contractile response to 5-HT in functional and binding studies (MacLean et. al., 1996; 
Morecroft et. al., 1999). 
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Figure 1.8 Signalling cascades of the 5-HT G-protein coupled receptors. 
Signalling cascades of the G-protein coupled 5-HT receptors. 5-HT1 receptors typically 
inhibit AC through the Gαi family of G-proteins, whereas 5-HT4, 5-HT6, and 5-HT7 
receptors typically stimulate AC through Gαs family G-proteins. Activation of AC results 
in increased production of cAMP, leading to activation of protein kinase A (PKA). 5-HT2 
receptors activate PLC-β through Gαq family G-proteins, resulting in accumulation of PIP2 
to IP3 and DAG. Generation of IP3 results in elevation [Ca
2+
]i, whereas DAG activates 
PKC.  Figure adapted from Raymond et. al., (2001). 
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1.6.2 5-HT and PAH 
5-HT has a dual effect on pulmonary vasculature.  5-HT has been shown to induce PA 
vasoconstriction and PA remodelling, two important characteristics of PAH (figure 1.9). 
 
1.6.2.1  5-HT and pulmonary vasoconstriction 
5-HT is known to have a pressor effect on the lung vasculature.  Pharmacological studies 
have been carried out to investigate the identity of receptors involved in the 5-HT-induced 
contraction of pulmonary arteries.  There is a species difference in the mechanism by which 
5-HT causes this effect.  In rat, mouse, cow and dog pulmonary arteries, 5-HT causes 
vasoconstriction via the 5-HT2A receptor (Chand et. al., 1980; MacLean et. al., 1994 & 
1996; Witzenrath et. al., 2006).  In comparative studies using human large pulmonary 
arteries, 5-HT was found to act via the 5-HT2A and 5-HT1B receptors (Morecroft et. al., 
1999).   
 
The specificity of 5-HT receptor agonists and antagonists has been used to identify the 
receptors involved in 5-HT responses.  5-HT and sumatriptan (a 5-HT1B/1D agonist), 
caused vasoconstriction of human small muscular pulmonary arteries.  The response to 5-
HT was inhibited by ketanserin (a selective 5-HT2A antagonist) at concentrations of 5-HT 
which were considered pathological (> 0.1 µM), however GR55562 (5-HT1B/1D-selective 
antagonist) inhibited 5-HT-induced contractions at all concentrations of 5-HT tested.  SB-
224289 (a selective antagonist for 5-HT1B receptors) and BRL15572 (a selective antagonist 
for 5-HT1D receptors) were tested on the sumatriptan-induced vasoconstriction, and only 
SB-224289 inhibited the response indicating the importance of 5-HT1B receptors in 
mediating vasoconstriction in human small muscular arteries (Morecroft et. al., 1999).  
Drugs that block 5-HT1B receptors could prove to be beneficial in the treatment of PAH.  
As it is the 5-HT2A receptor that is important for mediating vasoconstriction effects in the 
systemic system (Saxena & Villalon, 1990), 5-HT1B antagonists would not cause systemic 
hypotension (Herve et. al., 1995; MacLean et. al., 2000). 
 
An uncovering of receptor participation in the 5-HT induced vasoconstriction response has 
been shown to occur in the presence of tone in the PA.  In bovine PAs, sumatriptan failed to 
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induce vasoconstriction under basal conditions. However, when thromboxane-mimetic 
U46619 was added to the preparation to induce tone, sumatriptan induced a potent 
vasoconstriction. In the absence of tone, 5-HT responses were shown to be mediated by 5-
HT2A receptors whereas in the presence of tone, 5-HT activated 5-HT1D/1B receptors to 
induce the vasoconstriction response (MacLean et. al., 1994).  In chronic hypoxic rats, 
whose endogenous pulmonary arterial tone was increased relative to control rats (in both 
large and resistance arteries), 5-HT induced contraction was mediated by both 5-HT2A 
receptors and 5-HT1B receptors (Maclean et. al., 1996).  The involvement of the 5-HT1 
receptors in the presence of tone can be seen as an example of pharmacological synergism.  
This phenomenon describes a situation in which a greater than additive effect (synergism) 
results from the amplification of signal transduction signals resulting from crosstalk 
between two GPCRs, and could lead to the unmasking of receptors that are otherwise 
‘silent’.  For example in rat small PAs, increased vascular tone via either Gαq-coupled 
receptor activation or elevated KCl potentiated Gαi-coupled 5-HT1 receptor-induced 
vasoconstriction (MacLean & Morecroft, 2001).  
 
1.6.2.2  5-HT and pulmonary vascular remodelling 
5-HT is a known mitogen for SMCs isolated from bovine, porcine and rat aorta and it is a 
potent inducer of rat and bovine PASMC proliferation (Lee et. al., 1991, Eddahibi et. al., 
1999b, Pitt et. al., 1994). Proliferation of PASMCs has been shown to be an important 
factor in PA remodelling seen in PAH, and 5-HTT over-expression has been shown to be 
associated with PASMC hyperplasia in patients with PAH (Eddahibi et. al., 2001).  The 
mechanism by which 5-HT induces PA hyperplasia involves the transport of 5-HT into 
PASMCs.  Evidence for this was provided using the 5-HTT blockers, fluoxetine and 
paroxetine.  These drugs inhibit both 5-HT uptake and 5-HT induced SMC proliferation at 
similar concentrations, which suggests that 5-HT uptake and 5-HT-induced PASMC 
proliferation are related (Eddahibi et. al., 1999b).  The proliferation response of PASMC to 
5-HT was blocked by drugs which block 5-HT transport, but not by antagonists of 5-HT 
receptors, in bovine vessels (Lee et. al., 1991).  These results indicate that 5-HT needs to be 
taken into the PASMC to induce its mitogenic effect (see figure 1.10).   
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Figure 1.9 Diagram showing the effects of 5-HT on a PASMC.   
5-HT is synthesized in the PA endothelial cells by Tph1. 5-HT can then influence PASMC 
proliferation and/or contraction via activity at the 5-HTT and 5-HT receptors (particularly 
the 5-HT1B receptor in humans).  Figure adapted from Dempsie & MacLean, (2008)  
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Figure 1.10 Diagram illustrating the proposed role of 5-HTT in the development of 
vascular medial hypertrophy.   
5-HT interacts with 5-HTT on the cell membrane, which leads to activation of GTPase-
activating protein (GAP) and/or Ras and/or Rac. The ensuing signal leads to the formation 
and release of ROS, which in turn activates extracellular signal-regulated kinase (ERK)-1 
or ERK-2 and mitogen-activated protein (MAP) kinases. This results in upregulation of the 
expression of genes involved in both cellular hypertrophy and proliferation.  Figure adapted 
from Mandegar et. al., (2004) 
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The proposed intracellular signalling response is 5-HT entry via 5-HTT, which results in 
activation of GTPase-activating protein (GAP) and/or Ras and/or Rac. These intracellular 
molecules induce the formation and release of reactive oxygen species (ROS), which in 
turn activates extracellular signal-regulated kinase (ERK)-1 or ERK-2 and mitogen-
activated protein (MAP) kinases (Lee et. al., 1999). The signalling cascade result is 
upregulation of the expression of genes involved in both cellular hypertrophy and 
proliferation (Mandegar et. al., 2004).  
 
1.6.4 The role of PASMC membrane potential in 5-HT uptake  
The transport of 5-HT into PASMC via 5-HTT is coupled directly to the electrochemical 
potential associated with the co-transported ions.  The removal of 5-HT from the plasma 
has been shown to be closely linked to the Na
+
/ K
+
 ATPase by studies in which removal of 
Na
+
 from the extracellular environment inhibited the uptake of 5-HT, and similar removal 
of K
+
 inhibited 5-HT uptake by about one third (Dubilei, 1976).  The action of Na
+
/ K
+
 
ATPase maintains the ionic gradients of K
+
 and Na
+
 across the membrane, which in turn 
helps to determine the membrane potential of the PASMC. 
 
1.7  K+ and membrane potential of PASMCs 
The resting membrane potential arises from the movement of ions across the PASMC 
membrane.  Partly due to the electrogenic nature of the Na
+
/K
+
 ATPase, pumping three Na
+
 
out of the cell for every two K
+
 it brings into the cell, the membrane potential is negative at 
rest.  Na
+
/K
+
 ATPase action results in a high [K
+
]i.  This results in a net electrochemical 
gradient being established that favours the passive movement of K
+
 out of the cell (Al-
Habori, 1994).  The resting membrane is more permeable to the movement of K
+
 relative to 
any other ions, and therefore the resting membrane potential arises partly from K
+ 
ion 
efflux along its electrochemical gradient (Nelson & Quayle, 1995), and this drives the 
membrane potential towards the Nernstian K
+
 equilibrium potential for K
+
 (EK = ~ 80 mV) 
(Gurney et. al., 2002).  However, the outward movement of K
+
 ions is opposed by a non-
specific leakage conductance, the distinct permeability of the membrane to other ions such 
as Ca
2+
, Na
+
 and Cl
-
 results in the resting membrane potential being more depolarised 
(positive) than EK.  The actual membrane potential of PASMCs is approximately –50 mV 
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to –60 mV, found in both intact and isolated preparations of PASMCs (Casteels et. al., 
1977; Suzuki & Twarog 1982; Clapp & Gurney, 1992).  There is universal consensus that 
the resting potential of PASMCs is determined mainly by a non-inactivating K
+
 
conductance, IKN (Gurney et. al., 2002; 2003).  However, there is debate as to the specific 
K
+
 channels that transmit the current which maintains resting membrane potential in 
PASMCs.  
 
The link between vessel tone and K
+
 channel activity is the membrane potential.  As K
+
 
channels set the membrane potential in SMCs, they control the possibility of voltage 
operated Ca
2+ 
channels (VOCC) being open, and hence regulate Ca
2+
 entry into the cell 
(Nelson et. al., 1990).  Depolarisation of the membrane potential opens VOCCs, increasing 
Ca
2+ 
entry, which leads to vasoconstriction (Nelson & Quayle, 1995).  It has been suggested 
that reduced K
+
 current, leading to a depolarised PASMC membrane, in turn gives rise to 
increased Ca
2+
 within the cytoplasm and this may play a critical role in stimulating PASMC 
contraction and proliferation (Platoshyn et. al., 2000).  
 
1.7.1 K+ channels – general features 
K
+
 ion channels are membrane-spanning proteins with three functional properties: (1) a 
central pore through
 
which ions flow along their electrochemical gradient, (2) a selectivity
 
filter that determines what types of ion are transmitted through the pore,
 
and (3) a gating 
structure that controls when the pore opens
 
and closes therefore dictating whether 
permeation
 
occurs.  There are a number of K
+
 channels found in PASMCs.  Each specific 
K
+
 channel is assigned to a family by structure, with all K
+
 channels being related members 
of a single protein family.  They consist of a primary pore-forming α-subunit, often 
associated with accessory or regulatory β-subunits.  A common feature between all K
+
 
channel α-subunits is that they contain a “P loop” domain.  This is an amino acid segment 
between two trans-membrane helices that dips into the membrane without fully crossing it.  
K
+
 channel P-loops have a consensus amino acid sequence (Thr-Val-Gly-Tyr-Gly) that has 
been called the K
+
 channel ‘’signature sequence’’(Doyle et. al.,  1998).  This sequence has 
been proposed to correspond to the selectivity filter of the aqueous pore forming region of 
the channel protein (Doyle et. al., 1998).  K
+
 channels are tetrameric and therefore four 
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copies of the filter motif come together to form the pore (Sansom et. al., 2002).  The pore 
forming α-subunits may form homomeric or heteromeric channels between subfamilies.  
There are more than seventy different genes encoding K
+
 channel α-subunits in the human 
genome.  The criterion for the sub-grouping of K
+
 channels is the number of TM regions 
possessed by the α-subunits. 
 
1.7.1.1  Families of K+ channels 
K
+
 channels have been sub-grouped into three main groups based on their structural 
properties: 2TM, 4TM and 6TM K
+
 channels (figure 1.11 and 1.12). While all these 
channels are selective for K
+
 over other ions, they exhibit distinct biophysical properties. 
 
1.7.1.1.1 Two transmembrane domain (2TM) K+ channels 
The 2TM channels are also know as the inwardly rectifying K
+
 (KIR) channel family.  Each 
subunit contains a single pore domain between two membrane spanning regions (S1 and 
S2).  Both the N and C termini of these subunits are located intracellularly.  This KIR family 
of channels consists of 7 subfamilies (KIR1-7), which can be further subdivided.  KIR3 
channels are also known as G-protein regulated K
+
 channels (GIRK) and KIR6 channels are 
also known as ATP-sensitive K
+
 channels (KATP) (Alexander et. al.,  2006).   
 
Approximately two thirds of the KIR channel is found within the cell cytoplasm, and this 
domain forms a cytoplasmic pore (Nishida & MacKinnon, 2002).  This is the section of the 
channel which is crucial for modulation by intracellular gating compounds (Yang et. al., 
1995).  Inward rectification refers to the ability of an ion channel to allow greater influx 
than efflux of ions.  KIR channels conduct K
+
 ions from outside to inside the cell more 
readily than in the opposite direction (Doupnik et. al., 1995).   Inward rectification is 
induced by cytoplasmic ions such as polyamines and magnesium ions.  These ions plug the 
pore upon depolarisation and thereby inhibit the outward flow of K
+
 (Vandenberg, 1987; 
Matsuda et. al.,  1987; Lopatin et. al.,  1994).  Within this sub-group of K
+
 channels, they 
are differentiated from one another by their individual strength of rectification and gating.  
GIRK channels (KIR3) are strongly rectifying and activated by Gβγ.  KATP (KIR6.2) 
channels are weakly rectifying and gated by the ATP/ adenosine diphosphate (ADP) ratio 
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(Bichet et. al.,  2003).   KATP channels link the cell membrane potential to the metabolic 
status of the cell.  At physiological levels of intracellular ATP these KATP channels are 
inhibited, however, when ATP levels within the cell are reduced the KATP channels open.  
KATP channels are bound to a protein sulfonylarea receptor of the ATP-binding cassette 
(ABC) family and they are inhibited by sulfonylurea drugs (Demolombe & Escande, 1996).  
Another feature of KIR channels is that they can be regulated by phosphotidylinositol 4,5-
bisphosphate (PIP2) (Huang et. al.,  1998).  KIR channel opening requires PIP2 binding to 
basic cytoplasmic domains, whereas depletion of PIP2 seems to close the channel
 
(Huang 
et. al., 1998; Shyng et. al., 2000).  pH has also been shown to play a role in the regulation 
of some KIR channels, decreasing internal pH increased
 
the sensitivity of KIR1.1 channels to 
extracellular K
+
 by altering the properties
 
of the selectivity filter (Dahlmann et. al.,  2004). 
 
1.7.1.1.2 Four transmembrane domain (4TM) K+ channels 
Each of the subunits of these channels contains two rather than one pore-forming sequence.  
These channels contain two copies of the selectivity filter motif in one polypeptide chain, 
two chains merging to form the intact channel (Sansom et. al., 2002).  4TM channels have 
an extended extracellular loop between transmembrane segment S1 and the pore-forming 
segment P1 and a short cytoplasmic N-terminus (Salinas et. al., 1999).  This family 
includes seven different members: TWIK (tandem pore weakly inward-rectifying K
+
 
channel), TREK (TWIK-1 related K
+
 channel), TRAAK (TWIK-1 related
 
arachidonic acid-
stimulated K
+
 channel), TASK (two-pore domain acid-sensitive K
+
 channel), TALK (two-
pore domain alkaline-activated K
+
 channel), THIK (two-pore domain halothane inhibited 
K
+
 channel) and TRESK (TWIK-related spinal cord K
+
 channel) (Alexander et. al.,  2006).  
4TM domain K
+
 channels are also named
 
using an alternative nomenclature as KCNKx, 
where
 
x is a number indicating the order in which each member was
 
identified.  There are
 
17 members of this family, according to the Human
 
Genome Organization Nomenclature 
Committee database. 
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Figure 1.11 Diagram showing the α-subunits of each family of K+ channel.  
A) 2TM/P channels  
B) 6TM/P channels 
C) 4TM/2P channels  
Figure adapted from Choe, (2002) 
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Figure 1.12 Phylogenetic tree of K+ channels. 
The tree shown consists of only one representative member of each subfamily.  The 
branching shown is expected to preserve evolutionary relationships.  Figure adapted 
from Hille, (2001). 
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4TM K
+
 channels are voltage independent, remaining open at all membrane potentials.  
In this way they transmit leak K
+
 (background) currents, open at potentials where KV 
channels are closed.  For this reason these K
+
 channels are suggested to be responsible 
for mediating the background K
+
 ion current that is thought to set the resting membrane 
potential in several cells (Lesage et. al., 1996). 
 
TREK and TRAAK channel activity is mechanosensitive and activated by arachidonic 
acid (Patel et. al., 1998; Lesage et. al., 1996; Maingret et. al., 1999). TREK channels 
are also opened in response to heat, mild intracellular acidosis, and inhalation 
anaesthetics (Patel et. al., 1998; 1999; Maingret et. al., 2000).  TASK channels are 
sensitive to external pH variation and inhibited by mild external acidosis (Durprat et. 
al.,  1997; Leonoudakis et. al.,  1998). TWIK-1 is a weakly inward rectifying K
+
 
channel that is stimulated by protein kinase C (PKC) and inhibited by mild internal 
acidification (Lesage et. al.,  1997).  TALK channels are also pH sensitive, being 
inhibited by acidic conditions and activated by alkaline conditions (Johansson,  2003).  
THIK channels have been shown to transmit current that is activated by arachidonic
 
acid 
and inhibited by the volatile anaesthetic, halothane (Rajan et. al., 2000). 
 
1.7.1.1.3 Six transmembrane domain (6TM) K+ channels 
This is the main family of voltage gated K
+ 
(KV) channels.  Both the N and C termini of 
these subunits are located intracellularly.  Subfamilies of the α-subunits of KV channels 
arise from diverse gene coding.  These include KV1- KV6, KV8 and KV9 (Coetzee et. al., 
1999), and each subfamily can be subdivided again (KVX..X).  Accessory subunits 
attached to the α-subunits increases the diversity of KV channels and alters their 
biophysical and pharmacological properties.  These include auxiliary β-subunits, K
+
 
channel-associated proteins (KChAP), KV channel-interacting proteins (KChIPs), 14-3-
3 Proteins, and A-Kinase Anchoring proteins (AKAPs).  The KV7 sub-family of the KV 
family of K
+
 channels are also known as the KCNQ subfamily.  Another group of 6TM 
channels are known as KCa channels (BKCa, SKCa and IKCa).  BKCa channels have 7TM 
domains but are classified alongside the 6TMs.  SKCa and intermediate conductance KCa 
channels (IKCa) are voltage independent so classed separately from KV channels.  KV10, 
11 and 12 make up the ‘EAG’ subset of channels.  For the purposes of this study KV1-4, 
5-6, 8-12 will be referred to as KV
 
channels and KV7 channels will be referred to as 
KCNQ channels. 
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KV channels were named originally when they were identified in the fruit fly Drosphila 
melanogaster, and the first one identified was Shaker (Tempel et. al.,1987; Papazian et. 
al., 1987).  Following this channel, related channels were identified from Drosphila 
also, and these were Shab, Shaw and Shal, based on homology to Shaker. (Butler et. al., 
1989; Wei et. al., 1990). Shaker, Shab, Shaw and Shal channels are also found in 
mammals, and are named accordingly, with Shaker’s mammalian counterpart being 
named KV1, (Shab = KV2, Shal = KV3,  Shaw = KV4).  The membrane potential 
determines whether the channel is open, and therefore provides a means for the 
membrane voltage to feedback onto itself.  KV channels are activated by depolarisation, 
but exhibit a wide diversity of activation and inactivation kinetics.  When a voltage 
gated channel opens, charged amino acids move through the membrane electrical field, 
coupling electrical work to the opening process (Sigworth, 1994). Ongoing 
depolarisation causes some KV channels to open and then close, a process known as 
inactivation.  KV channels show inactivation with sustained depolarisation, with the rate 
of inactivation varying between subfamilies (Standen & Quayle 1998).  Certain KV 
channels inactivate slowly and these types are known as delayed rectifiers, and carry 
what is known as delayed rectifier K
+ 
current (IKDR).  IKDR exhibits little inactivation 
over a 100 – 200 ms depolarisation (Mathie et. al., 1998).  Other KV channels show 
rapid inactivation and carry transient outward current, known as the “A” current (IKA).  
Fast inactivation, which occurs on the order of milliseconds
 
to tens of milliseconds, is 
also referred to as N-type inactivation (Rasmusson et. al., 1998).  Fast inactivation of 
the KV channel occurs via a ‘ball and chain’ mechanism.  KV channels that undergo fast 
inactivation have an ‘inactivation ball’ that precedes the S1 domain of each α-subunit.  
This ‘inactivation ball’ is approximately 20 amino acids in length, found at the N-
terminal of the channel protein, and is connected to S1 by approximately 30 amino acids 
(also referred to as the chain region).  The function of the region is to plug the pore, and 
it does so by binding to the internal mouth of the channel upon activation (Hoshi et. al., 
1990).  It has been shown that only one ‘inactivation ball’ is enough to inactivate the 
channel (even though there are four ‘inactivation balls’ within the channel unit).   
 
KCNQ channels are encoded by the genes KV7.1- KV7.5.  These genes were shown to 
encode K
+
 channel subunits with the ‘shaker-like’ motif of 6TM domains and a single 
P-loop, but they have distinct properties (Robbins, 2001).  K
+ 
currents transmitted when 
different KCNQ are heterologously expressed are activated at negative membrane 
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potentials (below - 60 mV), and are outwardly rectifying with little or no inactivation 
(Robbins, 2001). 
 
There are five subfamilies of KCa channels (KCa1-5), which have also been subdivided 
on the principle of channel conductance and pharmacology.  The subfamilies include 
BKCa, with single channel conductance of ~100 – 300 pS.  These channels are encoded 
by KCa1.1,
 
also known as Slo or Slo1 (Marty, 1981).  IKCa with single channel 
conductance of ~25 – 100 pS is encoded by the KCa3.1 gene (Ishii et. al.,
 
1997; Joiner 
et. al., 1997)) and SKCa with single channel conductance of ~2 – 25 pS is encoded by 
the KCa2.1, 2.2, 2.3 genes (Park 1994; Kohler et. al., 1996).  Compared with the Kv 
channels, the α-subunit of the BKCa channel has an extra hydrophobic domain that leads 
to 7TM domains and an extracellular N-terminus (Wallner et. al., 1996).  The N-
terminus acts as a binding domain for the modulatory transmembrane β-subunit.  There 
is a regulatory domain located C-terminal to the pore-forming TM domain, which is 
known as the RCK domain (regulates conductance of K
+
).  The position of this ancillary 
domain allows it to exert control over the transmission of ions through the channel pore 
(Sansom et. al., 2002).  It has been suggested that upon Ca
2+ 
binding to the channel, 
there is a transition in RCK that results in the S2 segment helices being pulled out so as 
to open the channel (Sansom et. al., 2002).  The C-terminus determines the Ca
2+
 
sensitivity of the channel (Wei et. al., 1994). A series of highly conserved negatively 
charged residues are present in the C-terminus, which are known to have the Ca
2+
 
binding sites and are called the “Ca
2+
 bowl” (Schreiber & Salkoff, 1997).  IKCa and 
SKCa channels are exclusively gated by Ca
2+
 and exhibit no voltage sensitivity.  IKCa 
channels are bound to CaM via a binding domain (CaMBD) and the channel opens 
when Ca
2+
 binds to calmodulin (Sansom et. al., 2002).    
 
1.7.2  K+ channels found in PASMCs 
There is much diversity of K
+
 channel expression and function in the pulmonary arterial 
vasculature.  K
+
 channels found in PASMCs include four different classes, each class 
distinguished by specific physiological, kinetic and pharmacological properties.  These 
include:  
• KV & KCNQ channels 
• KCa channels 
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• KATP channels   
• K2P channels 
 
1.7.2.1  KV & KCNQ channels 
To date PAs have been found to express five α-subunit genes from the Shaker family 
(KV1.1- KV1.5), one α-subunit gene from the Shab family (KV2.1), one α-subunit gene 
from the Shaw family (KV3.1), one α-subunit gene from the Shal family (KV4.2), a KV 
channel modulatory subunit (KV9.3), and three β-subunits KVβ1.1, KVβ2 and KVβ3 
(Patel et. al.,  1997; Osipenko 2000; Yuan 1998; Hulme et. al., 1999; Platoshyn et. al., 
2001; Archer 1998).  Activation of KV causes an increase in K
+ 
efflux, (i.e. K
+
 current), 
which leads to PASMC hyperpolarisation.  This induces the closure of VOCCs, causing 
reduced Ca
2+
 current (ICa) flow into the cell, and results in vasodilation.   
 
KCNQ1 and the regulatory subunit KV3.4 have been shown to be present in lung (Teng 
et. al., 2003).  More recently, mRNA expression of KCNQ1, 4, 5 was identified in rat 
PASMCs, with KCNQ4 expression greater than KCNQ1 or KCNQ5 (Joshi et. al., 
2008(submitted)).  These channels can form homo-multimers or co-assemble 
functionally with other subfamilies or β subunits to form hetero-multimeric channels 
(Kubisch et. al., 1999; Lerche et. al., 2000).  Joshi et. al., 2006, suggest a functional role 
for KCNQ channels in the regulation of resting membrane potential of PASMCs.   
 
It has been postulated that KV1.5 and KV2.1 channels play a major role in controlling 
resting membrane potential in PASMCs (Yuan, 1995; Archer et. al., 1998; Platoshyn et. 
al.,  2000).  Evidence supporting the role of KV channels includes pharmacological 
studies, such as when KV current (IKV) was inhibited by 4-aminopyridine (4-AP), the 
resulting membrane depolarisation opened VOCCs, causing Ca
2+
 influx and an increase 
in the [Ca
2+
]i within the PASMC (Yuan, 1995; Platoshyn et. al.,  2000).  Using anti 
KV1.5 antibodies, Archer et. al., (1998) demonstrated K
+
 current (IK) inhibition, and 
selective inhibition of the increase in [Ca
2+
]i in response to 4-AP in rat PA.  Anti  KV2.1  
induced an increase in resting tension and wiped out 4-AP induced contraction in rat 
pulmonary rings also (Archer et. al. 1998).  It has also been suggested that NO promotes 
the opening of KV channels in PASMCs, the resulting membrane hyperpolarisation 
causing a decrease in [Ca
2+
]i within the PASMC cytoplasm (Yuan et. al.,  1996).  
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However, this role of KV channels in regulating the resting membrane potential of 
PASMCs has been questioned, since the voltage dependence of these channels does not 
make them suitable candidates for setting resting membrane potential over the 
physiological range (Gurney et. al.,  2002).  The role of KCNQ channels in the 
maintenance of the resting membrane potential of PASMCs is now receiving more 
attention, as these channels are open at the resting membrane potential (Robbins et. al., 
2001).  Further evidence suggesting the involvement of KCNQ channels arises from the 
fact that KCNQ channel blockers appear to inhibit the background K
+
 conductance in 
mice and rat PASMCs and cause vasoconstriction (Gurney et. al., 2005; Joshi et. al., 
2006). 
 
1.7.2.2  Ca2+ activated K+ channels (KCa) 
BKCa are found in high density and ubiquitously in vascular SMCs (Kume et. al., 1992) 
and have been implicated in the regulation of vascular tone (Hasunuma et. al., 1991).  
Activation of BKCa channels causes an increase in K
+
 current out of the cell, leading to 
hyperpolarisation of PASMCs, and subsequent vasodilation.  Activation provides a 
negative feedback mechanism to limit further Ca
2+
 entry and hence regulate contraction, 
because the opening and closing of BKCa channels is maintained not only by the 
membrane potential of the PASMC, but also by [Ca
2+
]i.  Therefore upon arterial 
constriction and corresponding increase in [Ca
2+
]i, BKCa channels are activated, 
promoting hyperpolarisation, and subsequent closure of VOCC. Numerous studies have 
shown that KCa channel activity increases as the cell membrane depolarises and the 
[Ca
2+
]i increases (Nelson & Quayle, 1995; Brayden, 1996).   
 
1.7.2.3 K+ channels inhibited by intracellular ATP (KATP)   
Although these channels are present in PASMCs, when ATP levels in the cytosol are 
within normal limits, the contribution that this family of channels make to the 
movement of K
+ 
is minor (Clapp & Gurney, 1992).  In PASMCs, the main role of KATP 
channels is to hyperpolarise the membrane in response to changes in the metabolic state 
of the cell.  They also have a role in mediating the hyperpolarisation response to 
vasodilators acting as K
+
 channel openers (Gurney, 2004).  Examples of vasodilators 
that activate KATP include endogenous mediators such as vasoactive peptide (VIP) and 
PGI2 (Brayden, 2002). 
 49 
 
1.7.2.4  Two-pore domain K+ channels (K2P) 
Mammalian lung expresses mRNA for several types of 4TM K
+
 channels, including 
TASK1, TASK2, TASK3, TWIK1, and TWIK2 (Lesage et. al., 2000; Kim et. al., 
2000).  TASK1 and TASK2 were found to be present in the vessels in both the PASMC 
and the endothelial cell layers (Gardener et. al., 2004).  This group concluded that 
TASK1 channels were important in the regulation of vascular tone.  There is evidence 
that TASK1 and TASK2 have an important role in transmitting the K
+
 current that sets 
the resting membrane potential (Em) in PASMCs (Gurney et. al.,  2003; Gonczi et. al.,  
2006).   
 
1.8 K+ channels and PAH 
K
+ channels are thought to play a role in the molecular mechanisms of PAH.  Down-
regulation of KV channel genes has been found in PAH patient lungs (Geraci et. al., 
2001) and down-regulation of K
+
 channel expression and inhibited K
+
 channel function 
has been observed in PASMCs from patients with IPAH (Yuan et. al., 1998).  K
+ 
channel dysfunction could be related to some of the contributing factors in the 
development of PAH.  
 
PASMCs from human and experimental hypoxic PAH animals are deficient in K
+
 
channels, resulting in a depolarised PASMC membrane and the activation of VOCC 
channels (Yuan et. al., 1998; Sweeney & Yuan, 2000; Platoshyn et. al., 2001).  Oral 
dichloroacetate which has been shown to increase IK (Rozanski et. al., 1998) was shown 
to restore the expression and function
 
of KV channels, decreased remodelling and PVR 
in rats with hypoxic pulmonary hypertension (Michelakis et. al., 2002). 
 
In PASMC, inhibition of KV channels is associated with cell proliferation, the resultant 
depolarisation induced increase in cytoplasmic Ca
2+ 
 allowing for progression through 
the cell cycle (Platoshyn et. al.,  2000).  Altered K
+
 channel activity was shown to result 
in cell proliferation and increased tone, which are two important factors that contribute 
to the development of PAH. 
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1.8.1  5-HT and K+ channels in PAH 
Evidence shows that the decreased expression/ function of K
+
 channels in PASMCs 
may be involved in the pathogenesis of PAH and anorexigen-induced PH (Weir et. al., 
1996; Yuan et. al., 1998).  Anorexigens inhibit both the expression and function of KV 
channels in PASMCs (Wang et. al., 1998; Perchenet et. al., 2001).  This may be due to 
the increase in plasma 5-HT resulting from the inhibition of 5-HTT activity.  It has been 
shown that 5-HT can inhibit KV1.5 currents and increase the membrane potential of 
PASMC (Cogolludo et. al., 2006).  These results implicate both 5-HT and K
+
 in the 
disease process of PAH.   
 
The uptake of 5-HT in PASMCs is determined by the 5-HTT, which is linked to the 
electrochemical gradient of Na
+
.  This suggests that the uptake of 5-HT may be voltage 
dependent.  If this is the case, then the resting membrane potential of PASMCs becomes 
important in the proliferating action of 5-HT within the PASMCs.  As K
+
 channels are 
responsible for the resting potential, any dysfunction in these K
+
 channels may disrupt 
the membrane potential and hence disrupt the function of the 5-HTT.    Alternatively, a 
rise in the plasma 5-HT concentration could inhibit K
+
 channel activity and give rise to 
membrane depolarisation, which would exacerbate the 5-HT induced vasoconstriction 
by causing Ca
2+
 entry.  
 
1.9  Study Aims 
The hypothesis under investigation in this study is that 5-HT and K
+
 channels can 
interact and that this may be an important contributor to the development of PAH.  
There could be a synergistic interaction between 5-HT and K
+
 channels, whereby 5-HT 
promotes depolarisation, which in turn enhances 5-HT action.  It is therefore proposed 
that the inhibition or down-regulation of K
+
 channels contributes to increased vascular 
tone in PAH, and the effect is potentiated by 5-HT.  5-HT receptors and transporters are 
recognised targets for FPAH.  This study will examine the modifying factors that may 
influence these proteins as therapeutic targets. 
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Chapter 2 
 
 
Materials and methods 
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2.1  Animal models 
Animal models are an essential method for investigating animal physiology and 
pharmacology.  They have provided investigators with the means of identifying and 
developing novel therapeutic strategies.   
 
2.1.1  The 5-HTT+ mouse model of pulmonary hypertension  
The C57BL/6_CBA wild-type strain used to generate the 5-HTT+ mouse (MacLean et. 
al., 2004). The transgene was a 500-kb yeast artificial chromosome (YAC35D8) 
containing the h5-HTT gene flanked by 150 kb of 5’ and 300 kb of 3’ sequence, with 
the “short” allele of the 5-HT transporter gene (5-HTTLPR) in the promoter region and 
the 10-repeat allele of the variable number tandem repeat in intron 2 (Shen et. al., 
2000).  The 5-HTT+ mice (female) were used at 5-6 month, with weights of 25 - 40 g.  
Female wild type (WT) mice were also used at 5-6 months of age, with weights of 25-
40 g.  Mice were bred in the central biological services research facility, University of 
Glasgow.   
 
2.1.2  Hypoxic Mouse model 
WT mice were maintained in a hypobaric hypoxic environment to induce PAH.  As 
atmospheric pressure decreases, the partial pressures of the gaseous components 
decrease, and hence the partial pressure of inspired O2 decreases.  However, the 
percentage of the gaseous components of air remains constant (O2 ~21 %, N2 ~78 % and 
CO2 ~1 %).  The environment was controlled by withdrawing air from the chamber via 
a vacuum pump, until the pressure within the chamber was equivalent to ~0.5 
atmosphere.  The chamber was continuously flushed with room air to maintain 
conditions of low humidity and CO2.  Mice were kept in this environment for a period 
of 14 days.   
 
2.1.2.1  Maintenance of animals 
The hypobaric chamber was kept in an animal holding room, which was set up to 
maintain the temperature at approximately 21 ˚C, humidity at 55 % and gave 20 changes 
of filtered air per hour.  A 12 hour on, 12 hour off light cycle was maintained.  An 
animal cage was placed in the chamber, with food and water dispensers facing the rear 
of the cage which allows the animals to be monitored. 
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2.1.2.2  Hypobaric chamber design and components 
A picture of the chamber used is shown in figure 2.1.  The chamber holds two standard 
mouse cages, with up to six mice in each individual cage.  The chamber was constructed 
from transparent highly resistant Perspex, with a door that can be removed.  Air was 
passed into the chamber through a valve on the top right hand of the door and it was 
continuously removed via a pump.  The pressure within the chamber was constantly 
displayed on a gauge.  The pressure was maintained by the inlet air valve.  Opening the 
valve allowed more air to circulate into the chamber and hence increased the pressure to 
atmospheric pressure; closing the valve stopped air entering the chamber and therefore 
decreased air pressure within the chamber.  The air temperature within the chamber was 
similar to that outside the chamber and was monitored daily via an internal and external 
thermometer.   
 
The animals were placed in the chamber, the chamber door was locked into place and 
the pump was turned on.  When the inlet valve was closed slightly, this tightly sealed 
the chamber door.  By adjusting the inlet valve, chamber air pressure was reduced 
gradually.  The pump at the back of the cage continuously pumped a fixed volume of air 
out of the cage.  By adjusting the inlet valve, and hence the volume of air entering the 
chamber, a vacuum condition could be created.  The desired pressure to induce chronic 
hypoxia in mice is 550 mbar.  The chamber air pressure was reduced in a series of steps 
of 50 mbar over a two day period.  The chamber conditions were checked daily and 
records were made of pressure, temperature (inside and outside the chamber) and 
humidity.  Checks were also made to ensure animals had enough food and water.  Daily 
checks were also important to ensure the animals were not showing any signs of 
distress.  Food and water was also maintained daily throughout the study.  Animal cages 
were changed every three days in order to provide clean and fresh bedding for the 
animals. 
 
2.1.3  Hemodynamic measurements 
Mice were anaesthetised with 3 % isoflurane in oxygen.  Maintenance of anaesthesia 
was via 1 – 1.5 % isoflurane in oxygen.  The level of anaesthesia was constantly 
monitored throughout the procedure by absence of hind limb withdrawal and tail 
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withdrawal reflexes.  Under maintenance anaesthesia, a portion of skin inferior to the 
rib cage was removed.  A hypodermic (25 gauge) needle attached to a transducer was 
used to measure right ventricular pressure.  The needle was attached to a pressure 
transducer (Elcomatic E751A) connected to a MP100 data acquisition system (BIOPAC 
Systems Inc, Santa Barbra).  The results obtained were analysed using Acquiknowledge 
3.5 software. 
 
The needle was placed onto the skin above the diaphragm and advanced under the rib 
cage into the abdomen, it was then slowly advanced into the right ventricle (RV).  The 
position of the needle was confirmed by the waveform of the pressure tracing recorded 
and displayed on a computer screen.  To record left ventricular pressure, the needle was 
further advanced into the left ventricle (LV).  Once this procedure was completed and 
recordings of pressure were made, the animal was killed by cervical dislocation.  The 
heart and lung tissue were subsequently removed. 
 
2.14  Determination of heart weights 
The chambers of the heart were opened and excess blood was blotted out.  The heart 
was then weighed.  The atria and large blood vessels were then dissected from the 
ventricular mass, which was separated into the RV wall and the LV, including the 
septum.  These tissues were weighed separately, and the ratio of right ventricular (RV) 
free wall weight to left ventricle plus septum (LV + S) was used as an index of right 
ventricular hypertrophy.   
 
2.2  In-vitro pharmacological studies  
2.2.1  Wire myography 
Wire myography was introduced by Mulvany & Halpern in 1976, and is now an 
established technique used to investigate small vessel contractility and relaxation.  
Measurements of muscle contraction can be made from small vessels and other tubular 
tissues with diameters of 60 – 400 µm. 
 
2.2.2  Equipment 
The wire myographs used were DMT610M units, purchased from Danish Myo-
technology Ltd., Aarhus, Denmark (figure 2.3).  The setup had four individual organ 
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chamber baths, each capable of having one vessel mounted in it.  Each individual 
myograph chamber had two stainless steel jaws to hold the vessel in place, and had 
individually controlled gas flow and suction (for removing solution and washing tissue).  
Myograph chamber temperature (± 0.1 ˚C), was controlled electronically at 37.5 ˚C ± 
0.1 ˚C, via internal heating units.  The temperature and tension for each chamber was 
displayed digitally on the base unit (figure 2.3).  The entire setup was connected to a 
computer, via a analogue to digital converter.  The output from the transducer 
(measuring force) from each chamber was recorded via a programme called Myodaq20 
and analysis of the recordings was carried out using a computer programme called 
Myodata  (MyoDaq software, Danish Myotech, Aarhus, Denmark).   
 
2.2.3 Tissue preparation - Dissection of intralobar pulmonary 
arteries (IPAs) 
Mice were killed with an overdose of sodium pentobarbitone (200 mg/ kg 
intraperitoneally).  Lungs were rapidly removed and placed in ice cold physiological 
salt solution (PSS).  PSS used consisting of (in mM): NaC1 119, NaHCO3 25, KCl 4.7, 
KH2PO4 1.2, MgSO4 0.6, CaC12 2.5, glucose 11.1, [pH 7.4].   
 
The larger left lobe of the lungs was identified, removed and mounted on a dissection 
plate.  The lobe was placed with the visceral surface facing up from the dish, and the 
parietal side lying inferiorly.  During dissection, the lobe was periodically washed with 
fresh PSS, to prevent the tissue drying out.  A dissecting microscope was used to 
identify the airway.  An incision was made into the opening of the airway, this incision 
carried on down the airway length, cutting from the large proximal airway along the 
bronchial tree to the distal bronchiole.  When the airway was dissected out, the IPA was 
found immediately underneath.  The IPA (internal diameter ~ 200 - 300 µm) was 
carefully dissected from the lobe and surrounding connective tissue removed (figure 
2.3).  The vessel was kept on ice cold PSS before being mounted on the myography 
setup.   
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Figure 2.1 Picture of hypobaric chamber used to generate hypoxic mice. 
 
 
 
 
 
Figure 2.2 Picture of wire myograph used to measure vessel constriction.  
Image from www.adinstruments.com/products/hardware/research/product/DMT610M 
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Figure 2.3 Diagram showing location of main intralobar pulmonary artery 
which was used in myography experiments. 
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Figure 2.4 Diagram showing the artery mounting procedure. 
(1 & 2) Vessel cannulated with wire is transferred to the myography chamber, and 
mounted to myography chamber head. 
(3 & 4) Vessel is cannulated with second wire, which is the mounted to the second 
myography chamber head. 
(5) Vessel is stretched during the normalisation procedure (section 2.2.4) 
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2.2.4  Myograph mounting procedure 
All vessels underwent the same mounting procedure (figure 2.4).  Each myograph 
chamber was filled with 5 ml Krebs and bubbled with 16 % O2 / 5 % CO2 (balance N2).  
Prior to each experiment, a bag was filled from a combination of gas cylinders with this 
gas mixture to mimic in vivo partial pressure of oxygen (pO2), and this was pumped into 
each chamber. 
 
In order to carry out time-matched control experiments, each vessel dissected was cut to 
provide two sections of ~ 2 mm each.  Each section of artery had a 40 µm diameter 
stainless steel wire placed through its lumen.  This was then placed in the myograph 
chamber and was secured in place by adjusting the adjacent heads of the myograph so 
that they met trapping the wire between them.  Wire at each side of the vessel was 
manipulated under the screws of one of the jaws, in a clockwise fashion, and the screws 
secured.  Excess wire was removed (figure 2.4 (1 & 2)).  The second head of the 
myograph was moved back from the first, and a second wire was carefully inserted 
through the vessel lumen (figure 2.4 (3)).  Again the two myograph heads were adjusted 
so they met and the second wire was mounted in an identical fashion on the second 
head.  Finally the two heads were separated slightly, without stretching the vessel, and 
the wires were adjusted until they were on the same plane.  When the heads were 
slightly opened this provided the zero level of tension for set-up measurements.  This is 
shown in figure 2.4 (1 – 5).   
 
2.2.5  Transmural pressure applied to vessels and normalisation 
The internal circumference (IC) of a vessel when under no active tone but distended by 
a transmural pressure of 100 mmHg is termed IC100.  For systemic preparations the 
figure of 0.9 x L100 is chosen as maximum active tension development is optimal at this 
point.  Under these conditions the equivalent pressure of the vessel is between 60 - 70 
mmHg.  The pulmonary vasculature is normally under the conditions of low resistance 
and low pressure, and therefore must be set up under conditions which replicate this.   
 
Normoxic mice IPAs were set up to mimic in-vivo transmural pressure at ~16 mmHg.  
The hypoxic mouse lung circulation experiences a higher transmural pressure, (30 
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mmHg), to that of the normoxic lung, and so different conditions were used by 
normalising the vessels to a transmural pressure of ~ 30 mmHg.   
 
Mulvany and Halpern developed the original normalisation procedure in 1977.  
Normalisation allows for vessels to exhibit a resting transmural pressure, based on the 
Law of Laplace.  The first measurement necessary for normalisation of each vessel was 
the ICi (internal circumference for given amount of stretch (i) applied to the vessel) (see 
equation 2.1).  ICi was calculated using the micrometer readings, and the IC value when 
no stretch was applied (IC0).  For two wires with a 40 µm diameter, IC0 would be equal 
to 205.6 µm.  In equation 2.1, point ‘X O’ refers to the point at which the two 40 µm 
wires were just touching, and point ‘Xi’ being the point to which the vessel is stretched.  
The difference between the two micrometer readings at the two points is equivalent to 
the distance between the two wires.   
 
(equation 2.1)   ICi = (IC0) + 2(Xi –X O)  
 
Arteries were incrementally stretched using the micrometer and passive force (F) was 
displayed on the baseunit.  Wall tension was calculated by dividing the passive force (F) 
(which is measured and displayed on the base unit), by twice the segment length, as the 
vessel has both an upper and lower wall, and is therefore, for vessels 2 mm in length 
was equal to Force / (2 x 2).   
 
The effective pressure (Pi) is an estimate of the pressure necessary to extend a vessel to 
the measured internal circumference, and was determined using the Laplace equation 
2.2.  Rearranging equation 2.2 gives equation 2.3. 
  
equation 2.2   Pi = Wall tension / (ICi/ 2pi)  
 
equation 2.3    Pi = (2pi) x Wall tension / ICi 
 
Equation 2.4 shows equation 2.3 substituting the values for wall tension and ICi: 
 
equation 2.4   Pi = (2pi) x F/ 2 x L (205.6 + (Xi- Xo)) 
 
 61 
2.2.6  Protocol for myography experiments 
Vessels were allowed to equilibrate for 30 min after mounting in a myograph chamber 
prior to the beginning of an experiment.  During this period the chambers were heated 
to 37 ˚C and bubbled with the O2 / CO2/ N2 gas mixture.  The appropriate tension was 
applied to each vessel, (dissected to 2mm in length), as described in section 2.2.5.   
 
50 mM KCl was added to each chamber in order to stimulate and check the viability of 
the vessel.  Upon reaching a maximal response, the chamber was washed out six times 
using bicarbonate PSS, and the vessels were allowed to return to baseline tension for 30 
minutes.  The vessels were then stimulated again with KCl and if the vessel contracted ≥ 
1 mN, the vessel was considered viable and the response to the second 50 mM KCl 
application was used as a contractile reference for the subsequent experiment.  Again, 
each vessel was washed, allowed to return to baseline tension and left for 30 minutes to 
equilibrate, before any drug was added. 
 
When performing a vasoconstrictor concentration response experiment, for 5-HT and 
K
+
 channel blocking agents, a suitable time period was left between each dose until 
contraction began.  From this point each subsequent dose was added when contraction 
of the vessel had stabilised.  In vasodilator concentration response curve experiments, 
(responses to KCNQ channel openers) each vessel was pre-constricted to ~ 70 % of its 
maximum response (response to 50 mM KCl), using phenylepherine (PE), (10 – 100 
nM).  Once the vessels started to relax, subsequent doses of agonist were added when 
the response had levelled off.   
 
2.2.7  Data Analysis of pharmacological studies 
Maximum contractile responses to agonists were calculated as a percentage of the 
contraction produced by KCl (50 mM) and were expressed as the means  standard error 
of the mean (SEM).  In the case where relaxation was measured, data were expressed as 
a percentage of the response relative to PE-induced pre-contraction in the vessels and 
were also expressed as the means  SEM. 
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2.2.7.1  Measurement of agonist potency 
The potency of a drug is commonly quantified as the EC50, the concentration that leads 
to 50 % maximal response.  The pEC50, equal to the – log of the EC50 is used as 
standard to compare drug potencies.  A computer statistics programme, GraphPad 
Prism, (for Windows) (version 4.03), was used to measure pEC50 values.  pEC50 
values were measured after constructing individual concentration response curves for 
each drug and the mean  SEM calculated for each group of vessels. 
 
2.2.7.2  Statistical analysis of pharmacological studies 
When comparing two groups of data, Student’s t-test was the statistical method chosen 
to investigate statistical difference.  One way analysis of variance (ANOVA), followed 
by an appropriate ad hoc post test, was used to investigate statistical differences 
between three or more groups of data.  P< 0.05 was deemed to indicate statistical 
significance.   
 
2.3  Flupirtine dosing study  
Animal dosing studies provide a means of investigating the actions of drugs in vivo, and 
have become an established, though highly regulated practice.   
  
In this dosing study, the WT and 5-HTT+ mice described in section 2.1 were used.  
Each mouse was given a unique identification number, which was used throughout the 
study to identify the animal during in vivo experiments and tissues which were removed 
from the animal subsequent to culling.  Animals were housed in a manner that would 
allow each animal to be identified by means of ear tag and colour. 
 
Prior to commencing and during the dosing study, each animal was weighed.  Body 
weight measurement allowed the health of the animal to be identified.  These 
measurements were also used to calculate the amount of drug/ vehicle that each mouse 
should receive.  Mice were kept in groups of 5 per cage and kept in either a hypoxic 
chamber or control environment.  Each cage contained mice from the same group, i.e. 
WT and 5-HTT+ mice were housed in separate cages.  The mice were observed daily.  
The procedure used to dose the animals involved the oral gavage technique.  A 1 ml 
syringe containing the solution to be administered was connected to a small diameter 
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straight gavage tube.  Animals were manually restrained, and the gavage tube was 
inserted through the mouth into the oesophagus.  The solution was then delivered 
directly into the stomach.  Care was taken to ensure that the tube did not enter the 
trachea, or cause any damage to the oesophagus. 
 
Flupirtine is not readily soluble in water, so was prepared as a suspension in 1 % 
Carboxymethylcellulose (CMC).  The concentration of flupirtine used was 30mg/ kg/ 
day.  The mixture was then homogenised.  The vehicle and flupirtine suspensions were 
frozen until required.   
 
2.3.1  Dosing protocol 
Oral doses of flupirtine were administered as it has been shown that flupirtine is almost 
completely absorbed from the gastro-intestinal tract in experimental animals (Obermeier 
et. al., 1985).  In vivo studies to date have used doses of 15 mg/ kg/ day in mice 
(Diamantis et. al., 1987); 40 mg/ kg in rats (Nickel, 1987) and 8, 16, 25 and 50 mg/ kg 
in rats (Sofia et. al., 1987).   Mackie et. al., (2008) dosed rats with 0.01 – 3.0 mg/ kg 
flupirtine to show that flupirtine produced significant dose-dependent
 
decreases in mean 
arterial pressure and mesenteric vascular resistance.  Sofia et. al., (1987) found that the 
oral ED50 for analgesic activity of flupirtine in mice was 27.4 mg/ kg after one test day, 
and this level rose to 33.8 mg/ kg after nineteen test day.  Based on the data obtained 
over this dose range, it was decided that 30 mg/ kg/ day would not be toxic to the mice 
and would be an appropriate dose.  The plasma half life of flupirtine in rats and dogs is 
2.5 – 3.5 hrs (Schuster et. al., 1998). 
 
A total of 60 female mice were used; 40 WT mice (section 2.1.1) and 20 5-HTT+ mice.  
Half of the WT mice were subject to 2 weeks hypoxia (section 2.2.3), with the other 
half being age matched controls.  From each group, 10 mice were dosed with flupirtine 
and 10 were dosed with vehicle (CMC) once per day for 14 consecutive days.  Dosing 
occurred at the same time of day throughout the study. 
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2.4  Membrane potential measurement 
2.4.1  Isolation of PASMCs 
PASMCs were isolated from intralobar pulmonary arteries.  This allowed the cell 
membrane potential of individual cells to be measured, as in the intact vessel they are 
coupled electrically to other PASMCs and are under the influence of endothelial cells. 
 
In order to dissociate PASMCs an appropriate digesting protocol was constructed.  A 
dissociation medium (DM), of the following composition was used (mM): NaCl 110; 
KCl 5; NaH2PO4 0.5; NaHCO3 10; HEPES 10; phenol red 0.03; taurine 10; EDTA 0.5; 
CaCl2 0.16; MgCl2 2; glucose 10.  This medium was bubbled with air and the pH 
adjusted to 7.0 using NaOH.  Into this solution the following enzymes were added and 
the final solution was mixed by vortexing: 
• 1 mg/ ml collagenase type XI 
• 0.45 mg/ ml protease (type XXIV bacterial, EC no.232-642-4) 
• 2 mg/ ml bovine serum albumin (fatty acid and globulin free) 
• 2 mg/ ml trypsin inhibitor 
 
When the solution was fully mixed, five or six strips of intralobar pulmonary artery 
were added.  The solution containing the vessels was then incubated at 37 °C for 8 min 
(the mixture was titrated gently after 4 min in incubation).  The strips of artery were 
removed from the solution and washed in 0.5 ml enzyme-free DM.  Using a glass 
Pasteur pipette with wide fire-polished tip (~ 2 mm), the artery strips were transferred to 
an eppendorf tube containing 0.5 ml DM.  Subsequently, isolation of the smooth muscle 
cells was carried out by gentle titration with the Pasteur pipette.  Examination of the 
cells was carried out with a microscope and the solution of PASMCs was titrated to 
dislodge PASMCs from the vessel tissue as required.  The final solution containing 
freshly isolated PASMCs was stored at 4 °C until use.  This protocol was carried out 
daily.  
 
Initial attempts to isolate PASMCs from 5-HTT+ mice using the above procedure were 
unsuccessful.  Success was obtained using the same procedure but with the 
concentrations of collagenase and protease doubled, and the initial incubation time at 37 
°C extended to 20 min.  
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2.4.2  Electrophysiology  
The patch clamp technique was used to measure membrane potential.  This method 
allows ion channel behaviour to be investigated by monitoring the movement of ions as 
an electrical current.  Patch clamp is mostly used to voltage clamp cells and record 
current flow, however in this study, the current clamp mode was used to measure 
membrane potential under conditions of zero current flow. 
 
The original voltage-clamp technique was developed by Cole, (1949) and Hodgkin, 
Huxley, (1952), who worked on squid giant axon.  Their version of voltage-clamp 
controlled the membrane potential using wires inserted into and along the length of the 
axon.  This type of approach was limited to large cylindrical preparations.  Subsequent 
developments led to the introduction of glass intracellular microelectrodes.  These were 
hard glass capillaries which were melted and pulled to a fine tip, much less than 1 µm in 
diameter.  The advantage of this technique was that the tip of the microelectrode could 
penetrate the plasma membrane, and the membrane resealed around the tip of the 
electrode as it entered the cell.  This type of voltage clamp is used to make 
measurements from medium sized cells, such as neurons, and can be used to record 
membrane potential from smooth muscle in intact arteries. 
  
The patch-clamp technique was invented by Neher & Sakmann, (1976) and further 
developed by Hamill et. al., (1981).  This technique allows small fragile cells, such as 
smooth muscle cells, to be voltage clamped.  In this procedure the tip of a fire-polished 
glass micropipette (~ 1 µm in diameter) is brought onto the cell surface and a small 
amount of suction is applied to the back of the patch pipette (figure 2.7).  This enables a 
high resistance seal (>10 GΩ), referred to as a ‘giga seal’, to form between the pipette 
and the cell membrane. Depending on the nature of the study there are a number of 
patch clamp configurations, however in this study the whole cell mode was used (figure 
2.6). 
 
2.4.2.1  Patch-clamp protocols 
A few drops of cells were allowed to settle for ~ 10 min on the glass bottom of an 
experimental chamber, placed on an inverted microscope in a patch clamp set-up.  
When the cells had adhered to the surface they were superfused with PSS (section 2.4) 
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at a rate of 0.5 ml/ min at room temperature, and the solution was bubbled with 20% O2/ 
5% CO2.   
 
The patch pipette, contained an internal solution that mimicked the internal environment 
of the cells, composed of (mM): 130 KCl, 1 MgCl2, 1 EGTA, 20 HEPES, 0.5 Na2GTP; 
pH adjusted to 7.2 with 1M KOH.   The patch pipette was attached to a pipette holder.  
Positive pressure was applied to the patch pipette via a 2 ml syringe attached by tubing 
to the pipette holder via a side arm.  This prevented any debris from attaching to the 
pipette as it entered the bathing solution and was positioned near a cell using a 
micromanipulator.  The amplifier was set to voltage clamp mode and an oscilloscope 
displayed the voltage and current outputs.  As the patch pipette entered the bathing 
solution a junction potential was formed, which was cancelled out manually using a 
pipette offset control.  A hyperpolarising step of 10 mV (from -80 mV to -90 mV) and 
30 ms duration, repeated every 350 ms, was applied to the circuit.  This resulted in a 
rectangular waveform being displayed on the current trace.  Using Ohms Law pipette 
resistance was calculated:  pipette resistances of 3-5 MΩ were found to be the most 
suitable for recording membrane potential from mice PASMCs.  Viewing through the 
microscope, and using the micromanipulator, the tip of the patch pipette was moved 
until it was just above the cell.  As the patch pipette was brought slowly onto the surface 
of the cell membrane, the amplitude of the current trace reduced.  Negative pressure was 
applied to the patch pipette via gentle suction, using the 2 ml syringe.  This resulted in 
further reduction in the current amplitude, leaving only small transient currents at the 
onset and offset of the voltage step, caused by pipette capacitance, which were 
cancelled by adjusting the fast and slow capacitance compensation dials on the control 
box.  This indicated the formation of a giga seal. 
 
Subsequent to giga seal formation, the membrane under the pipette tip was ruptured by 
applying further negative pressure to the patch pipette, to form a low resistance pathway 
between the cytosol and the pipette.  This is the whole-cell mode of the patch-clamp 
technique.  Successful entry into the cytosol was indicated by large sharp current 
transients at the onset and offset of the applied voltage step, due to charging of the cell 
capacitance.   
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In order to measure membrane potential, the amplifier was switched to current-clamp 
mode with current set at zero.  Recording from the cell was started immediately after 
seal formation, and the membrane potential was continuously recorded throughout the 
experiment.  Each cell from which recordings were made was allowed to equilibrate, 
until a steady membrane potential was recorded, which was seen as a steady trace on the 
computer monitor.  This was recorded as the resting cell membrane potential.   
 
Experiments were also carried out to investigate the membrane potential response to 5-
HT.  After recording resting membrane potential 5-HT was then added to the local 
environment of the cell via a gravity fed perfusion pipette positioned close to the cell.  
Membrane potential was measured in the presence of 5-HT. Initially 1 µM 5-HT was 
added, and any change in membrane potential was measured.  The membrane potential 
was allowed to stabilise.  10 µM 5-HT was subsequently added to the cell’s local 
environment, and membrane potential was measured until a steady trace was shown on 
the computer monitor. 
 
2.4.2.2  Pipettes & Pipette solution  
Recording pipettes were made from borosilicate glass capillaries (Harvard Apparatus 
Ltd).  Pipettes were pulled in two stages using a vertical multi-stage pipette puller 
(Narishige, Japan, model PB-7).  The tips of the pipettes were fire polished to produce a 
smooth and clean tip (aids seal formation), and the shank of the pipette was then lightly 
coated with beeswax.  The beeswax produced a hydrophobic coating of the shank, 
which reduces pipette capacitance and noise in the recording.  Recording pipettes were 
back filled with enough internal solution (~ 5 µl) to contact a Ag/ AgCl electrode wire 
in the pipette holder, which connected the cell to the patch-clamp amplifier.  Any air 
bubbles were removed by gently flicking the pipette.  In order to complete an electrical 
circuit, an Ag/ AgCl pellet, which was connected to ground, was placed in the bathing 
solution containing the PASMCs and formed a reference electrode. 
 
2.4.2.4  Sources of error 
During current flow a potential difference was created between the electrodes, known as 
a junction potential.  This can lead to incorrect recordings.  The use of a Ag/ AgCl wire 
in the pipette holder and Ag/AgCl pellet in the bath stabilises this junction potential.  
Ag/ AgCl dissociates into Ag
+
 and Cl
-
 ions when electrons flow through a circuit.  
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When electrons (and therefore current) flow in the opposite direction, the reverse occurs 
and the ions recombine.  This allowed the charge in the solution near the electrodes to 
be constant.  As these ions are continually in transition, a potential difference is created 
between the bathing (or pipette) solution and the electrode, which at equilibrium is 
known as the half cell potential.  This was kept stable for each Ag/ AgCl electrode by 
keeping the Cl
-
 ion concentration constant in each experiment.  These potential 
differences remained constant during the experiments and were compensated for at the 
beginning of each experiment.  
 
Junction potentials arise between two different solutions when the two solutions are a) 
in contact, b) composed of ions at different concentrations and c) contain ions of 
different mobilities.  A liquid-liquid junction potential occurred when the recording 
pipette was first inserted into the bathing solution.  This was due to the pipette solution 
and the bath solution having different Na
+
 and K
+
 activities.  The pipette offset control 
was used to zero the output when the pipette was in the bathing solution.  Upon the 
formation of a giga-seal with the cell membrane, the pipette solution was no longer in 
direct contact with the bathing solution, and hence the liquid junction potential 
disappeared, but the compensating offset remained.  This was not corrected for in the 
current clamp experiments carried out in this study, but gave rise to a recording error of 
less than 2 mV. 
 
2.4.2.5  Data analysis of current clamp studies 
Membrane potentials were recorded and analysed using WinWCP software (Whole cell 
program, WCP, Strathclyde Electrophysiology Software, John Dempster 2005).  Data is 
expressed as the means  SEM of n cells.  These were compared using Student’s t-test.  
P< 0.05 was deemed to indicate statistical significance.   
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Figure 2.6 Diagram showing the Whole Cell Patch Clamp technique. 
Patch pipette was brought to the PASMC surface.  Light suction was applied to the back 
of the patch pipette in order to form seal with the cell membrane.  Once a tight seal was 
achieved, further suction was applied to the pipette, which ruptured the cell membrane, 
resulting in whole cell formation. 
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2.5  Drugs and solutions 
PSS used in myography and patch clamp experiments is shown in table 1.  Internal 
solution used in patch clamp experiments is shown in table 2.  A list of all drugs and 
reagents used as part of this study is shown in table 3.  Table 4 indicates the solvents in 
which drugs were dissolved. 
 
 
 Concentration (mM) 
Salt 
5.9mM K+ 
PSS 
20 mM K+ 
PSS 
50 mM K+ 
PSS 
NaCl 119 99 69 
KCl 4.7 18.8 48.8 
MgSO4.7H2O 0.6 0.6 0.6 
KH2PO4 1.2 1.2 1.2 
CaCl2 2.5 2.5 2.5 
NaHCO3 25 25 25 
Glucose 11.1 11.1 11.1 
 
Table 2.1 PSS solutions.  Unless otherwise stated in each chapter results section, 
experiments were carried out using 5.9 mM K
+
 PSS. 
 
 
 
Salt Concentration (mM) 
KCl 130 
MgCl2 1 
EGTA 1 
HEPES 20 
Na2GTP 0.5 
 
Table 2.2 Internal pipette solution. 
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Compound Supplier 
4-aminopyridine Sigma 
5-hydoxytryptamine Sigma 
bovine serum albumin (BSA) (fatty acid and globulin free)  Sigma 
CaCl2 Sigma 
capsaicin Tocris 
collagenase (type XI) Sigma 
ethylenediaminetetraacetic acid (EDTA) Sigma 
ethylene glycol tetraacetic acid (EGTA) Sigma 
flupirtine Sigma 
glucose Sigma 
glibenclamide Sigma 
HEPES Sigma 
KCl Sigma 
HEPES Sigma 
KH2PO4 Sigma 
ketanserin tartrate Tocris 
linopirdine Tocris 
magnesium chloride Sigma 
MgCl2 Sigma 
MgSO4.7H2O Sigma 
NaCl Sigma 
NaHCO3 Sigma 
NaH2PO4 Sigma 
NaOH Sigma 
protease (type XXIV bacterial, EC no.232-642-4) Sigma 
retigabine Astra Zeneca 
phenol red Sigma 
taurine Sigma 
tetraethylammonium Tocris 
trypsin inhibitor Sigma 
zinc chloride Tocris 
Table 2.3 Drugs & reagents. 
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Compound Solvent 
 
4-aminopyridine PSS  
2-aminoethyl diphenylborinate DMSO 
5-hydoxytryptamine PSS  
capsaicin DMSO  
flupirtine CMC   
glibenclamide DMSO 
ketanserin tartrate PSS 
linopirdine PSS  
magnesium chloride PSS 
retigabine DMSO 
tetraethylammonium PSS  
zinc chloride PSS  
 
Table 2.4 List of solvents used to dissolve drugs. 
PSS = 5.9 mM K
+
 PSS  
DMSO = Dimethylsulphoxide 
CMC = Carboxymethylcellulose 
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Chapter 3 
 
 
Characterisation of K+ channels mediating 
resting tone in PASMCs and the effects of K+ 
channel blockers on 5-HT induced 
contraction 
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3.0  Introduction 
PA tone and SMC contraction depend largely on the [Ca
2+
]i.  [Ca
2+
]i is influenced by 
several signalling pathways, and by the membrane potential of the SMC.  It is a well 
recognised phenomenon that depolarisation of SMC membrane results in the opening of 
VOCCs, through which Ca
2+
 enters the cell and induces contraction.  Changes in the 
resting membrane potential have been described in animal models of pulmonary 
vasculature disease.  For example, PASMCs were depolarised during PAH caused by 
chronic exposure to hypoxic conditions (Post et. al., 1992, Archer et. al., 1993, 
Osipenko et. al., 1997, Yuan et. al., 1993).  The changes found in the disease state may 
be due to an alteration in the expression or activity of K
+
 channels that maintain the K
+
 
efflux at rest (Smirnov et. al., 1994, Osipenko et. al., 1998).   
 
A number of studies have described KV channels in mediating the resting potential in 
PASMCs (Yuan et. al., 2005, Archer et. al., 1998).  KV1.5, KV2.1 and KV9.3 have been 
proposed as the K
+
 channel subunits of most importance in regulating membrane 
potential (Archer et. al., 1998; Patel et. al., 1997).  In contrast, another study has 
indicated that classical delayed rectifier KV channels are unlikely to mediate resting K
+
 
conductance, as they have a very low probability of opening at resting membrane 
potential (Gurney et. al., 2006; Gurney et. al., 2002).  KCNQ channels were recently 
implicated in playing a role in the maintenance of resting K
+
 conductance in SMCs 
within the pulmonary vasculature (Joshi et. al., 2006; 2008(submitted)).  These channels 
are proposed to be involved as they have a low voltage threshold for activation, show 
little or no inactivation during sustained depolarisation and are outwardly rectifying 
(Robbins, 2001).  When the KCNQ channel blockers, linopirdine and XE991, were 
applied to rat PA it was found that these drugs were potent vasoconstrictors.  The 
constriction was found to be due to an action on the underlying PASMCs and a 
functional role for KCNQ channels in regulating the resting membrane potential was 
suggested (Joshi et. al., 2006).  Two-pore domain K
+
 channels are also candidates for 
mediating resting potential, as their biophysical properties make them likely candidates 
for involvement as background conductance pathways (Lesage & Lazdunski, 2000).  
There are several members of the TASK family, but TASK1 appears to be of major 
significance in rabbit and rat PASMCs (Gurney et. al., 2003; Gardener et. al., 2004) 
while TASK2 may play a lesser role in mediating resting K
+
 conductance (Gonczi et. 
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al., 2006).  The activation of BKCa and KATP channels can also affect membrane 
potential.  However, these channels appear to be silent at the resting potential and their 
main role in the pulmonary vasculature seems to be to dilate arteries in response to a 
change in the metabolic state of the cell (Clapp & Gurney, 1991; 1992).  BKCa channels 
were shown not to be necessary to maintain the resting membrane potential in rabbit 
PASMCs (Osipenko et. al., 1997).  IK flowing through BKCa channels has been 
identified in rabbit PASMCs (Clapp & Gurney, 1991; Vandier & Bonnet, 1996), and 
this current was shown to result from a high [Ca
2+
]i and depolarisation of the cell 
membrane.  The Ca
2+
-activated K
+
 current serves as a negative feedback mechanism in 
regulating the degree of membrane depolarisation and hence vascular tone (Brayden & 
Nelson, 1992).  Contributions of KATP channels to resting membrane potential of rabbit 
PASMCs have been reported (Clapp & Gurney, 1992).  Within the intact pulmonary 
circulation, KATP channels can contribute to reducing basal vascular tone, but do so 
primarily at the conduit artery level rather than in resistance segments of the cat PA tree 
(Shirai et. al., 2001).  At normal physiological conditions, with intracellular ATP 
concentration in the millimolar range, nearly all KATP channels are closed (Nelson & 
Quayle, 1995).  This would explain why the addition of glibenclamide (a KATP channel 
inhibitor) had no effect on membrane potential or [Ca
2+
]i (Yuan et. al., 1995).  
Therefore, the role of KATP channels may be modulatory in times of metabolic stress. 
 
KV channels transmit currents, which can be subdivided into rapid inactivating currents 
(IKA) and delayed rectifier currents (IKDR) and non inactivating currents (IKN).  
Depending on the alpha-subunits composing KV channels different biophysical 
properties are conveyed that resemble IKA or IKDR channels found in native cells.  It is 
been proposed that expression of certain alpha subunits give rise to currents which 
behave in a classical delayed rectifier manner, these subunits are KV1.1, 1.2, 2.1, 2.2, 
3.1 and 3.2 (Mathie et. al., 1998).  Expression of the alpha subunits KV1.4, 3.4, 4.1, 4.2 
and 4.3 results in the transmission of currents that correspond to IKA type currents 
(Mathie et. al., 1998).  The main pharmacological agents used to block KV channels are 
tetraethylammonium ions (TEA) and 4-AP, however these classical KV channel 
blockers are not specific (table 3.1).  TEA acts on two separate sites on the KV channel, 
one site located on the external side and one located on the internal face of the channel 
(Mathie et. al., 1998).  The external TEA binding site is located on the carboxyl end of 
the pore region of the alpha-subunit, and it has a cysteine residue located here which 
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confers sensitivity to TEA (Kavanaugh et. al., 1991, 1992).  The alpha-subunits that 
have this residue include KV1.1, 1.6, 2.1, 2.2, 3.1-3.4, making channels composed with 
these subunits, more sensitive to external TEA blockade.  In the case of KV1.1, for TEA 
to bind it requires all of the four alpha subunits to contribute to the binding process, 
therefore heteromeric channels may show varying degrees of TEA blockade 
(Kavanaugh et. al., 1992; Mathie et. al., 1998).  TEA (10 mM) has been shown to 
depolarise the membrane of rabbit PASMCs (Casteels et. al., 1977), and 1 mM TEA 
depolarised and contracted rat PASMCs (Suzuki & Twarog, 1982).  Within this 
concentration range (1 – 10 mM) TEA inhibits a number of KV channels, including 
KV1, 2 and 3 (table 3.1).  Using TEA to identify KV
 
channels involved in maintaining 
the resting membrane potential is complicated further as TEA has also been shown to 
block KCa
 
channels; ≤ 10 mM TEA has been shown to be a blocker of BKCa channels in 
VSMCs (Nelson & Quayle, 1995).  TEA also has an effect on KCNQ channels 
(Robbins, 2001).   
 
Most of the evidence supporting the role of delayed rectifier channels in resting 
potential regulation involved the use of 4-AP.  For example, 4-AP sensitive KV channels 
that are active under resting conditions have been suggested to be the major contributors 
to the regulation of resting membrane potential in rat PASMCs (Yuan et. al., 1995).  
This drug is a blocker of KV channels, and it has been shown to reduce the resting 
potential in PASMCs and increase tension in the intact PA (Hara et. al., 1980; Osipenko 
et. al., 1997; Doi et. al., 2000).  Hara et. al., (1980) showed that 10 mM 4-AP 
depolarised the cell membrane of guinea pig PA and induced contraction.  Using mice 
PASMCs, Yuan et. al., (1995) presented evidence that 0.3 -10 mM 4-AP depolarised 
myocytes in a dose-dependent manner and furthermore 10 mM 4-AP induced an 
increase in [Ca
2+
]i.  4-AP acts by blocking the channel pore (Bouchard & Fedida, 1995) 
and the specific KV channels blocked by this drug are determined by the concentration 
used.  The concentrations of 4-AP that block various KV channels are presented in table 
3.1.  The concentration of 4-AP which Yuan et. al., (1995) showed to depolarise mice 
PASMCs (0.3 - 10 mM) indicates that KV 1, 2 and 3 were blocked (table 3.1).  At 5 - 10 
mM 4-AP, the concentration shown to increase [Ca
2+
]i (Yuan et. al., 1995; Doi et. al., 
2000) KV 1, 2 and 3 channels would be inhibited.  Like TEA, 4-AP has been seen to 
affect both IKA and IKDR currents; however it has little effect on KCNQ currents.  
Another drug that has been shown to have an effect on KV channels is capsaicin.  
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Capsaicin is a drug with several effects.  It has been shown that the main site of action 
of capsaicin is vanilloid receptors on sensory nerve fibres (Oh et. al., 1996; Wardle et. 
al., 1996; Wood et. al., 1997).  However, it has also been shown to cause pronounced 
inhibition of IKDR in PASMCs (Osipenko et. al., 2000).  Dubois, (1982) carried out a 
study in which capsaicin blocked the fast but not the slowly inactivating outward K
+
 
current in the frog node of Ranvier.  This inhibitory action of capsaicin was also studied 
using rat pituitary cells; it was shown to produce a time dependent block of fast-
activating, fast-inactivating K
+ 
current and slowly-activating, slowly-inactivating K
+ 
current (Kehl, 1994), and this block of K
+ 
current by capsaicin was due to open channel 
blockade.  The concentration of capsaicin required to block KV1 channels is 100 µM 
(Fischer et. al., 2001). 
 
KCNQ channels transmit currents which have similar biophysical properties which are 
similar to IKN (Robbins, 2001; Evans et. al., 1996), and it has been suggested that 
KCNQ channels may transmit a component of this current (Joshi et. al., 2006).  
Linopirdine inhibits KCNQ channels with the following potency profile KCNQ2 = 
KCNQ3 > KCNQ1 > KCNQ5 > KCNQ4 (Robbins, 2001).  KCNQ currents are 
inhibited by 10 µM linopirdine in SMCs, resulting in systemic arterial contraction 
(Mackie et. al., 2008) however another group found that linopirdine did not affect the 
systemic circulation, however, it did contract rat PA (Joshi et. al., 2008(submitted)).  
TASK channels have been implicated in conducting IKN (Gurney et. al., 2003).  IK 
transmitted by 2-pore domain channels, such as TASK K
+ 
channels, is blocked by zinc 
ions (Zn
2+
).  The sensitivity of TASK channels has been debated, with some authors 
suggesting that TASK1 channels are more sensitive to Zn
2+
 than TASK3 channels 
(Leonoudakis et. al., 1998; Kim et. al., 2000; Cooper et. al., 2004).  This was disputed 
by another study, which showed the reverse; that TASK3 is more sensitive to Zn
2+
, with 
TASK1 channels being relatively insensitive to the ion (Clarke et. al., 2004).  However 
it is generally agreed that TASK2 channels are insensitive to Zn
2+ 
blockade.  TASK1 
and TASK2 channels are expressed in PASMCs and the TASK current in PASMCs was 
substantially inhibited by 200 µM Zn
2+
 (Gurney et. al., 2003; Gardener et. al., 2004), 
therefore Zn
2+ 
was used to distinguish between these two channel types for the purposes 
of this study.  Zn
2+ 
has also been shown to inhibit certain KV channels (Bardoni et. al., 
1994), therefore any potential rise in PA basal tone in response to Zn
2+ 
application could 
also be attributable to KV channel blockade. 
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ATP activated K
+
 channels are sensitive to glibenclamide, with maximal inhibition at 
around 1 µM (Clapp & Gurney 1991; Clapp et. al., 1993).  KATP channels are hetero-
octomers composed of two disparate subunits.  Four of the subunits belong to the KIR 
superfamily of K
+ 
channels.  It is the other four subunits, known as SUR subunits, 
which contain sites that have high affinity for sulfonylurea compounds such as 
glibenclamide (Bryan et. al., 2004).   
 
The K
+ 
channel blockers discussed above were used in the following experiments to 
investigate the classes of K
+ 
channels involved in regulating the resting membrane 
potential in mouse PA.  Most studies to date have focused on other species of PA and 
therefore the following experiments would allow mouse PA to be compared to other 
animals in response to the K
+ 
channel blockers used.  The effects of K
+ 
channel blockers 
were investigated on WT and 5-HTT+ mice IPAs.  The aim of these experiments was to 
investigate if the classes of K
+ 
channels involved in maintaining the low tone of WT 
mouse IPA was similar to those in the PAH model, the 5-HTT+ mouse.   As mentioned 
previously, K
+ 
channel down regulation has been shown in other models of PAH.  For 
example, a loss of KV current has been observed in rat PASMCs that had chronic 
hypoxic PAH induced (Sweeney & Yuan, 2000).  The experiments carried out as part of 
this study could potentially identify if this down regulation occurs in 5-HTT+ mice 
IPAs, in which the cause of PAH is known. 
 
It has been shown that 5-HT can inhibit K
+ 
channels in a number of cell systems.  For 
example, 5-HT was found to inhibit TASK1 like K
+ 
currents and cause depolarisation in 
neurons (Czirjak et. al., 2001; Talley et. al., 2000).  TASK1 and TASK3 conductances 
are inhibited by a wide variety of Gαq-coupled receptors (Talley et. al., 2000) and more 
specifically by 5-HT2A receptors (Hopwood & Trapp, 2005).  In a recent study by 
Cogolludo et. al., (2006), it was indicated that 5-HT2A receptor activation inhibits KV 
currents in rat PASMCs and human KV1.5 channels.  In the third set of experiments 
described in this chapter, 5-HT contractile responses were investigated in the presence 
of K
+
 channel blockers in order to investigate any links between K
+
 channels and 5-HT, 
thereby potentially identifying possible interactions between K
+
 channels and 5-HT in 
mouse PA.  By repeating these experiments using IPAs from 5-HTT+ mice, this would 
highlight if any interactions between 5-HT and K
+
 channels seen in WT vessels were 
altered in the PAH model. 
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K+ channel blockers Channel of action in 
PASMC 
Concentration required to 
inhibit channel 
 
TEA (extracellular) 
 
 
1) Kv1x,  
     a)1.1 
     b)1.2 
     c)1.3 
     d)1.6 
2) Kv2x,  
3) Kv3X 
4) BKCa 
5) KCNQ (incomplete) 
1) 
    a) 0.5 mM 
χ
 
    b) > 10 mM 
χ 
 
    c) 10- 50 mM 
χ
   
    d) 1.7 – 7 mM 
χ
 
2) 4-10 mM
 χ
 
α
 
3) 0.09-0.3 mM 
χ  α
 
4) 1 mM 
β 
5) 30 mM 
γ
 
4-AP 
 
 
1) Kv1x,  
     a)1.1 
     b)1.2 
     c)1.3 
     d)1.4 
     e)1.5 
     f)1.6 
     g)1.7 
2) Kv2x 
3) Kv3x 
4) Kv4.1 (4.2 and 4.3  blocked 
incompletely) 
1) 
    a) 0.16 - 1.1 mM 
χ
 
α       
                                 
b) 0.2 - 0.8 mM 
χ
 
α 
 
    c) 0.2 - 1.5 mM 
χ
 
α
   
    d) 0.7 - 13 mM 
χ
 
α
 
    e) < 0.1 – 0.4 mM
 χ
 
α
 
    f) 0.3-1.5 mM 
χ
 
α     
    
    g) 0.25 mM 
χ
 
2) 0.5- 4.5 mM
 χ
 
α
 
3) 0.02 – 1.2 mM
 χ
 
α
  
4) 9 mM 
χ
 (2 – 10 mM) 
  
 
Capsaicin 
 
 
1) KV1.1, 1.2, 1.3, 1.5  
2) KV3.1  
1) 100 µM* 
1 – 3 µM
 θ
 
 
Glibenclamide 
 
 
KATP  10 µM 
β , λ
  
 
Zinc chloride 1) TASK1 
2) KV1.1, 1.4, 1.5 
1)175 µM 
ν
  
2) ≥ 200 µM 
τ
 
Linopirdine 
 
 
KCNQ 10 µM 
ο
 
pi
  
  
 
Table 3.1  Pharmacology of K+ channel blockers.  
χ
 Coetzee et. al., 1999; 
α 
Mathie et. al., 1998; 
β 
Yildiz et. al., 2006; 
γ
 Suh & Hille, 2007;  
* Grissmer et. al., 1994; 
θ 
Lo et. al., 1995; 
λ
 Lopez-Valverde et. al., 2005; 
ν
 
Leonoudakis et. al., 1998;  
τ 
Harrison et. al., 1993; 
 ο 
Joshi et. al., 2006;  
pi
 Mackie et. al.,  
2008. 
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3.2 Results 
3.2.1  Effect of 50 mM KCl in WT and 5-HTT+ mice IPAs 
Contractions in WT and 5-HTT+ mice IPA were measured relative to the contraction 
induced by 50 mM KCl (figure 3.1).  The contraction to 50 mM KCl in WT tissues was 
1.7 ± 0.13 mN (n = 12) and in 5-HTT+ vessels the contraction induced was 1.7 ± 0.12 
mN (n = 12).  There was no significant difference between these values. 
 , 
          3.2.2  Effects of K+ channel blockers in WT and 5-HTT+ mice 
IPAs. 
Increasing concentrations of TEA (1 nM – 1 M), were applied to vessels under resting 
tone. The resulting contractions were measured and concentration response curves 
constructed.  In IPAs from WT and 5-HTT+ mice, the blocker had very little effect on 
resting tone within the concentration range that has been shown to inhibit K
+
 channels 
(figure 3.2).  From the concentration response curves it can be seen that TEA only 
began to have an effect on resting tone at concentrations above 10 mM.  The pEC50 
value of the response in WT mice IPAs was 1.5 ± 0.1, and in and 5-HTT+ vessels the 
pEC50 value was 1.0 ± 0.03 and there was no statistically significant difference 
between these values.   
 
4-AP produced concentration dependent constriction in mice IPA vessels (figure 3.3), 
however contraction was not seen until a concentration of 3.5 mM was reached in the 
bathing solution.  The maximum response was not reached at the highest concentration 
of 4-AP tested (10 mM). In response to 10 mM 4-AP, the contraction induced in WT 
vessels was 25.3 ± 7.0 % (n = 6) of the response induced by 50 mM KCl, whereas in 5-
HTT+ vessels 10 mM 4-AP induced a much greater contraction of 75.0 ± 8 % (n = 5) (P 
< 0.001), but overall the sensitivity to 4-AP was similar in the vessels from both types 
of mice. 
 
 
 
 
 
 
 81 
 
 
 
 
 
WT 5-HTT+
0.0
0.5
1.0
1.5
2.0
C
o
n
tr
a
c
ti
o
n
 r
e
s
p
o
n
s
e
 t
o
 5
0
 m
M
 K
C
l 
(m
N
)
 
 
 
Figure 3.1 Effect of 50 mM KCl in WT and 5-HTT+ mice IPAs. 
Concentration obtained to KCl (50 mM).  Data are expressed as force induced in mN.  
Columns represents the mean ± SEM (n = 12). 
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Figure 3.2 TEA induced contractions in WT and 5-HTT+ mice IPAs. 
Concentration response curve obtained to TEA (1 µM – 1 M).  Data are expressed as a 
percentage of the reference contraction to 50 mM KCl in each vessel.  Each point 
represents the mean ± SEM (n = 6 – 7). 
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Figure 3.3 4-AP induced contractions in WT and 5-HTT+ mice IPAs. 
Concentration response curve obtained to 4-AP (1 µM – 10 mM).    Data are expressed 
as a percentage of the reference contraction to 50 mM KCl in each vessel.  Each point 
represents the mean ± SEM (n = 5 - 6). *** = P < 0.001 indicates difference from WT 
value. 
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WT and 5-HTT+ mice IPAs failed to constrict in response to glibenclamide at 
concentrations where this drug has been shown to block KATP channels.  At 10 µM 
glibenclamide, there was no change in the tension of WT or 5-HTT+ mice IPAs (figure 
3.4). 
 
Capsaicin induced very little vasoconstriction in WT and 5-HTT+ mice IPAs, (figure 
3.5).  At the highest concentration of tested (100 µM), which has been shown to block 
KV1 channels (Grissmer et. al., 1994), the amplitude of contraction in WT mice IPA 
was only 2.2 ± 3 % (n = 5) of the contraction induced by 50 mM KCl and 0.12 ± 0.1 % 
(n = 8) in 5-HTT+ mice.  There was no significant difference between these responses.   
 
At the concentration required to inhibit TASK channels (100 – 500 µM), ZnCl2 had no 
effect on resting tone in WT or 5-HTT+ mice IPAs.  Vasoconstriction in both types of 
vessel occurred at concentrations of 1 mM and above (figure 3.6). The maximal 
contraction was not reached even at the highest concentration tested (350 mM). 
 
In mice IPAs, linopirdine produced concentration dependent constriction over the range 
of concentrations that inhibits KCNQ channels (< 10 µM) (Coetzee et. al., 1999) (figure 
3.7).  The maximum response to linopirdine in WT vessels was reached at 3.5 µM.  
However, linopirdine relaxed WT vessels at concentrations above 10
 
µM, as previously 
described (Joshi et. al., 2006).  There was a significant difference (P < 0.05) in the 
Emax for PA constriction between WT and 5-HTT+ mice.  The maximum contractile 
response to linopirdine in WT mice IPAs was measured at approximately 3.5 µM with 
an Emax value of 56 ± 9 %, (n = 7) of the contraction induced by 50 mM KCl.  In the 
case of the 5-HTT+ vessels the Emax was 27 ± 2 %, (n = 8), measured at 100 µM.  The 
difference in the linopirdine response between the vessels from the two animals is also 
shown by a significant difference between the pEC50 values, which were 7 ± 0.2 for 
WT vessels and 5 ± 0.1 for 5-HTT+ vessels (P < 0.001).  In WT mice IPAs, linopirdine 
produced relaxation at 100 µM, whereas in 5-HTT+ vessels relaxation was not seen 
until 300 µM.  
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Figure 3.4 Glibenclamide induced contractions in WT and 5-HTT+ mice IPAs. 
Concentration response curve obtained glibenclamide (1 nM – 1 mM).  Data are 
expressed as a percentage of the reference contraction to 50 mM KCl in each vessel.  
Each point represents the mean ± SEM (n = 4 - 6). 
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Figure 3.5  Capsaicin induced contractions in WT and 5-HTT+ mice IPAs. 
Concentration response curve obtained to capsaicin (1 nM – 100 µM).  Data are 
expressed as a percentage of the reference contraction to 50 mM KCl in each vessel.  
Each point represents the mean ± SEM (n = 5 - 8). 
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Figure 3.6 ZnCl2 induced contractions in WT and 5-HTT+ mice IPAs. 
Concentration response curve obtained to ZnCl2 (1 nM – 350 mM).  Data are expressed 
as a percentage of the reference contraction to 50 mM KCl in each vessel.  Each point 
represents the mean ± SEM (n = 6). * = P < 0.05 indicates difference from WT value. 
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Figure 3.7 Linopirdine induced contractions in WT and 5-HTT+ mice IPAs. 
Concentration response curve obtained to Linopirdine (1 nM – 350 µM).  Data are 
expressed as a percentage of the reference contraction to 50 mM KCl in each vessel.  
Each point represents the mean ± SEM (n = 7 – 8).  *** = P < 0.001 indicates difference 
from WT pEC50.  δ = P < 0.05 indicates difference from WT Emax.  
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3.2.3 Effects of K+ channel blockers on 5-HT induced constriction  
Having established the effects of K
+
 channel blockers on resting tone, the next step was 
to determine if they had an effect on the constrictor response to 5-HT.  5-HT has been 
shown to induce contraction in rat PAs over a 1 nM to 350 µM concentration range 
(MacLean et. al., 1996b).  The 5-HT-induced concentration dependent contraction 
responses found in WT mice IPAs were also seen in 5-HTT+ mice IPAs.  5-HT elicited 
contraction in IPA vessels from WT mice more potently than in 5-HTT+ mice (figure 
3.8).  5-HT began to induce contraction in WT mice IPAs at 35 nM – 100 nM, whereas 
in 5-HTT+ vessels, the first contraction to 5-HT occurred at 1 µM.  The pEC50 values 
were significantly different between the WT and 5-HTT+ vessels, with values of 7 ± 0.1 
(n = 11) and 5 ± 0.1 (n = 6) respectively (P < 0.001).  The maximum response induced 
by 5-HT did not differ between the vessels; the Emax value in WT vessels was 98 ± 7 % 
of that induced by 50 mM KCl, and 86 ± 8 % for 5-HTT+ vessels.    
 
In experiments investigating the effects of K
+ 
channel blockers on 5-HT induced 
contraction, tissue matched IPA were used.  In each experiment one segment of IPA 
was pre-treated with a K
+ 
channel blocker.  A segment of IPA from the same mouse 
lung was treated with vehicle.  The sensitivity of WT and 5-HTT+ mice IPAs to 5-HT 
was unaffected by the presence of 10 mM TEA (figure 3.9).  This was evident in WT 
vessels as pEC50 values were the same for both control responses and responses in the 
presence of TEA, which were 7 ± 0.1 (n = 6 – 7).  A similar pattern was seen between 
5-HTT+ control vessels and 5-HTT+ vessels pre-treated with TEA; pEC50 values were 
5.3 ± 0.1 (n = 6) compared to 5.6 ± 0.1 (n = 6), respectively.  The original 5-HT potency 
difference between WT and 5-HTT+ mice IPAs remained in the presence of TEA, as 
pEC50 values remained different (P < 0.001). 
 
In the presence of 3 mM 4-AP, the 5-HT induced contraction response remained 
unchanged in WT mice IPAs (figure 3.10).  5-HT was equally as potent in the control 
environment as when in the presence of 4-AP in contracting WT vessels; the pEC50 
value was 7 ± 0.1 (n = 5 – 7) in both environments.  In 5-HTT+ mice IPAs there was 
significant difference between the potency of 5-HT in control environment and when 4-
AP was present.  In 5-HTT+ vessels, the 5-HT concentration response curve was shifted 
to the left in the presence of 4-AP, resulting in a pEC50 value of 5.8 ± 0.1 (n = 7) 
compared with 5.4 ± 0.1 (n = 7) in the control environment (P < 0.01).    
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ZnCl2 did not affect the potency of 5-HT in WT or 5-HTT+ vessels (figure 3.11).  In the 
case of WT mice IPAs, 5-HT induced contraction had a pEC50 value of 7 ± 0.1 (n = 6) 
and 7 ± 0.04 (n = 6) in the presence and absence of 300 µM ZnCl2, respectively.  The 
pEC50 value for 5-HT acting on 5-HTT+ vessels was unchanged by the presence ZnCl2 
in the bathing solution, at 5 ± 0.1 (n = 6). 
 
Pre-incubation of IPAs with 100 nM linopirdine did not alter the potency of 5-HT in 
WT or 5-HTT+ mice.  This KCNQ channel blocker failed to change the pEC50 value in 
WT or 5-HTT+ mice IPAs (figure 3.12). The pEC50 value for 5-HT induced 
contraction in WT mice IPAs in the presence of 100 nM linopirdine was 7 ± 0.2 (n = 7) 
compared with 7 ± 0.1 (n = 7) in the control environment.  In 5-HTT+ mice vessels, the 
pEC50 value for 5-HT induced contraction was 5. ± 0.1 (n = 7 - 8) in the presence and 
absence of linopirdine. 
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Figure 3.8 5-HT-induced contractions in WT and 5-HTT+ mice IPAs. 
Concentration response curve obtained to 5-HT (1nM – 350 µM).  Data are expressed as 
a percentage of the reference contraction to 50 mM KCl in each vessel.  Each point 
represents the mean ± SEM (n = 6 – 11).  *** = P < 0.001 indicates difference from WT 
pEC50.   
 
 
 
 
 
 
 
 
 
 
 89 
-10 -9 -8 -7 -6 -5 -4 -3
-10
0
10
20
30
40
50
60
70
80
90
100
110
WT control (n = 6)
5-HTT+ control (n = 6)
WT & 10 mM TEA
(n = 7)
5-HTT+ & 10 mM TEA
 (n = 6)
log [5-HT]
C
o
n
tr
a
c
ti
o
n
 (
%
 r
e
s
p
o
n
s
e
 t
o
 5
0
m
M
 K
C
l)
 
Figure 3.9 Lack of effect of 10 mM TEA on 5-HT-induced contraction on IPA 
from WT and 5-HTT+ mice. 
Concentration response curve obtained to 5-HT, (1 nM – 350 µM).  Data are expressed 
as a percentage of the reference contraction to 50 mM KCl in each vessel.  Each point 
represents the mean ± SEM (n = 6 – 7). 
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Figure 3.10 Effect of 3 mM 4-AP on 5-HT-induced contraction on IPA from WT 
and 5-HTT+ mice. 
Concentration response curve obtained to 5-HT (1 nM – 350 µM).  Data are expressed 
as a percentage of the reference contraction to 50 mM KCl in each vessel.  Each point 
represents the mean ± SEM (n = 5 – 7). ** = P < 0.01 indicates a significant difference 
of the 5-HTT+ & 4-AP pEC50 from 5-HTT+ control value.   
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Figure 3.11 Lack of effect of 300 nM ZnCl2 on 5-HT-induced contraction on IPA 
from WT and 5-HTT+ mice. 
Concentration response curve obtained to 5-HT, (1 nM – 350 µM).  Data are expressed 
as a percentage of the reference contraction to 50 mM KCl in each vessel.  Each point 
represents the mean ± SEM (n = 6). 
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Figure 3.12 Lack of effect of 100 nM Linopirdine, on 5-HT-induced contraction 
on IPA from WT and 5-HTT+ mice. 
Concentration response curve obtained to 5-HT (1 nM – 350 µM).  Data are expressed 
as a percentage of the reference contraction to 50mM KCl in each vessel.  Each point 
represents the mean ± SEM (n = 7 – 8). 
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3.3  Discussion 
The effects of K
+
 channel inhibitors were tested on baseline tone in intralobar PA from 
WT and 5-HTT+ mice in order to identify potential K
+
 channels that might be important 
in regulating resting tone in these vessels.  The response to these K
+
 channel inhibitors 
were measured relative to the contraction induced by 50 mM KCl in the vessels.  The 
response to KCl was similar in both WT and 5-HTT+ IPA.  TEA, 4-AP, capsaicin, 
glibenclamide and Zn
2+
 ions all failed to change the resting tone in these vessels, within 
the concentration ranges that are specific to the blockade of K
+
 channels.  However, 
linopirdine, a blocker of KCNQ channels, did increase tone in these vessels within the 
concentration range known to inhibit KCNQ channels (< 10 µM) (Coetzee et. al., 1999). 
 
There is overlap of K
+ 
channels that are blocked by some of the K
+ 
channel inhibitors 
used in this study.  For example TEA, 4-AP and capsaicin have all been shown to block 
KV1 channels.  In these experiments, none of these blockers affected resting tone until 
very high concentrations were tested.  TEA inhibits KV1.1, 1.2, 1.3 and 1.6, with KV1.1 
channels the most sensitive, being blocked at 0.5 mM TEA (table 3.1) (Coetzee et. al., 
1999).  Between 4 – 10 mM TEA, KV2 channels are also inhibited, while a much lower 
concentration is required to inhibit KV3 channels, ~ 0.1 – 0.3 mM (Coetzee et. al., 
1999).  BKCa channels are also inhibited by 1 mM TEA (Yildiz et. al., 2006).  In this 
study, TEA failed to cause constriction of mice IPAs until a concentration of 35 - 100 
mM. This is similar to what has been reported in rat PA, were 10 mM TEA had little 
effect on basal tone (Archer et. al., 1996).  The resting potential was similarly found to 
be insensitive to TEA in rabbit and rat PASMCs (Archer et. al., 1996; Evans et. al., 
1996).  At concentrations of 35 – 100 mM, the action of TEA may not be specific to 
blockade of K
+
 channels, and therefore constriction at high TEA concentrations could 
be due to an action distinct from K
+ 
channel blockade altogether. At concentrations of > 
10 mM, the osmolarity of the Krebs solution bathing the IPA vessels would change, 
which may lead to hyperosmostic stress and affect the way the vessels respond to TEA.  
Osmolarity of the bathing solution has been shown to affect responses to agonists in 
other studies.  For example, in rat tail artery, the response to the constrictor agonist PE 
was nearly doubled in a hyperosmotic environment relative to that in an isosmotic 
medium (Rocha et. al., 1995).    
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4-AP inhibits KV1 channels within the very low mM range (see table 3.1).  KV1.5 is the 
most sensitive, being blocked by < 0.1- 0.4 mM 4-AP (Coetzee et. al., 1999).   4-AP 
also inhibits KV2, KV3 and KV4, with KV3 channels, (blocked at 0.02 – 1.2 mM), being 
the most sensitive of the three groups (Coetzee et. al., 1999).  4-AP had no effect on the 
resting tone of mice IPAs until the concentration of 4-AP within the bathing solution 
reached 3.5 mM.  This concentration is well above the concentration required to block 
most KV channels, with the exception of KV 4.1.  In addition, 4-AP has been shown to 
be much less potent in blocking heteromeric KV1.4/ KV 1.5 channels, with an IC50 value 
of 7 – 8 mM (Po et. al., 1993).  The maximum contraction was not necessarily reached 
with the maximum concentration of 4-AP tested (10 mM), but at 10 mM, contraction 
was greater in WT mice IPA relative to 5-HTT+ mice IPA.  If the contractile effect of 
4-AP reflects inhibition of K
+
 channels, the channels involved are likely to be Kv4.1 or 
heteromeric KV1.4/ KV 1.5 channels, and the expression of these may be altered in the 
5-HTT+ mouse.  However due to the non-specific nature of 4-AP at these high 
concentrations, the observed effects may be unrelated to an action on K
+ 
channels.  As 
with TEA, osmotic changes may also become relevant at these concentrations.  It has 
previously been found that hypertensive pulmonary vessels show an increased 
sensitivity to 4-AP (Osipenko et. al., 1998; Priest et. al., 1998), which suggests that 4-
AP sensitive channels may make a greater contribution to the resting membrane 
potential in PAH.  Osipenko et. al. (1998) showed that 1 mM 4-AP induced a greater 
contraction in the hypertensive rat PA relative to control rat vessels when the PAH was 
induced by chronic hypoxia.  The results shown in this chapter were conducted using a 
different model of PAH, the 5-HTT+ mouse model.  If the contractile effect of 10 mM 
4-AP on 5-HTT+ mice vessels does reflect inhibition of KV channels, then the results 
suggests that any change in K
+
 channel expression that develops in the 5HTT+ mouse is 
different from that seen in the chronic hypoxic mouse.   
 
The ability of capsaicin to induce vasoconstriction was revealed in canine arteries (Toda 
et. al., 1972).  Capsaicin induces contraction in canine mesenteric arteries with an IC50 
value of 3 µM (Porszasa et. al., 2002).  KV currents are blocked by capsaicin in rat 
pituitary cells (Kehl, 1994).  At 100 µM capsaicin inhibits the KV1 family of voltage 
gated K
+
 channels, and this concentration has been shown to block KV1 channels in 
rabbit PASMCs (Osipenko et. al., 2000).  In this study, however, capsaicin failed to 
induce a change in tone in IPAs from WT or 5-HTT+ mice.   
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Taken together, the results from the experiments with TEA, 4-AP and capsaicin imply 
that the K
+ 
channels underlying the resting membrane potential of mouse IPA are not of 
the KV1 type, because these drugs failed to consistently alter the resting tone within the 
concentration ranges known to inhibit the KV1 channels.  It is therefore most unlikely 
that these channels are open at rest.  Using the results from the TEA and 4-AP 
experiments, the same rationale can be used to suggest that the KV2 subfamily of KV 
channels are not involved in maintaining the low resting tension in mouse IPA.   
 
The contribution of KATP channels to resting tone in mice IPAs was investigated using 
glibenclamide.  In this study glibenclamide failed to alter IPA tone from WT and 5-
HTT+ mice.  This would suggest that KATP channels are not involved in the regulation 
of tone in these vessels.  This is consistent with the proposal that this subset of K
+ 
channels is not open under basal conditions (Clapp & Gurney, 1992). 
 
TASK channels were investigated in WT and 5-HTT+ mice IPAs using ZnCl2.  ZnCl2 
failed to constrict mice IPAs until the millimolar range.  This may have been due to an 
action of Zn
2+
 independent of its effect on K channels, as Zn
2+
 can block VOCCs 
(Busselberg et. al., 1994).  Therefore the possibility that this effect counteracted any 
constriction must be considered.  However data discussed below suggests that this 
explanation is unlikely. Thus the lack of effect of Zn
2+
 until mM concentrations argues 
against a substantial involvement of TASK channels in regulating the resting membrane 
potential of PASMCs in mice IPA.   
 
This study provides evidence of a potential role for KCNQ channels in the regulation of 
low resting tone in mice IPAs.  In WT mice IPAs, linopirdine induced contraction at a 
concentration of ~ 10 nM.  Linopirdine is considered to be a selective blocker of KCNQ 
channels (Jentsch, 2002; Robbins, 2001).  Thus it seems likely that KCNQ channels 
were open at rest and contributing to the resting membrane potential in the WT mice 
PASMCs.  Linopirdine was less effective in 5-HTT+ vessels, but again it induced an 
increase in tone < 10 µM.  This concentration corresponds to KCNQ channels being 
open at rest even in 5-HTT+ mice PASMCs, so they may contribute to regulating the 
membrane potential in these vessels also.  This is consistent with previous studies; for 
example KCNQ channels have been proposed as the K
+ 
channels setting the resting 
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membrane potential in neurons (Oliver et. al., 2003).  A paper under review suggests 
that KCNQ channels are major regulators of resting membrane potential in PASMCs 
(Joshi et. al., 2008(submitted)).   
 
The reduced activity of linopirdine in 5-HTT+ mice IPAs is interesting.  In the diseased 
state, there may be down regulation of KCNQ channels or altered activity of KCNQ 
channels (e.g. β-subunit regulation).  A loss of KCNQ channel expression in 5-HTT+ 
mice PASMCs might be expected to lead to depolarisation of these cells, if KCNQ 
channels are important in the regulation of low resting tone.  It could be the case that 
linopirdine was more potent in WT vessels relative to 5-HTT+ mice IPAs due to 5-
HTT+ PASMCs being more hyperpolarised than those in WT vessels.  If the latter was 
the case then a higher concentration of linopirdine may be required to depolarise the 5-
HTT+ mice PASMCs sufficiently to reach the threshold of contraction.  This is because 
a greater proportion of K
+
 channels would need to be blocked in order for the membrane 
to reach a level of depolarisation at which VOCCs would open.  It is interesting that the 
differential response to linopirdine in WT and 5-HTT+ vessels resembles the 
differential sensitivity to 5-HT.  Therefore, another possible explanation for reduced 
sensitivity to linopirdine in 5-HTT+ mice IPAs relative to WT vessels could be that 
linopirdine could be interacting with 5-HT receptors, the expression of which is altered 
in 5-HTT+ mice, with an increased expression of 5-HT2A receptors (Dempsie et. al., 
2008(submitted)).   
 
5-HT was more potent in WT mice IPAs relative to 5-HTT+ mice.  This has also been 
shown in a recent publication, which also showed that this reduction in 5-HT sensitivity 
in 5-HTT+ mice was reversed by a 5-HTT+ inhibitor (Dempsie et. al., 
2008(submitted)).  This indicates that the reduction in potency of 5-HT is due to the 
over-expressed 5-HTT removing 5-HT
 
from receptor sites in 5-HTT+ mice.   
 
Experiments were conducted in this study to investigate possible inhibition of K
+
 
channels by 5-HT in WT and 5-HTT+ mice IPAs, as this has been suggested to occur in 
PA from rats (Cogolludo et. al., 2006).  Due to the increased number of 5-HTT in 5-
HTT+ mice IPAs (which act to remove 5-HT from solution) a higher concentration of 
5-HT is required to act on the 5-HT receptors to initiate contraction, relative to WT 
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vessels.  Of all the K+ channel inhibitors tested only 4-AP altered the 5-HT response, 
and this potentiation of the 5-HT response was only found in 5-HTT+ mice, (with the 5-
HT concentration response curve shifted to the left).  This may be due to a synergistic 
action between 5-HT and 4-AP, leading to a greater effect of these drugs in combination 
than what is found when they are acting in isolation.  At a concentration of 3 mM 4-AP, 
most of the KV1, 2 and 3 channels should be blocked (table 3.1).  This inhibition of KV 
may induce some depolarisation of the underlying PASMCs, but not enough 
depolarisation to activate VOCC sufficiently to evoke contraction.  Chapter four 
presents results indicating that a proportion of the 5-HT induced increase in [Ca
2+
]i is 
not voltage dependent.  Therefore with 5-HT acting to increase [Ca
2+
]i within PASMCs 
(by voltage independent mechanisms), and 4-AP depolarising the membrane, these 
agents would collectively result in a potentiation of the 5-HT response in 5-HTT+ 
vessels.  The results suggest a potentially small contribution of KV
 
channels in 
maintaining resting membrane potential of PASMCs in 5-HTT+ vessels, but not enough 
to allow membrane potential to depolarise sufficiently to evoke contraction when 4-AP 
when is applied on its own.  Thus it is possible that in the PASMCs of 5-HTT+ vessels 
there is a greater contribution of KV channels to the resting potential than in WT vessels.  
In this way, the nature of the K
+
 channels regulating membrane potential in PAH caused 
by 5-HTT over-expression may show a similar, but smaller, shift to that observed in 
PAH induced by chronic hypoxia (Osipenko et. al., 1998). 
 
5-HT induced contraction of WT and 5-HTT+ mice IPA was not inhibited by any of the 
K
+ 
channel blockers tested (TEA, 4-AP, ZnCl2 and linopirdine).  This result could be 
analysed in two different ways.  Firstly, it may be suggested that as the K
+ 
channel 
blockers did not inhibit the 5-HT induced response, then 5-HT was not inducing its 
effect via inhibition of the K
+ 
channel being blocked by one of the drugs above.  
However, it may be argued, that if 5-HT was acting to inhibit the K
+
 channel under 
investigation (i.e. acting in the same manner as TEA, 4-AP, ZnCl2 or linopirdine) , then 
addition of the K
+ 
 channel blocker would not alter the response to 5-HT.  Further 
investigation is necessary to investigate if 5-HT inhibits K
+
 channels in mice IPA.  
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3.4  Conclusion 
The experiments carried out in this part of the project suggest that of all the KV channels 
investigated, only members of the KCNQ subfamily are open at rest and play an 
important role in maintaining the resting tone within mouse IPA, with a potentially 
minor role for 4-AP sensitive channels also involved in the 5-HTT+ mice vessels.  A 
further finding was that the potency of linopirdine inducing contraction was reduced in 
the 5-HTT+ mouse model of PAH.  The linopirdine potency difference observed 
between the two vessel types mirrored that seen with 5-HT, with the WT vessels being 
more sensitive to both linopirdine and 5-HT.  Despite the apparent contribution of 
KCNQ channels to resting tone, linopirdine did not alter the sensitivity of mice IPAs to 
5-HT in either WT or 5-HTT+ mice, implying that a change in activity of KCNQ 
channels was not involved in the mechanism leading to 5-HT induced constriction. 
 
Experiments investigating potential links between 5-HT contraction and K
+
 channel 
blockade indicated that 4-AP was the only blocker that affected the 5-HT induced 
contraction, and only in 5-HTT+ mice IPAs.  This result could suggest a potential role 
for 4-AP sensitive KV channels in the 5-HT response.   
 
The chapters that follow aim to investigate the mechanisms underlying the difference in 
potency of 5-HT and linopirdine between WT and 5-HTT+ mice IPAs. 
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Chapter 4 
 
 
Mechanisms of action underlying 
vasoconstriction induced by 
5-HT and linopirdine 
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4.1  Introduction 
Vasoconstriction mediated by 5-HT is induced via an increase in the concentration of 
free Ca
2+ 
within the cytoplasm (Yuan et. al., 1997).  The mechanism by which 5-HT 
increases [Ca
2+
]i and hence induces vasoconstriction in WT and 5-HTT+ mice IPA was 
investigated in this chapter. 
 
The free [Ca
2+
]i in muscle and other cells at rest is approximately 20-50 nM (Martonosi 
& Pikula, 2003).  A large concentration gradient exists between the extracellular 
medium, the sarcoplasmic reticulum (SR) and the cytoplasm.  In smooth muscle the free 
[Ca
2+
]i is approximately 10,000 times lower than that present in the extracellular space, 
which is in the millimolar range (Marin et. al. 1999), whereas in the SR the Ca
2+ 
concentration is approximately 0.1 - 2.0 mM (Martonosi & Pikula, 2003).  The large 
gradients are maintained by three main mechanisms; Ca
2+ 
entry from the extracellular 
space, exchange of Ca
2+ 
between the cytoplasm and the intracellular stores and Ca
2+ 
extrusion (Karaki et. al., 1997).  Factors that determine the extent of Ca
2+ 
entry include 
the magnitude of the membrane potential, the transmembrane Ca
2+ 
gradient and Ca
2+
 
channel activity.  Ca
2+
 enters the cytoplasm through Ca
2+ 
channels located in the plasma 
and SR membranes.  VOCC opening is regulated by membrane potential.  VOCCs 
transmit Ca
2+ 
into SMCs when the membrane is depolarised.  The VOCC channels 
involved in regulating Ca
2+
 influx in PASMCs are L-type channels (McMurtry et. al., 
1976).  A group of drugs known as dihydropyridines (e.g. nifedipine, nicardipine) block 
these channels directly and are used as vasodilators (Spah et. al.,1988; Turlapaty et. al., 
1989).  Contractile responses to 5-HT are partially inhibited by VOCC blockers in PA 
from human, canine and sheep tissue (Drummond & Wadsworth, 1994; Mikkelsen et. 
al., 1983; Wilson et. al., 2005).  However, in IPA derived from rat lungs, nicardipine 
did not significantly reduce the increase in free [Ca
2+
]i observed in response to 5-HT 
(Guibert et. al., 2003).  As part of the 5-HT induced response in PA involves VOCC in 
the above tissues, then it may be the case that 5-HT induces membrane depolarisation of 
PASMCs, causing the membrane potential to move towards a potential at which 
VOCCs are open, resulting in Ca
2+
 influx (McMurtry et .al,. 1976), and hence SMC 
contraction.  5-HT was shown previously to induce membrane depolarisation, for 
example, in rat PASMCs (Cogolludo et. al., 2006).  5-HT induced contraction of 
isolated rat PASMCs was proposed to be due to 5-HT acting on 5-HT2A receptors to 
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reduce K
+
 current through K
+
 channels and cause depolarisation (Cogolludo et. al., 
2006). 
  
Contraction of PASMCs can also occur via a mechanism known as 
pharmacomechanical coupling, which depends neither on changes in membrane 
potential (although changes may occur) nor, consequently, on Ca
2+ 
entry via VOCCs.  
Pharmacomechanical coupling results in a rise in free [Ca
2+
]i induced by a combination 
of Ca
2+ 
release from intracellular stores and Ca
2+
 entry through non voltage operated 
channels.  One major (non voltage dependent) route by which Ca
2+
 can cross the 
membrane is via store operated Ca
2+
 channels (SOCCs).  These are defined as plasma 
membrane Ca
2+ 
channels that are opened in response to a decrease in the concentration 
of Ca
2+ 
within the intracellular stores, (Putney, 1993).  Activation of SOCCs allows 
Ca
2+
 entry into the cytoplasm and the re-loading of intracellular Ca
2+
 stores (Berridge 
1995).  This is also known as capacitative Ca
2+
 entry (CCE) or depletion activated entry 
(Putney 1999, 2001).  A second important non voltage dependent route by which Ca
2+
 
can enter the cell is via receptor-operated Ca
2+
 channels (ROCCs) which are activated 
by agonists acting on a range of GPCRs.   ROCCs provide a variety of pathways by 
which Ca
2+ 
can be delivered into the cytoplasm and the SR in order to initiate and/or 
maintain specific types of intracellular Ca
2+ 
signals (Barritt et. al., 1999).  In the SR 
membrane of SMCs there are two types of Ca
2+
 channel that play a role in releasing 
Ca
2+
 from the stores.  The IP3 receptor (IP3R) is activated by IP3 and provides the main 
mechanism by which the activation of GPCRs causes a rise in [Ca
2+
]i. 
 
5-HT receptor 
activation results in IP3 production and Wilson et. al. (2005) showed that activation of 
IP3 receptors is critical to the initiation of cytosolic Ca
2+ 
rises in response to 5-HT.   
    
Although [Ca
2+
]i is the primary regulator of SMC contraction, it has been demonstrated 
that this Ca
2+
-calmodulin dependent MLC kinase pathway does not solely account for 
the
 
mechanisms of agonist induced contraction.  Ca
2+
 sensitisation, (an increase in force 
at a constant [Ca
2+
]i, accounts for another important mechanism in contraction of SMCs 
(Somlyo & Somlyo, 1994).  Small G protein RhoA and its downstream effector Rho 
kinase were demonstrated to play important roles in mediating the Ca
2+ 
sensitivity of 
SMC contraction through the inhibition of MLCP (Somlyo & Somlyo, 1994).  As stated 
previously MLCP plays a major role in the
 
control of MLC dephosphorylation and 
hence the level of contraction of SMCs.  The drug Y-27632 inhibits Rho kinase and 
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therefore promotes relaxation (Chiba & Misawa, 2004).  Agonists and second 
messengers modify
 
the MLCK/ MLCP activity ratio independently of the level of 
[Ca
2+
]i, giving rise to changes in contractile forces
 
even in the presence of a constant 
[Ca
2+
]i.  It was shown previously that 5-HT induced contraction is dependent on rho-
kinase activation (Rodat-Despoix et. al., 2008).   
 
The potency of the linopirdine induced contraction of IPA was altered in the same 
manner as the potency of 5-HT induced contraction in 5-HTT+ mice.  In this chapter it 
was investigated whether or not linopirdine behaved similarly to 5-HT due to the two 
drugs acting via the same pathways. The main aim of the work in this chapter was, 
however, to determine the mechanisms by which 5-HT induced contraction of mouse 
IPA.  The second aim was to determine if the mechanism by which 5-HT induced 
contraction differed between the WT mouse and the mouse model of PAH, the 5-HTT+ 
mouse.  The role of extracellular Ca
2+
 ([Ca
2+
]ext.) in the 5-HT induced response was 
examined to determine if it was a pre-requisite for contraction in WT and 5-HTT+ mice 
IPA.  The roles of different Ca
2+
 entry pathways were investigated in the 5-HT induced 
responses; SOCC entry, IP3 induced Ca
2+
 release and VOCC entry.  The role of 
increased Ca
2+ 
sensitivity in response to 5-HT was investigated by blocking rho kinase.  
The role of the PASMC membrane potential in response to 5-HT was determined both 
by measuring the effect of 5-HT on membrane potential in isolated PASMCs and 
examining how the contractile response of IPA was affected by conditions that 
depolarise PASMC.   It was also investigated if depolarising the membrane potential 
could remove the potency differences of 5-HT and linopirdine between WT and 5-
HTT+ mice.   
 
4.2  Methods 
Methods are described in chapter two, using the following protocols. 
 
4.2.1 Effect of ketanserin on contractile responses to 5-HT and 
linopirdine 
Linopirdine was the only K
+
 channel blocker that was more potent in causing 
contraction of WT mice IPA relative to IPA from 5-HTT+ mice.  It was therefore 
important to distinguish if the differing level of potency of linopirdine between the 
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vessel types was due to linopirdine acting as a 5-HT receptor agonist.  Therefore the 
linopirdine induced contractions were investigated in the presence of the 5-HT2A 
receptor antagonist, ketanserin (10 nM).   
 
4.2.2  Resting membrane potential measurement 
Experiments were conducted to investigate if 5-HT induced contraction was the result 
of 5-HT changing the membrane potential of PASMCs in IPAs from WT and 5-HTT+ 
mice.  5-HT was added to the local environment of the cell at 1 µM and subsequently 10 
µM, with the resting potential continuously recorded.  Recordings were made until the 
membrane potential was stable. 
 
4.2.3 Influence of extracellular K+ concentration ([K+]ext.) on 
contraction responses to 5-HT and linopirdine 
In PASMCs the contractile response is induced by depolarisation of the membrane and/ 
or by pharmacomechanical coupling, which does not depend on depolarisation (Casteels 
et. al., 1977).  Raising [K
+
]ext. shifts the K
+ 
equilibrium potential and causes membrane 
depolarisation.  Subsequently VOCCs are opened, leading to Ca
2+
 entry and an increase 
in free [Ca
2+
]i, resulting in vasoconstriction.  The ability to change membrane potential 
by changing [K
+
]ext was used to investigate the method by which 5-HT and linopirdine 
induced their contractile responses in IPA from WT and 5-HTT+ mice.  Myography 
experiments were conducted in the presence of varying [K
+
]ext. in the bathing PSS.   
 
4.2.4 Influence of [Ca2+]ext. and VOCC on contractile responses 
to 5-HT and linopirdine 
To role of [Ca
2+
]ext.
 
in the contractile response to 5-HT in WT and 5-HTT+ mice was 
investigated by removing [Ca
2+
]ext. from the bathing solution.  Experiments were 
conducted in which 5-HT was added to IPAs in control bathing PSS, which were then 
washed with Ca
2+
 free PSS.  The response to 5-HT was then measured in the absence of 
[Ca
2+
]ext. in the bathing PSS. 
 
To investigate if constriction induced by 5-HT and linopirdine was mediated by Ca
2+
 
influx through VOCCs, the L-type Ca
2+
 channel blocker nifedipine was used.  
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Contractions to 5-HT and linopirdine were investigated in the presence of 1 µM 
nifedipine in WT and 5-HTT+ mouse IPA.   
 
4.2.5 Effect of SOCC and store release inhibitors on contractile 
responses to 5-HT  
To investigate the role of SOCCs in the contractile response to 5-HT in mouse IPA, 
vessels from WT and 5-HTT+ mice were tested with increasing concentrations of 5-HT 
in the presence 50 µM NiCl2 and 75 µM 2-APB. 
 
4.2.6  Influence of Rho kinase on contractile responses to 5-HT  
To investigate the role of rho kinase in the 5-HT induced contraction of IPA from WT 
and 5-HTT+ mice, increasing concentrations of 5-HT were applied in the presence of 10 
µM Y-27632.   
 
4.3  Results 
4.3.1  Influence of ketanserin on linopirdine-induced contraction  
Ketanserin (10 nM) did not inhibit the linopirdine induced contraction in IPA from WT 
or 5-HTT+ mice (figure 4.1).  The sensitivity of WT mice IPAs to linopirdine remained 
the same in the absence and presence of ketanserin: pEC50 values in WT control and 
WT treated tissues were 6 ± 0.1 (n = 8). The pEC50 values in the 5-HTT+ control and 
5-HTT+ treated vessels were 6 ± 0.2 (n = 9 - 10). 
 
4.3.2  Membrane potential measurement  
The resting membrane potentials of PASMCs are shown in figure 4.2 for WT and 5-
HTT+ mice cells.  There was no statistically significant difference between the resting 
membrane potentials of PASMCs isolated from WT and 5-HTT+ mice.  The absolute 
resting membrane potentials measured for WT mice PASMCs in this study was - 42 ± 4 
mV (n = 12). The cell capacitance and input resistance calculated for these cells were 21 
± 2 pF and 6 ± 2 GΩ, respectively.   PASMCs from 5-HTT+ mice had a resting 
membrane potential of -42 ± 3 mV (n = 14), the cell capacitance and input resistance 
were 18 ± 3 pF and 4 ± 1 GΩ, respectively.  
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5-HT (1 µM and 10 µM) was added directly to the area around the PASMC that was 
patch clamped.  In the PASMCs from WT mice, 5-HT significantly depolarised the 
membrane potential by 4 ± 1 mV (n = 7) at 1 µM (P < 0.01) and by 7 ± 1 mV (n = 7) at 
10 µM (P < 0.001) (figure 4.2).  Six of the seven cells responded with >3 mV 
depolarisation to 1 µM 5-HT, and all seven cells depolarised in response to 10 µM 5-
HT.    
 
The response to 1 µM 5-HT in the cells isolated from the 5-HTT+ mice tissue was a 
small but measurable depolarisation in four of the six recordings, however there was 
little overall change in membrane potential.  At 1 µM, 5-HT depolarised the membrane 
potential by 1 ± 0.3 mV (n = 6), with only one of the six cells patched clamped 
depolarising by > 1 mV.   The effect of 10 µM 5-HT on the 5-HTT+ cells was highly 
variable, with four of the six recordings showing a hyperpolarising response.  On 
average the response was depolarisation of 1 ± 2 mV (n = 6).   
 
PASMCs from WT tissue depolarised more than cells from 5-HTT+ vessels in response 
to 1 µM 5-HT (P < 0.01) and to 10 µM 5-HT (P < 0.05) (figure 4.2).  The depolarising 
action of 5-HT was not always reversible when washing the cells with PPS. 
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Figure 4.1 Lack of effect of 10 nM ketanserin on linopirdine induced 
contraction on IPA from WT and 5-HTT+. 
Concentration response curve obtained to linopirdine (1 nM – 100 µM) in A) WT mice 
IPAs and B) 5-HTT+ mice IPAs.  Data are expressed as a percentage of the reference 
contraction to 50 mM KCl in each vessel.  Each point represents the mean ± SEM (n = 8 
– 10). 
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Figure 4.2 Effect of 5-HT on resting membrane potential of PASMCs. 
Mean values for the resting membrane potential and the 5-HT induced depolarisation in 
WT mice IPA smooth muscle (n = 7) and 5-HTT + mice IPA smooth muscle (n = 6) in 
response to A) 1 µM 5-HT and B) 10 µM 5-HT.  Data are the mean ± SEM.  (** = P < 
0.01, *** = P < 0.001 indicates difference from control value..   
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4.3.3 Contraction of IPA to 5-HT and linopirdine in the 
presence of various [K+]ext  
 
4.3.3.1  5-HT and varying [K+]ext. 
IPA vessels from WT mice were significantly more sensitive to 5-HT in the presence of 
20 mM [K
+
]ext. relative to control concentrations (figure 4.3).  The pEC50 value of the 
5-HT induced responses from WT vessels in the control environment were measured as 
7 ± 1 (n = 7) and in the presence of 20 mM [K
+
]ext. 
 
the pEC50 value was 7.6 ± 0.1 (n = 
6) (P < 0.001).  However, in the presence of 50 mM [K
+
]ext. 
 
the maximum amplitude of 
the 5-HT concentration effect curve was significantly reduced compared to that 
measured in the control environment, with the maximum response being 106 ± 3 % of 
50 mM KCl induced contraction (n = 7) in the presence of 5 mM [K
+
]ext.  and 41 ± 3 %, 
(n = 4) in the presence of 50 mM [K
+
]ext., (P < 0.001).   
 
In the presence of 20 mM [K
+
]ext. IPA vessels from 5-HTT+ mice were significantly 
more sensitive to 5-HT relative to control concentrations, with the pEC50 value of the 
5-HT induced response in the control environment measured as 5.7 ± 0.1 (n = 7), were 
as in presence of 20 mM [K
+
]ext. the pEC50 value was 6 ± 0.1 (n = 6) (P < 0.05).  The 
maximum response to 5-HT was reduced under conditions of 50 mM [K
+
]ext.   The Emax 
of the 5-HT-induced response was 97 ± 3 % of 50 mM KCl induced contraction (n = 7) 
in the presence of 5 mM [K
+
]ext., however in the presence of 50 mM [K
+
]ext. the Emax 
value was 46 ± 4 % (n = 6) (P < 0.001). 
 
Increasing the concentration of [K
+
]ext. to 20 mM in the PSS bathing WT tissue did not 
mimic the effect of 5-HTT over expression in terms of the 5-HT-induced response.  
When the [K
+
]ext. was increased to 50 mM in the PSS bathing WT IPAs, the effect on 
the 5-HT induced concentration response curve mimicked the effect of 5-HTT over 
expression to some extent, in that it shifted the curve to the right.  The pEC50 value of 
the 5-HT response in the presence of 50 mM [K
+
]ext. also remained significantly 
different to that of the 5-HTT+ control response (P < 0.001).  Therefore even a 
depolarisation of approximately 30 mV at 50 mM [K
+
]ext., which by itself caused a large 
contraction, was not able to mimic shift in the concentration response curve  seen in 5-
HTT+ mice. 
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4.3.3.2  Linopirdine and varying [K+]ext. 
In the presence of 20 mM [K+]ext., linopirdine induced contractions responses in WT 
mice IPAs was unaffected relative to the responses measured in the presence of control 
PSS (figure 4.4).  By depolarising the SMC membrane of WT vessels with 50 mM 
[K
+
]ext., linopirdine failed to induce tension, with vasorelaxation of the vessels occurring 
at approximately 10 µM linopirdine.  Under conditions of 20 mM [K
+
]ext., the sensitivity 
to linopirdine was increased in 5-HTT+ mouse IPA, shown by a shift of the 
concentration response curve to the left and an increased amplitude (P < 0.001).  In the 
presence of 50 mM [K
+
]ext., the IPA vessels from 5-HTT+ mice failed to contract in 
response to linopirdine application and exhibited vasorelaxation at ~ 10 µM. 
 
4.3.4  Effect of 5-HT in the absence of [Ca2+]ext. 
To verify whether or not [Ca
2+
]ext. was a pre-requisite for 5-HT-induced contractions in 
WT and 5-HTT+ mouse IPA, the level of contraction to 10 µM 5-HT was recorded in 
the presence and absence of [Ca
2+
]ext. (figure 4.5).  In WT mice IPAs, the contraction 
induced by 5-HT was 90 ± 8 % (n = 3) of the response to 50 mM KCl.  This contraction 
was abolished when Ca
2+
 was removed from the bathing solution (4.3 ± 3 %, P < 0.001).  
The response to 5-HT in vessels from 5-HTT+ mice was 61 ± 5 % of the response 
induced by 50 mM KCl (n = 3) and this response was also abolished in the absence of 
[Ca
2+
]ext. (4.3 ± 3 %, P < 0.001).  A significant difference between the potency of 10 µM 
5-HT in the vessels from WT mice and those from 5-HTT+ mice remained when 
[Ca
2+
]ext. was present (P < 0.05).  Since contraction only occurred when [Ca
2+
]ext.
 
was 
present, the results indicate that the Ca
2+ 
involved in the 5-HT contractile response 
enters the cell from the extracellular environment.   
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Figure 4.3 Effect of 20 mM and 50 mM [K+]ext on 5-HT induced contraction. 
Concentration response curve obtained to 5-HT (1 nM – 100 µM) in different [K
+
]ext.  in 
A) WT mice IPAs and B) 5-HTT+ mice IPAs.  Data are expressed as a percentage of 
the reference contraction to 50 mM KCl in each vessel.  Each point represents the mean 
± SEM (n = 8 – 10).  *** = P < 0.001, ** = P < 0.01  indicates difference from control 
pEC50.  δδδ = P < 0.05 indicates difference from control Emax. 
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Figure 4.4 Effect of 20 mM and 50 mM [K+]ext on linopirdine induced 
contraction. 
Concentration response curve obtained to linopirdine (1 nM – 100 µM) in different 
[K+]ext. in A) WT mice IPAs and B) 5-HTT+ mice IPAs.  Data are expressed as a 
percentage of the reference contraction to 50 mM KCl in each vessel.  Each point 
represents the mean ± SEM (n = 8 – 10).  *** = P < 0.001 indicates difference from 
control pEC50.  δδδ = P < 0.05 indicates difference from control Emax. 
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Figure 4.5 Contractile responses of IPAs to 5-HT in the presence and absence of 
[Ca2+]ext.. 
Contractile responses to 10 µM 5-HT are compared in normal medium and after the 
removal of [Ca
2+
]ext., in WT and 5-HTT+ mice IPA.  Data presented as % of 50 mM 
KCl induced response.  Each bar represents mean ± SEM (n = 3) (* = P < 0.05, *** = P 
< 0.001). 
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4.3.5 Effect of nifedipine on 5-HT and linopirdine induced 
contraction  
Increasing concentrations of 5-HT (1 nM – 100 µM) were applied to mice IPAs in the 
presence of 1 µM nifedipine.  DMSO was the vehicle for nifedipine, and therefore the 
concentration response curve constructed for 5-HT in the presence of nifedipine was 
compared to that recorded from control experiments where vessels were exposed to 
DMSO (control responses). 
 
Nifedipine partially inhibited the maximum response to 5-HT in WT vessels (figure 4.6 
A).  In WT mice IPAs the maximum response to 5-HT in the presence of DMSO was 98 
± 7 % (n = 6) of the response induced by 50 mM KCl, however in the presence of 
nifedipine, the maximum 5-HT response was partially inhibited to 64 ± 5 % (n = 7) (P < 
0.001).  Nifedipine had a similar action on the maximum response of 5-HT in 5-HTT+ 
vessels.  In 5-HTT mice IPAs the maximum response to 5-HT in the presence of DMSO 
was 86 ± 5 % (n = 6) of the response induced by 50 mM KCl, which was significantly 
reduced in the presence of nifedipine to 59 ± 2 % (n = 6) (P < 0.001). 
 
Increasing concentrations of linopirdine (1 nM – 350 µM) were applied in the presence 
of 1 µM nifedipine and the resulting contractions measured and concentration response 
curve constructed.  Again, control experiments were carried out using the vehicle 
DMSO as with the above experiments.   
 
Nifedipine completely obliterated the linopirdine induced contraction seen in WT 
vessels (figure 4.6 B).  In WT vessels the maximum response to linopirdine in the 
presence of DMSO was 40 ± 6 % (n = 7) of the response induced by 50 mM KCl, and 
this was reduced to 4 ± 2 % (n = 8) in the presence of 1 µM nifedipine, which was a 
significant reduction (P < 0.001).  IPAs from 5-HTT+ mice also failed to contract in 
response to linopirdine in the presence of nifedipine.  The maximum response to 
linopirdine in 5-HTT+ mice IPAs was 38 ± 2 % (n = 6) of the response induced by 50 
mM KCl, which was reduced to 2 ± 1 % (n = 6) (P < 0.001) in the presence of 
nifedipine. 
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4.3.6 Influence of SOCC and store release inhibitors on 5-HT 
induced contraction  
NiCl2 (50 µM) significantly reduced the maximum response to 5-HT in WT mice IPAs 
from 119 ± 6 % (n = 6) of the response induced by 50 mM KCl to 95 ± 16 % (n = 6) (P 
< 0.01).  These results are shown in figure 4.7.  NiCl2 did not significantly reduce the 
maximum response to 5-HT in 5-HTT+ mice vessels, which in the control environment 
was 106 ± 4 % (n = 6) of the response induced by 50 mM KCl and 101 ± 7 % (n = 8) in 
the presence of NiCl2.  However, NiCl2 did reduce sensitivity to 5-HT in 5-HTT+ tissue: 
the pEC50 values were 5.9 ± 0.04 (n = 8) and 5.7 ± 0.5 (n = 8) in the absence and 
presence of NiCl2 respectively (P < 0.001).  
 
The maximum contraction induced by 5-HT in WT mice IPAs was significantly 
reduced in the presence of 2-APB (75 µM) (figure 4.8).  The WT control 5-HT 
maximum response was 101 ± 2 % (n = 5) of the contraction induced by 50 mM KCl, 
which was reduced to 44 ± 3 % (n = 6) (P < 0.001).  The sensitivity to 5-HT was also 
reduced in WT vessels when in the presence of 2-APB: pEC50 values in control and 
treated IPAs were 6.9 ± 0.05, and 6.6 ± 0.1, respectively (P < 0.05).   
 
2-APB significantly reduced the maximum level of contraction induced by 5-HT in 5-
HTT+ mice IPAs.  In control 5-HTT+ vessels, 5-HT induced a maximum contraction of 
112 ± 9 % of the contraction induced by 50 mM KCl.  However, the presence of 2-APB 
reduced the amplitude of the response to 66 ± 13 % (P < 0.05).  2-APB had a much 
larger inhibitory effect on 5-HT induced contraction in WT mice IPAs relative to that of 
NiCl2, (which only reduced the maximum response induced by 5-HT, and had no effect 
on 5-HT sensitivity).  
 
 
4.3.7  Influence of Y-27632 on 5-HT induced contractions 
Y-27632 (10 µM) reduced both the sensitivity of 5-HT in WT mouse IPA vessels and 
the amplitude of the maximum contraction that 5-HT induced (figure 4.9).   The pEC50 
value of the control 5-HT response in WT vessels was 6.8 ± 0.1 % (n = 4), while the 
pEC50 value of the response in the presence of Y-27632 was 6.2 ± 0.2 (n = 5) (P < 
0.05).  The maximum 5-HT contraction induced in control WT mice IPAs was 108 ± 4 
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% of the contraction induced by 50 mM KCl, which was reduced to 41 ± 4 % in WT 
treated tissue (P < 0.001). 
 
Y-27632 had a similar influence on the 5-HT induced response in 5-HTT+ mice IPAs, 
reducing both the sensitivity and amplitude of the maximum response (figure 4.8).  The 
pEC50 values of the control and treated 5-HTT+ vessels were 5.7 ± 0.1 (n = 5) to 5.2 ± 
0.1 (n = 5), respectively (P < 0.01).  Y-27632 also reduced the maximum 5-HT induced 
response in 5-HTT+ tissue from 108 ± 4 %, (n = 5) of the contraction induced by 50 
mM KCl to 33 ± 2 %, (n = 5) (P < 0.001). 
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Figure 4.6 Effect of nifedipine on 5-HT and linopirdine-induced contraction in 
WT and 5-HTT+ mice IPA. 
Concentration response curves obtained to A) 5-HT (1 nM – 100 µM) and B) 
linopirdine (1 nM – 350 µM) in the presence of 1 µM nifedipine in WT and 5-HTT+ 
mice IPAs.  Data are expressed as a percentage of the reference contraction to 50 mM 
KCl in each vessel.  Each point represents the mean ± SEM (n = 6 – 7).  *** = P < 
0.001 indicates a difference of both WT (& nifedipine) and 5-HTT+ (& nifedipine) 
Emax from control values.   
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Figure 4.7 Effect of NiCl2 on 5-HT-induced contraction in WT and 5-HTT+ 
mice IPA. 
Concentration response curve obtained to 5-HT (1 nM – 100 µM) in WT and 5-HTT+ 
mice IPAs in the presence of 50 µM NiCl2.  Data are expressed as a percentage of the 
reference contraction to 50 mM KCl in each vessel.  Each point represents the mean ± 
SEM (n = 6 – 8).  *** = P < 0.001 indicates a difference of 5-HTT+ (& NiCl2) pEC50 
value from 5-HTT+ control value.  δδ = P < 0.01 indicates difference of WT (& NiCl2 ) 
Emax value from WT control value. 
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Figure 4.8 Effect of 2-APB on 5-HT-induced contraction in WT and 5-HTT+ 
mice IPA. 
Concentration response curve obtained to 5-HT (1 nM – 100 µM) in WT and 5-HTT+ 
mice IPAs in the presence of A) 50 µM NiCl2 and B) 75 µM 2-APB.  Data are 
expressed as a percentage of the reference contraction to 50 mM KCl in each vessel.  
Each point represents the mean ± SEM (n = 4 – 8). * = P < 0.05 indicates a difference of 
WT (& 2-APB) pEC50 value from WT control value.  δδδ = P < 0.001 indicates 
difference of  both WT (& 2-APB ) and 5-HTT+ (& 2-APB) Emax values from control 
values. 
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Figure 4.9 Effect of Y-27632 (10 µM) on 5-HT and contraction in IPA from WT 
and 5-HTT+ mice. 
Concentration response curve obtained to 5-HT (1 nM – 100 µM) in WT and 5-HTT+ 
mice IPAs the presence of 10 µM Y-27632.  Data are expressed as a percentage of the 
reference contraction to 50 mM KCl in each vessel.  Each point represents the mean ± 
SEM (n = 4 – 6).  ** = P < 0.01, * = P < 0.05 indicates a difference of both WT ( & Y-
27632) and 5-HTT+ (& Y-27632) from control pEC50 values.  δδδ = P < 0.001 
indicates difference of  both WT (& Y-27632) and 5-HTT+ (& Y-27632) Emax values 
from control values. 
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4.4  Discussion  
The results show that [Ca
2+
]ext. is required for 5-HT induced contraction in WT and 5-
HTT+ mice IPAs.  However, only a proportion of this Ca
2+
 enters the PASMCs via 
VOCC channels, (5-HT was found to cause only a small membrane depolarisation in 
WT cells).  In WT mice IPAs, the SOCC channel inhibitors influenced 5-HT induced 
contraction, with NiCl2
 
reducing the overall maximum contraction and 2-APB reducing 
the sensitivity to 5-HT and reducing the maximum response induced.  As nifedipine 
only partially affected the 5-HT response and NiCl2 only inhibiting 5-HT contraction at 
larger concentrations, there appears be a component of Ca
2+
 influx that is not through 
VOCC or SOCC.   
 
Overall the mean membrane potential of WT vessel PASMCs was - 42 mV.  This is 
similar to what has been reported previously, with values of - 46 mV being reported in 
rat PASMCs (Cogolludo et. al., 2006) and - 40 mV in human PASMCs (Olschewski et. 
al., 2006).  In the present study there was no significant difference between the 
membrane potential of the PASMCs isolated from WT vessels and those isolated from 
5-HTT+ vessels.  The finding that 5-HTT+ mice PASMCs had the same resting 
membrane potential and input resistance as WT mice PASMCs suggests that there was 
no difference in the resting ion conductances.  It has been suggested that as part of PAH 
disease, the membrane potential of PASMCs are depolarised relative to control cells.  
Compared with normal human PASMCs, idiopathic PAH human PASMC had a 
depolarised membrane potential (Bonnet et. al., 2007).  The PAH found in 5HTT+ mice 
does not appear to involve such a change. 
 
5-HT (1 µM) induced a small membrane depolarisation of PASMCs from WT mice, 
with a depolarisation of ~ 7 mV observed at 10 µM 5-HT.  In chapter three, the 5-HT 
concentration response curve shows that at 1 µM 5-HT, the contraction induced in WT 
vessels was ~ 80 % of the contraction induced by 50 mM KCl, and at 10 µM 5-HT the 
contraction induced was ~ 95 %.  Consistent with the discussion above, the large 
contraction response to 1 µM and 10 µM 5-HT in WT mice IPAs (due to increase in 
[Ca
2+
]i) occurs via a non voltage dependent Ca
2+
 entry pathway, with only a small 
proportion arising through VOCC.  PASMCs from 5-HTT+ mice IPAs failed to 
significantly depolarise to the concentrations of 5-HT tested.  5-HTT+ vessels 
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responded to 1 µM 5-HT with a contraction of ~ 10 % of that induced by 50 mM KCl, 
and contracted ~ 65 % in response to 10 µM 5-HT.  Therefore the 5-HT induced 
contraction in 5-HTT+ mice IPAs is not due to depolarisation of the PASMC 
membrane, and subsequent opening of VOCC. 
 
At low 5-HT concentrations, contraction was increased in WT and 5-HTT+ mice IPAs 
in the presence of 20 mM [K
+
]ext.  This increase in sensitivity to 5-HT may be due the 
depolarisation induced by 20 mM [K
+
]ext..  The depolarisation induced by 20 mM 
[K
+
]ext. itself would increase the amount of Ca
2+
 influx and add to Ca
2+
 entry in 
response to 5-HT.   
 
The fact that 5-HT induced contraction is not solely due to electromechanical coupling 
(i.e. directly related to membrane depolarisation) has also been shown in previous 
studies. Rabbit PAs contracted to 1 µM 5-HT; however this concentration did not 
depolarise the rabbit PASMCs enough to induce the contraction observed (Buryi et. al., 
1991).  Development of contraction in rabbit PA was connected to activation of ROCCs 
(Buryi et. al., 1992).  The same study went on to show that 5-HT induced contraction 
has a voltage sensitive component, as it was abolished by membrane hyperpolarisation.  
However, in rat PASMCs, Cogolludo et. al. (2006) presented results that show 10 µM 
5-HT significantly depolarised the cells.  Therefore, it may be the case that the voltage 
sensitive and voltage insensitive components of the 5-HT induced contraction are 
species dependent. 
 
 To further characterise the mechanisms of contraction in WT and 5-HTT+ mice IPAs, 
experiments were carried out to investigate the source of Ca
2+
 involved in the response 
to 5-HT.  5-HT was applied to IPAs in the presence of control PSS (which contained 
Ca
2+
).  The vessels were then washed with Ca
2+
-free PSS, and 5-HT was reapplied.  5-
HT acts to induce contraction by increasing [Ca
2+
]i in PASMCs (Wilson et. al., 2005).  
As prolonged elevations of [Ca
2+
]i are toxic to the cell, Ca
2+
 pumps are rapidly activated 
in an attempt to limit the Ca
2+ 
signal.  A proportion of the [Ca
2+
]i is  extruded across the 
cell membrane and the rest is taken up by intracellular stores including the SR.  Overall 
a net loss of Ca
2+
 from the cell occurs which leads to depletion of intracellular Ca
2+ 
stores (Petersen, 1996).  These stores are then refilled via CCE (Putney, 1990).  In order 
to re-fill the stores Ca
2+
 must be present in the extracellular medium.  Following Ca
2+
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free PSS washout of the initial contraction induced by 5-HT (in the control PSS), 
reapplication of 5-HT did not result in contraction of the tissues.  By washing the 
vessels with Ca
2+
 free PSS, the intracellular stores were unable to re-fill.  This indicates 
that 5-HT induced contraction is dependent on Ca
2+
 being present in the extracellular 
environment.  The results from the experiments using nifedipine indicate that a 
proportion of the Ca
2+
 influx involved in the 5-HT induced contraction in WT and 5-
HTT+ mice IPAs enters the cell via L-type VOCC.  This result has been seen previously 
in rat PA (Cogolludo et. al., 2006).  NiCl2 reduced the maximum 5-HT induced 
response in WT mice, however at lower concentrations of 5-HT (< 1 µM), the 5-HT 
induced response was unaffected.  This suggests that at low concentrations of 5-HT, the 
responses are independent of SOCC Ca
2+
 entry, however, SOCCs may be involved in 
responses to higher 5-HT concentrations in WT mice.  The sensitivity of 5-HTT+ mice 
IPAs to 5-HT was reduced in the presence of NiCl2, suggesting that SOCCs may play a 
more important role in the 5-HT response in this mouse model.  The inhibitory effects 
of NiCl2 have been observed in the pulmonary vasculature of other animal also.  NiCl2 
inhibited SOCC Ca
2+ 
entry
 
in PASMCs isolated from rat main PA and IPA (McElroy et. 
al.,  2008; Ng and Gurney, 2001) and in canine PASMCs, NiCl2 reduced the increase in 
[Ca
2+
]i induced by 10 µM 5-HT (Wilson et. al., 2005).  The different effects of NiCl2 
between WT and 5-HTT+ mice IPA may be the result of a change in SOCC subunits, 
differences in accessory protein composition, or alterations in SOCC regulation.  
 
2-APB reduced the maximum 5-HT induced contraction in WT mice IPAs, an effect 
that was mirrored in 5-HTT+ vessels.   In addition to inhibiting SOCC, 2-APB is an 
inhibitor of InsP3 induced Ca
2+
 release
 
(Maruyama et. al., 1997), and does so over a 
range of 1 – 100 µM (Bootman et. al,. 2002).  This is consistent with the concentration 
of 2-APB used the present study, and therefore suggests a role for InsP3 induced Ca
2+
 
release in the response to 5-HT in mouse IPA.  This result provides further insight into 
the results obtained from experiments in which 5-HT responses were tested in the 
absence of extracellular Ca
2+
.  In the presence of 2-APB, the difference in 5-HT potency 
between WT and 5-HTT+ mice was abolished, suggesting that there may be a loss of 
IP3 induced constriction in 5-HTT+ mice PASMCs.  However the inhibition of Ca
2+
 
signalling, (and hence contraction) by 2-APB may not necessarily indicate a role for IP3 
receptors, since 2-APB can cause an unnoticed depletion of intracellular Ca
2+
 stores, 
and it can affect other cellular processes, such as mitochondrial morphology, which may 
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indirectly alter cellular Ca
2+
 signalling (Peppiatt et. al., 2003). Therefore further 
experiments are needed to investigate how 2-APB partially inhibited the 5-HT induced 
response. 
 
5-HT may activate the rho kinase pathway. Rho kinase activation can increase the 
sensitivity of the smooth muscle contractile apparatus to Ca
2+ 
(Fukata et. al., 2001), and 
if 5-HT did activate this pathway, it would amplify the effect of Ca
2+
 entering across the 
membrane.  The observation that the rho kinase inhibitor, Y-27632, partially inhibited 
the 5-HT-induced contraction, suggests that 5-HT receptors couple to the Rho-kinase 
pathway.  In this study Y-27632 greatly reduced the response to 5-HT in WT and 5-
HTT+ vessels in a similar manner.     
 
With regards to linopirdine induced contraction, ketanserin (an inhibitor of 5-HT2A 
receptors) did not alter the linopirdine induced response in either vessel type.  These 
experiments confirm that in WT and 5-HTT+ mice IPAs, linopirdine does not constrict 
vessels via the 5-HT2A receptor.  This study further demonstrates that linopirdine 
induced contraction of IPAs is mediated via Ca
2+
 entry entirely through VOCC, as 
nifedipine completely inhibited the linopirdine response, in both tissue types. 
 
To further investigate the method of linopirdine induced contraction, IPA vessels from 
WT and 5-HTT+ mice were treated with increasing concentrations of linopirdine in the 
presence of different [K
+
]ext.  Linopirdine induces PA contraction by blocking KCNQ 
channels and depolarising PASMCs (Joshi et. al., 2006).  Moreover, the open 
probability of KCNQ channels is increased at depolarised potentials (Robbins, 2001). 
Therefore it would be expected that depolarising the PASMCs by increasing [K
+
]ext. the 
effect of blocking KCNQ channels with linopirdine would be enhanced.  An increase in 
the contractile effect of linopirdine would also be expected as depolarisation of the 
membrane would lead to opening VOCC channels and subsequent Ca
2+
 entry.  
Surprisingly an increased potency to linopirdine was not seen in the WT tissue in the 
depolarised conditions.  This may have been due to KCNQ channels being maximally 
open under control conditions, and depolarising the PASMC membrane did not result in 
any more KCNQ channels being open and hence no further inhibition by linopirdine.  
Interestingly, the response to linopirdine in 5HTT+ vessels was enhanced by 
depolarisation with 20 mM [K
+
]ext.  It is possible that in 5-HTT+ vessels there is 
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reduced activity of KCNQ channels at rest, and upon depolarisation of the PASMC 
membrane the activity of KCNQ channels was increased, leading to a greater proportion 
of active KCNQ channels available for block by linopirdine.    
 
4.5  Conclusion 
Overall, the main mechanism of 5-HT induced contraction and hence increase of [Ca
2+
]i 
in PASMCs from WT and 5-HTT+ mice IPA involves Ca
2+
 entry from the extracellular 
environment, and from the SR, amplified by rho kinase activation and subsequent 
increased sensitivity to Ca
2+
.  Both voltage dependent and voltage independent routes of 
Ca
2+ 
entry are involved in the 5-HT contractile response in these vessels.  Part of this 
Ca
2+
 enters via VOCC in the plasma membrane of PASMCs, and at higher 
concentrations, some of the Ca
2+
 involved in the contraction response enters the cell via 
SOCC channels.  The results also indicate a greater contribution of IP3 induced 
constriction in WT mouse IPA relative to 5-HTT+ vessels.   
 
Linopirdine induced contraction is due to Ca
2+
 entry via VOCCs in WT and 5-HTT+ 
mice IPAs.  However the difference in potency between the vessels may be due to 
decreased activity of KCNQ channels in the 5-HTT+ mice IPAs. 
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Chapter 5 
 
 
Effects of the KCNQ channel openers, 
flupirtine and retigabine, 
on pulmonary arteries in PAH 
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5.1  Introduction 
To date 5 genes of the KV7 family of channels, KCNQ1-5 (KV7.1-7.5) have been 
reported (Robbins, 2001).  Most research to date has been on drugs modulating these 
channels in the central nervous system, where they have been shown to mediate the M-
current (Brown and Adams 1980; Main et. al., 2000).  KCNQ channels have also been 
described as functioning in cardiac cells (Snyders, 1999; Nerbonne, 2000) and the 
auditory pathways (Neyroud et. al., 2001).  KCNQ current is of particular interest as it 
is a non-inactivating, voltage dependent K
+
 current which is involved in regulating 
neuronal excitability (Brown, 1988) and hence is involved in stabilising neuronal 
membrane potential. 
 
Pharmacology data was provided in the previous chapters to suggest a role for KCNQ 
channels in IPA vessels from WT and 5-HTT+ mice.  Other studies have investigated 
the function of KCNQ channels in the vasculature: Joshi et. al., (2006) induced 
contraction of IPA from rats using the KCNQ blocking agent linopirdine and its more 
potent analogue, XE991; Yeung & Greenwood (2005) showed that linopirdine and 
XE991 increased the spontaneous contractile activity of murine portal vein; the KCNQ 
channel opener retigabine has also been shown to relax pre-contracted murine aortic 
segments (Yeung et. al., 2007). The above evidence reinforces the suggestion that 
KCNQ channels have a functional role in the vasculature.  Myography data (shown in 
previous chapters) additionally shows that the response of mice IPA to linopirdine is 
reduced in the 5-HTT+ vessels, suggesting that there is altered expression of KCNQ 
channels in PAH.   
 
In addition to drugs that block KCNQ channels, drugs have also been developed that 
open these channels.  The KCNQ channel activator flupirtine is used in Europe as a 
non-opioid analgesic and in several human trials has proven to be essentially free of 
cardiovascular side effects (Friedel & Fitton, 1993; Hummel et. al., 1991; Herrmann et. 
al., 1987).  Flupirtine is a less potent analogue of retigabine.  Clinical trials have been 
carried out investigating the use of retigabine in the treatment of patients with epilepsy 
(Sachdeo et. al., 2005).  The critical action of retigabine is to increase potassium current 
near resting potential, reducing excitability, and this explains at least in part, the 
anticonvulsant effect of retigabine (Rogawski, 2006).  Therefore in cells expressing 
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KCNQ channels it would cause hyperpolarisation and reduce the opening of VOCC 
channels.  In smooth muscle cells this would reduce contraction.  Retigabine selectively 
activates KCNQ2-5 (Tatulian et. al., 2001) and flupirtine, like retigabine, has no effect 
on KCNQ1 channels at < 100 µM (Schenzer et. al., 2005; Wuttke et. al., 2005).   
 
If KCNQ channel activation does relax IPA vessels, then KCNQ channel openers could 
potentially be effective at dilating pulmonary arteries and reducing pulmonary arterial 
pressure in PAH.  To investigate this possibility, the effects of KCNQ channel openers 
were investigated on pre-constricted IPA.  In addition, their effects on two mouse 
models of PAH were investigated in vivo.  The effect of flupirtine was investigated on 
pulmonary vascular haemodynamics and indices of PAH, in 5HTT+ mice and chronic-
hypoxic mice, a well characterised model of PAH (Paddenberg et. al., 2007; Raoul et. 
al., 2007; Fresquet et. al., 2006).   
 
It has been shown that by deleting the 5-HTT gene or
 
pharmacologically inhibiting 5-
HTT activity, mice were protected against
 
hypoxia-induced PH (Eddahibi et. al., 2000; 
Guignabert et. al., 2005), suggesting that 5-HTT+ is integral to the development of 
PAH.  5-HTT+ mice exhibit spontaneous PAH in the absence of other external 
environmental stimuli (Guignabert et. al., 2006). In these 5-HTT+ mice, right 
ventricular systolic pressure was found to be increased and the degree of
 
right 
ventricular hypertrophy and distal pulmonary vessel muscularisation was
 
more severe in 
5HTT+ mice than in wild-type mice
 
following exposure to hypoxia.  With regards to 
hypoxia-induced PAH, a proposed mechanism for this process is the direct action of 
hypoxia on certain specific genes within PASMC, such as hypoxia-inducible factor.  
Mice deficient in hypoxia-inducible factor-1 exhibit decreased development of hypoxic 
PH with reduced muscularisation of distal pulmonary vessels (Yu et. al., 1999).  By 
investigating both these PAH models, a broader role of KCNQ channels can be 
determined in the overall process of PAH. 
 
As part of this study mice were subject to hypobaric oxygen for two weeks or 
maintained in a normoxic environment, with age matched siblings used for comparison.  
Within each group, half were administered flupirtine.  The effect of flupirtine on the 
development of PAH in 5-HTT+ mice and chronic hypoxic mice was investigated by 
administration of oral flupirtine on a daily basis over a period of two weeks.   
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5.2  Methods 
5.2.1  Myography 
Myography experiments were performed as in chapter 2.  IPA vessels were 
preconstricted with phenylephrine (10 – 100 nmol/ L) and cumulative application of 
increasing concentrations of flupirtine or retigabine (1 nM - 0.1 mM) were applied.  
Concentration-response curves were constructed from the relaxation responses 
measured at each concentration of KCNQ opener.  Both drug stocks were prepared by 
dissolving in DMSO, so control experiments were carried out in parallel on matched 
vessels, using DMSO at the concentration reached around the vessels exposed to drugs.  
Relaxation was measured as % phenylephrine induced tone. 
 
5.2.2  In-vivo experiments 
In vivo experiments to investigate the effects of flupirtine on PAH were carried out as 
described in chapter 2, using the WT, WT hypoxic and 5-HTT+ mice.  Mice were 
treated orally with either flupirtine (30 mg/ kg/ day) or vehicle (1% 
carboxymethylcellulose) alone on each of the fourteen experimental days.  In each mice 
group measurements were made of right ventricular hypertrophy (RVP) and in vivo 
mean right ventricular pressure (mRVP) as described in chapter 2.  These are 
parameters of pulmonary hypertension and are widely used to investigate this disease 
(Van Suylen et. al., 1998).  IPA vessels were dissected from the experimental mice, and 
contraction to 5-HT was measured in vitro.  The purpose was to determine if 5-HT-
induced contraction was altered after the mice were treated with the KCNQ channel 
opener flupirtine.   
 
5.3  Results 
5.3.1   Responses of WT & 5-HTT+ IPAs to flupirtine and  
  retigabine 
PE (10 – 100 nM) induced a sustained vasoconstriction in vessels from WT and 5-
HTT+ mice.  The level of pre-constriction by PE was similar in both vessel types at ~ 
70 % of that induced by 50 mM KCl.  Cumulative addition of DMSO resulted in 
dilation of IPA from WT and 5-HTT+ mice which had been pre-constricted with PE.  .   
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Flupirtine induced substantial vasodilation in WT mice IPA vessels pre-constricted with 
PE (n = 6), and did so in a concentration dependent manner (figure 5.1A).  Flupirtine 
began to relax WT vessels at concentrations below 1 µM and induced approximately 50 
% relaxation of the PE induced tone at 35 µM in WT mice.  However, flupirtine was not 
an effective vasodilator in 5HTT+ vessels until above 10 µM (n = 5).  Flupirtine 
induced a relaxation of approximately 50 % at a concentration of 35 µM in 5-HTT+ 
mice also.  Retigabine also relaxed IPA vessels pre-contracted with PE, and as with 
flupirtine, it was more effective in WT than 5HTT+ mice (figure 5.1B).  Retigabine 
strongly relaxed IPAs from WT mice, producing an effect below 1 µM and inducing 
approximately 50 % relaxation of PE induced tone at 10 µM (n = 6).  In 5-HTT+ mice 
IPA, retigabine did not induce vasodilation until the concentration was 35 µM in the 
bathing solution (n = 5), and at this concentration the relaxation induced was 
approximately 55 %. 
 
5.3.2  In- vivo studies 
The measured indices of PAH were not altered in normoxic WT mice following 
flupirtine treatment.  There was no significant change in mRVP or RV/ (LV + S) ratio 
(ratio used to as an indicator of right ventricular hypertrophy) (figure 5.2 & 5.3).  Heart 
rate was unaffected by either flupirtine treatment or hypoxia (figure 5.4).   
 
Chronic hypoxia exposure led to changes in the indices of PAH in mice.  Hypoxic mice 
had an increase of ~ 50 % in mRVP relative to normoxic animals (figure 5.2).  Hypoxic 
mice exhibited right ventricular hypertrophy relative to WT controls (figure 5.3).  WT 
hypoxic mRVP was 22 ± 2 mmHg (n = 7, P < 0.01 relative to normoxic WT).  RV/ (LV 
+ S) ratio in hypoxic mice was 0.3 ± 0.01 (n = 7), however normoxic WT mice had a 
RV/ (LV + S) ratio of 0.2 ± 0.01 (n = 6, P < 0.001).  Flupirtine treatment resulted in 
reduced mRVP and right ventricular hypertrophy measurements compared to that of the 
control group of mice receiving vehicle (figure 5.2 & 5.3).  The mRVP measured in 
hypoxic mice treated with flupirtine was 15 ± 1 mmHg (n = 9, P < 0.01 relative to 
vehicle dosed mice) and RV/ (LV + S) ratio was 0.2 ± 0.02 (n = 7, P < 0.05 relative to 
vehicle dosed mice).  The values of mRVP and RV/ (LV + S) in the hypoxic animals 
treated with flupirtine did not differ significantly from the WT normoxic animals, 
indicating that flupirtine inhibited PAH.   
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Figure 5.2 shows that 5-HTT+ mice demonstrated markedly elevated mRVP when 
compared to WT mice (30 ± 3 mmHg (n = 6) compared to 13 ± 1 mmHg (n = 8) 
respectively (P < 0.001), which has been previously reported (MacLean et. al., 2004).  
Treatment with flupirtine markedly reversed this elevation in mRVP to levels which 
were not significantly different from that measured in normoxic WT mice, with mRVP 
in flupirtine treated 5-HTT+ mice measured as 17 ± 8 mmHg (n = 8, P < 0.001) 
compared to vehicle treated 5-HTT+ mice (figure 5.2). Right ventricular hypertrophy 
was observed in the 5-HTT+ mice compared with WT mice and this was also attenuated 
by flupirtine (figure 5.3).  RV/ (LV + S) ratio was 0.23 ± 0.004 (n = 6) in 5-HTT+ mice 
dosed with flupirtine relative to 0.25 ± 0.01 (n = 8) in 5-HTT+ mice dosed with vehicle 
(P < 0.05).  The RV/ (LV + S) ratio in flupirtine treated 5-HTT+ mice did not 
significantly differ from the WT mice vehicle treated value, which was 0.22 ± 0.005 (n 
= 6). 
 
5.3.2 In-vitro functional studies of vessels from drug-treated 
mice     
Normoxic WT vessels responded to 5-HT in an identical matter to that reported in 
previous chapters.  The amplitude of the 5-HT response was increased by ~ 70 % in 
hypoxic IPA from chronic hypoxic mice (n = 6) relative to the response in normoxic 
mice (n = 6, P < 0.001) (figure 5.5).   
 
The response to 5-HT did not differ between vessels derived from normoxic WT mice 
which had been dosed with flupirtine or vehicle (figure 5.5).  Flupirtine treatment did 
not alter pEC50 values for the 5-HT responses in WT normoxic mice (7 ± 0.1, n = 6 - 
7).  Flupirtine also had no influence on 5-HT-induced contraction in 5-HTT+ mice 
IPAs, the pEC50 values of the 5-HT-induced responses were 6 ± 0.1 (n = 7) for both 
treatment groups.  Prior treatment with flupirtine significantly reduced the contractile 
responses of 5-HT in the IPA vessels from chronic hypoxic WT mice.  The maximum 
5-HT response was reduced from 174 % ± 14 (n = 6) of the response to 50 mM KCl, to 
126 ± 3.0 (n = 7) (P < 0.01).    
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Figure 5.1 Flupirtine and retigabine induced relaxation in WT and 5-HTT+ 
mice IPAs.  
Concentration response curves obtained to A) flupirtine (10 nM –10 mM) and B) 
retigabine (10 nM – 3.5 mM/ 10 mM) in WT and 5-HTT+ mice.  Control (DMSO) data 
are also shown and illustrate the fall in vascular tone in vessels set up in parallel with 
those to which flupirtine and retigabine were added.  Data are expressed as a percentage 
of the response to PE induced preconstriction and each point represents the mean ± 
SEM (n = 5 – 6).  *** = P < 0.001, ** = P < 0.01, * = P < 0.05 indicates value 
significantly greater than corresponding value in vehicle treated WT vessels.  δ = P < 
0.05 indicates value significantly greater than corresponding value in vehicle treated 5-
HTT+ vessels.  
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Figure 5.2 Effect of flupirtine on mRVP.  
mRVP in normoxic WT, hypoxic WT and 5-HTT+ mice treated with vehicle () and 
flupirtine  (n = 6 to 8 mice in each group). * Value significantly greater than 
corresponding value in normoxic WT mice (* P < 0.05, ** P < 0.01, *** P < 0.001). δ 
Value significantly less than corresponding value in vehicle treated mice (δ P < 0.05, δδ 
P < 0.01, δδδ P < 0.001). Data are expressed as mean ± S.E.M. 
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Figure 5.3 Effect of flupirtine on RV/ LV + S.  
RV/ LV + S in normoxic WT, hypoxic WT and 5-HTT+ mice treated with vehicle () 
and flupirtine  (n = 6 to 8 mice in each group). * Value significantly greater than 
corresponding value in normoxic WT mice (* P < 0.05, ** P < 0.01, *** P < 0.001). δ 
Value significantly less than corresponding value in vehicle treated mice (δ P < 0.05, δδ 
P < 0.01, δδδ P < 0.001). Data are expressed as mean ± S.E.M. 
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Figure 5.4 Effect of flupirtine on heart rate. 
Heart rate in normoxic WT, hypoxic WT and 5-HTT+ mice treated with vehicle () and 
flupirtine  (n = 6 to 8 mice in each group).  Data are expressed as mean ± S.E.M. 
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Figure 5.5 5-HT-induced contraction in normoxic and hypoxic WT and 5-
HTT+ mice IPAs from vehicle and flupirtine dosed animals. 
 
Concentration response curve obtained to 5-HT (1 nM – 100/ 350 µM) in normoxic, 
hypoxic WT and 5-HTT+ mice IPAs from vehicle and flupirtine dosed animals.  Data 
are expressed as a percentage of reference contraction to 50 mM KCl in each vessel.  
Each point represents the mean ± S.E.M. (n = 6 – 7).  *** = P < 0.001 indicates WT 
hypoxic (vehicle treated) Emax significantly greater than WT normoxic value.  δδ = P < 
0.01 indicates WT hypoxic (flupirtine treated) Emax significantly lower than 
corresponding value in vehicle treated WT hypoxic vessels.  
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5.4  Discussion      
The KCNQ channel openers, flupirtine and retigabine, dilated IPA vessels from WT and 
5-HTT+ mice.  Flupirtine reduced the indices of PAH measured in this study in two 
models of PAH, the 5-HTT+ mouse model and the chronic hypoxic mouse model.   
 
In previous chapters it was found that linopirdine induced vasoconstriction of mice IPA.  
The results shown in this chapter are consistent with these observations.  KCNQ 
channel openers, flupiritine and retigabine, relaxed mice IPA.  Flupirtine and retigabine 
dilated mice IPA vessels, a result which has been also witnessed in mouse systemic 
arteries (Yeung et. al., 2007) and rat pulmonary arteries (Joshi et. al., 2008(submitted)).  
Vasodilation induced by flupirtine and retigabine in mice aortic segments was reversed 
with a KCNQ inhibitor (XE991), which indicates that the vasodilatory effects by these 
agents are mediated by increased flux of K
+ 
through KCNQ channels (Yeung et. al., 
2007). Retigabine was more potent than flupirtine in inducing vasodilation of WT mice 
IPA.  This is similar to their order of potency at opening KCNQ channels in other 
tissues such as mice aorta (Yeung et. al., 2007).  These results indicate that KCNQ 
channels are found in mice IPA and are important for regulating tone in mouse PA.  In 
addition, the relaxant effects of retigabine and flupirtine in PA suggests that the KCNQ 
channels present and active are KCNQ2-5, as these are the channels that are selectively 
activated by retigabine and flupirtine (Tatulian et. al., 2001; Pereta et. al., 2005).  The 
experiments conducted as part of this study show that KCNQ2-5 channel activators are 
more potent in WT mice IPA relative to 5-HTT+ vessels.  This finding is compatible 
with the results obtained with the KCNQ channel inhibitor, linopirdine (see chapter 3), 
which was more potent in WT vessels.  Overall, these results suggest a reduction in the 
number or activity of KCNQ2-5 channels in 5-HTT+ mice PA relative to WT vessels.      
 
As flupirtine was found to be an effective vasodilator in mice IPA, its actions on PAH 
indices (mRVP and right ventricular hypertrophy) were investigated.  Flupirtine 
treatment was found to prevent the increase in mRVP and right ventricular hypertrophy 
that was observed in vehicle treated chronic hypoxic mice.  Moreover, the 
measurements of mRVP and right ventricular hypertrophy in chronic hypoxic mice 
subsequent to flupirtine treatment were not significantly different from measurements in 
normoxic controls.  Therefore flupirtine prevented the development of PAH caused by 
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hypoxia.  These results suggest that KCNQ channels may be involved in the 
development of hypoxic PAH in the mice model.  Flupirtine also reduced mRVP and 
right ventricular hypertrophy in 5-HTT+ mice.  Flupirtine treatment attenuated these 
indices of PAH in 5-HTT+ mice to levels which were not significantly different those 
measured in normoxic WT mice.  These findings in 5-HTT+ mice (which have 
established PAH), indicate that flupirtine treatment could be effective in reversing PAH, 
as well as in the prevention of the condition. 
  
The vasodilatory response of 5-HTT+ mice IPAs to flupirtine application was reduced 
compared to WT vessels, however, flupirtine was still able to reverse PAH in the 5-
HTT+ mice.  If the reduced relaxation to flupirtine in the 5-HTT+ mice IPAs was due to 
a reduction in activity and/ or expression of KCNQ channels, it may be the case that the 
level of KCNQ channel activity was sufficient for flupirtine to act upon to reverse PAH.  
As flupirtine is an activator of KCNQ channels, it would cause hyperpolarisation of 
PASMCs; therefore it could prevent the depolarisation needed for contraction (which 
occurs in PAH).  By reducing the level of vasoconstriction, flupirtine treatment may 
reduce the overall rise in PVR and PAP which contribute to PAH.  However, it may 
also be the case that chronic flupirtine effects differ from acute effects, with flupirtine 
having a greater effect in the flupirtine dosed 5-HTT+ mice relative to the effects on the 
WT animal.  To establish if this is the case, experiments could be conducted on IPAs 
from flupirtine dosed 5-HTT+ mice to investigate if the vasodilatory response to acute 
flupirtine application recovered to that of the WT. 
 
Chronic hypoxic mice IPA vessels exhibited an increased level of response to 5-HT 
relative to WT normoxic IPAs.  The fact that the hypoxic model responded greater to 
contractile agents has been shown previously (MacLean et. al., 1996; McCulloch et. al., 
1998).  Chronic hypoxia has been shown to inhibit IKN in PASMCs (Osipenko et. al., 
1998).  Inhibition of IK results in membrane depolarisation and opening of VOCC, 
which results in an increase in [Ca
2+
]i and vasoconstriction.  Increased contractile 
responses to 5-HT in IPAs derived from chronic hypoxic mice, may have been the result 
of pharmacological synergism between 5-HT receptors (as described in chapter 1).  
Prior dosing of the chronic hypoxic mice with flupirtine prevented the increased 
contractile response to 5-HT significantly.  This may be due to flupirtine preventing 
vasoconstriction of PASMCs, and hence preventing the tone necessary for the 
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‘unmasking’ of 5-HT receptors (MacLean, 1999).  5-HT responses were unchanged in 
IPA derived from 5-HTT+ mice which were dosed with flupirtine.  The results from 
chapter 4 show that 5-HTT+ mice IPA SMCs are not depolarised relative to WT vessel 
SMCs, and therefore these vessels do not have the same pre existing tone as seen in 
chronic hypoxic mice. 
 
Retigabine relaxes mice aorta segments (Yueng et. al., 2007), and hyperpolarise mice 
VSM (Yueng et. al., 2008), which is compatible with the vasodilatory effects shown 
here in mice IPA.  The results presented in this chapter also show that retigabine was 
more potent than flupirtine, which would suggest retigabine may be more effective at 
reducing the indices of PAH than flupirtine.   
 
5.5  Conclusion 
Collectively the data in this chapter show that despite loss of sensitivity to the 
vasodilator action of flupirtine in the 5-HTT+ mouse model of PAH, the drug can 
prevent PAH from developing in chronic hypoxic mice and reverse established PAH in 
the 5-HTT+ model of PAH.  Therefore KCNQ channels may be a potential therapeutic 
target in the treatment of PAH.  Flupirtine has been shown to act on the systemic circuit 
attenuating MAP in rats (Mackie et. al., 2008), however it had no effect on MAP in 
rabbits (Yoro et. al., 2008) and despite published findings in rats, others found no effect 
of retigabine on systemic pressure in this species (Joshi et. al., 2008(submitted)).  
Overall, drugs that activate KCNQ channels may be of benefit in the treatment of PAH. 
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6.1  General discussion 
Elevated levels of circulating 5-HT have been reported under several conditions that 
lead to the development of PAH (MacLean, 2000), such as airway hypoxia and appetite 
suppressant induced PAH.  Plasma 5-HT is increased in patients
 
with PAH (Herve et. 
al., 1995).  Secretion of large amounts of 5-HT from neuroendocrine cells and 
neuroepithelial bodies within the lung occurs in response to airway hypoxia and 
increased local 5-HT may contribute to secondary PAH (Johnson & Georgieff, 1989). 
 
It has been shown that 5-HT induces a vasoconstrictor effect in human and other animal 
PAs, and in PAH this vasoconstriction is more intense (Wanstall & O’Donnell, 1990; 
MacLean & Morecroft, 2001).  This was also observed the present study, with increased 
vasoconstrictor responses to 5-HT seen in IPA vessels from chronic hypoxic mice.  
However, this was not observed in vessels from the 5-HTT+ mouse model of PAH.  
Mice over-expressing the 5-HTT had a reduced sensitivity to 5-HT-induced contraction 
relative to control vessels.  5-HTT over-expression in PASMCs is a characteristic of 
human
 
PAH, and studies indicate that 5-HT internalisation by
 
PASMCs plays a 
prominent role in the pathogenesis of human
 
PAH (Eddahibi et. al., 1999). 
 
Sustained pulmonary vasoconstriction contributes to the elevated pulmonary vascular 
resistance observed in PAH, and therefore understanding the precise mechanisms of 
contraction is important in identifying potential therapeutic targets.  Vasoconstriction 
occurs in PAs due to an increase in [Ca
2+
] within the PASMC cytoplasm.  This rise in 
[Ca
2+
]i sets in motion a series of events which results in cross-bridge formation between 
the myosin heads and the actin filaments and hence, SMC contraction.  The present 
study investigated what brought about this increase in [Ca
2+
]i to cause vasoconstriction 
in WT and 5-HTT+ mice IPA.  It was important to first characterise the
 
physiological 
IPA vasoconstriction in normal
 
mice and compare this to the PAH model to identify 
potential differences that may occur with the disease.  The results show that 
vasoconstriction of normal mouse IPA vessels in response to 5-HT involves both influx 
of Ca
2+
 from the extracellular space and release from the SR, as well as rho kinase 
activity.  Ca
2+
 influx in response to 5-HT enters the cell via both VOCC channels and a 
separate non voltage dependent Ca
2+ 
entry pathway.  Similar results have been described 
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in canine IPA; where removal of extracellular Ca
2+ 
inhibited the response to 5-HT, 
SOCC inhibition reduced the 5-HT response and VOCC channel inhibition also 
partially inhibited the 5-HT response (Wilson et. al., 2005).  A critical pathway in the 5-
HT induced increase in [Ca
2+
]i in canine IPA is the release of Ca
2+
 from the SR, via IP3 
receptor activation (Wilson et. al., 2005).  In the present study however, mouse IPA 
contraction in response to 5-HT involves a partial influence of the sacroplasmic 
reticulum IP3 receptor Ca
2+
 release pathway, but Ca
2+
 release from this pathway alone 
was not enough to induce contraction of mouse IPA.  Extracellular Ca
2+
 is necessary for 
contraction in response to 5-HT in other animals; for example in rat IPA, as removal of 
extracellular Ca
2+
 inhibited 5-HT induced contraction (Rodat-Despoix et. al., 2008).  In 
rat IPA, the influx of Ca
2+ 
through VOCC contributes to Ca
2+
 entry, however, it is not 
responsible for the entire increase in  [Ca
2+
]i
 
(Rodat-Despoix et. al., 2008), like the 
findings in this project for mouse IPA.  Another similarity with rat IPA was that in 
mouse IPA, rho kinase played a major role in the development of vascular tone, which 
was the case under both physiological and pathological conditions.  The involvement of 
intracellular components in generating a greater response to Ca
2+
 within the PASMC 
cytoplasm may indicate why Ca
2+
 channel inhibitors alone are not enough to reverse the 
increase in vascular resistance caused by 5-HT.  Ca
2+ 
entry via a pathway independent 
of VOCC, in response to 5-HT application in WT mice, occurred at higher 
concentrations of 5-HT.  However, in 5-HTT+ mice IPAs, this pathway was active at 
lower concentrations of 5-HT also.  Further studies would be needed to identify the 
precise nature of the pathway involved in the WT and 5-HTT+ mice,  as there are a 
large number of possible candidates, including the large transient receptor potential 
channel (TRP) superfamily (Snetkov et. al., 2003), of which there are six subfamilies 
(Alexander et. al., 2006).  This highlights a potential therapeutic pathway which could 
be further investigated in the search for treatments for PAH. 
 
This project investigated the role of K
+
 channels in the regulation of resting tone in WT 
and the 5-HTT over-expression model of PAH.  Certain studies in the literature suggest 
an important role for KV channels in the development of PAH (Remillard et. al., 2007; 
Yuan et. al., 1998), however in the present study KV channels did not have a major 
influence on resting tone in WT or 5-HTT+ mice IPAs.  The KCa and KV channel 
blockers TEA and 4-AP failed to induce contraction of mouse IPA until high 
concentrations, where they are likely to have non-specific effects.  4-AP at 1 mM, 5 
 140 
mM and 10 mM has been shown to cause measurable contraction of rat PA rings 
(Archer et. al., 1998).  However, in WT and 5-HTT+ mice IPAs, 4-AP failed to 
contract the vessels by more than 20 % (of the response induced by 50 mM KCl) until 
10 mM.  Contraction of mouse PA with 10 mM 4-AP has been shown previously (Xu 
et. al., 2008).  At 10 mM, 4-AP induced a greater response in 5-HTT+ mice IPAs than 
in WT mice IPAs, however at this concentration, 4-AP action is not specific to the 
blockade of KV channels (Doggrell et. al., 1999). Therefore it cannot be confirmed that 
the differential response to 4-AP is due to a difference in KV channel expression or 
function between the normal mouse vessels and vessels from the 5-HTT+ mouse.  
Externally applied TEA causes a relatively
 
high-affinity blockade of the BKCa channel 
with a dissociation constant
 
of 150 - 300 µM, and at higher
 
concentrations of TEA (5-20 
mM) it also inhibits delayed rectifier KV channels (Brayden & Nelson, 1992; Peng et. 
al., 1996).  In this project TEA induced contraction of WT mouse IPA at ~ 35 mM, and 
in 5-HTT+ mice IPA at ~ 100 mM.  At these concentrations the actions of TEA are 
non-specific.  Therefore the results from this study do not support a major role for these 
channels in determining the resting potential and resting tone of IPAs in WT or 5-HTT+ 
mice.  Glibenclamide and capsaicin failed to contract IPA from WT or 5-HTT+ mice, 
therefore the channels blocked by these agents (KATP and KV channels respectively) do 
not play a major role in mediating the resting K
+ 
conductance in the mice IPAs.  At rest, 
KATP channels may all be inhibited by intracellular ATP (Nelson & Quayle, 1995), 
therefore any potential blocking action of glibenclamide may already be being carried 
out by the intracellular ATP levels.   Zn
2+
 only began to contract IPA vessels from WT 
and 5-HTT+ mice at concentrations well above that necessary to inhibit TASK K
+
 
channels, with initial contractions being measured at only 1 – 10 mM.  This suggests 
that TASK K
+
 currents are not the major determinants of the resting membrane 
potential of the SMCs in these arteries either.   
 
The roles of KV, KCa, TASK and KCNQ channels were also investigated in the 5-HT 
induced vasoconstriction response.  Inhibiting KV and KCa channels with 4-AP or TEA 
did not block 5-HT induced contraction of IPA vessels from WT or 5-HTT+ mice.  In 
rat IPA, it has been suggested that 5-HT-induced contraction is mediated at least in part 
by KV inhibition, because activation of the 5-HT2A receptor was shown to inhibit KV 
current in rat PASMCs (Cogolludo et. al., 2006).  However, it has also been shown that 
in isolated perfused rat lungs, prior treatment with 4-AP did not reduce 5-HT induced 
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vasoconstriction (Belohlavkova et. al., 2001).  ZnCl2 and linopirdine also failed to 
inhibit the 5-HT contractile response in WT or 5-HTT+ mice IPAs.  As suggested in 
chapter 3, care must be taken when analysing these results, and further investigation is 
required to investigate if 5-HT induces contraction in these vessels via mechanism that 
involve the inhibition of K
+
 channels.  .   
 
One subset of K
+
 channels on which 5-HTT over-expression had an effect was KCNQ 
channels, shown by reduced responses to the KCNQ channel blocker, linopirdine, in 
IPA from 5-HTT+ mice.    It was further shown that this was specifically an action on 
KCNQ channels, because flupirtine and retigabine (KCNQ channels openers) were also 
more potent in WT mice relative to mice over-expressing the 5-HTT.  Linopirdine was 
acting on K
+
 channels to induce contraction, and not acting as a 5-HT agonist, because 
its effect was not blocked by ketanserin, a 5-HT2A receptor inhibitor.  In addition, 
linopirdine caused PASMC depolarisation and the subsequent opening of VOCCs.  The 
latter action was shown using the drug nifedipine.  Nifedipine blocks VOCCs, and when 
present, linopirdine failed to contract WT or 5-HTT+ mice IPA.  Further evidence that 
linopirdine was inducing contraction via an action on K
+
 channels was provided by 
depolarising the PASMCs using a high [K
+
]ext. in the bathing PSS.  Increasing [K
+
]ext. 
reduced the driving force on K
+ 
efflux from PASMCs, therefore reducing the 
effectiveness of agents that act by altering the activity of K
+
 channels.  Depolarising the 
PASMCs with elevated [K
+
]ext. reduced the contractile effect of linopirdine, and when 
vessels were exposed to an extracellular concentration of 50 mM KCl, linopirdine failed 
to cause contraction of the IPA vessels altogether.  To clarify if the action of linopirdine 
was due to KCNQ channel inhibition, flupirtine and retigabine were used.  Flupirtine 
and retigabine relaxed mice IPAs, and were more potent in WT IPAs relative to those 
from 5-HTT+ mice, which  is consistent with results of linopirdine addition.  It may be 
the case that KCNQ channels are downregulated in PAH, or that there activity is 
reduced.  The proposal of KCNQ channel activity is effected in PAH was investigated 
further.  
 
As flupirtine relaxed IPAs from the 5-HTT+ model of PAH, this identified KCNQ 
channels as a potential target for the treatment of PAH.  The influence of flupirtine was 
investigated on pulmonary vascular haemodynamics and indices of PAH in the 5-HTT+ 
mouse model, which has established PAH (transgenic mice with 5-HTT over-expression
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occurring selectively in SMCs spontaneously develop PAH (Guignabert et. al., 2006)) 
and the rat hypoxic-model of PAH, which develop hypoxia induced PAH over fourteen 
days exposure to hypobaric oxygen (Keegan et. al., 2001).  Flupirtine reduced mRVP 
and right ventricular hypertrophy in 5-HTT+ mice and chronic hypoxic mice, an effect 
which was not observed in WT mice.  As a KCNQ channel opener, flupirtine could 
have prevented the depolarisation of PASMCs and contraction of IPAs which occurs in 
PAH.  The effects of flupirtine collectively suggest that this KCNQ channel opener 
inhibited and attenuated PAH, in the developing and established disease.  The 
pharmacology of these results suggest that the KCNQ channels involved are KCNQ2-5, 
as retigabine and flupirtine are selective activators of these channels (Tatulian et. al., 
2001).  Consistent with this pharmacology is expression of KCNQ channels observed in 
a recent study which has indicated that KCNQ4 and KCNQ5 channels are expressed in 
rat PASMC, with KCNQ4 expression being greater than that of KCNQ5 (Joshi et. al., 
2008(submitted)). 
 
Experiments have been carried out in systemic vessels investigating the action of 
flupirtine, which was shown to induce concentration dependent vasodilation of rat 
mesenteric arteries (Mackie et. al., 2008).  In vivo application of flupirtine has also been 
shown to produce a concentration dependent decrease in mean arterial pressure and 
mean arterial resistance (Mackie et. al., 2008).  The expression of KCNQ channels in 
arterial vessels has also been described.  In rat mesenteric artery, KCNQ1, KCNQ4 and 
KCNQ5 have been identified (Mackie et. al., 2008).  KCNQ4 and KCNQ5 expression 
in mouse carotid and femoral arteries has also been shown (Yeung et. al., 2007).  
Although KCNQ channel subunits have been identified in different tissues, homomeric/ 
heteromeric KCNQ channels may be expressed PAs that are different to homomeric/ 
heteromeric KCNQ channels expressed in other tissues.  The exact composite of KCNQ 
channels in the pulmonary vasculature may confer different biophysical properties 
relative to that of KCNQ channels in the systemic vasculature, which could be targeted 
in the treatment of PAH.  Consistent with this suggestion is the findings that linopirdine 
did not constrict mesenteric arteries at concentrations causing maximal constriction of 
PAs (Yeung & Greenwood, 2007; Mackie et. al., 2008; Joshi et. al., 2008(submitted)).  
Thus flupirtine may be effective in PAH by providing selective dilation of PAs, but its 
impact may be limited due to the potential systemic side effects.  Nevertheless, KCNQ 
channels may represent a novel therapeutic target for the treatment of PAH if PAs are 
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shown to have a unique set of KCNQ channels or to express the channels at a 
sufficiently higher level than the systemic circulation to allow some selectivity of action 
of KCNQ opener drugs. 
 
Overall, this study has shown an interaction between KCNQ channels and the 5-HT 
system in the PAH disease process.  Further to this finding, KCNQ channels openers 
have been demonstrated to attenuate PAH in both developing and established PAH. 
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